

Approved



**Haiti**  
**Country Operational Plan**  
**FY 2017**



## Budget Summary Reports

### Summary of Planned Funding by Agency and Funding Source

Agency	Funding Source			Funding Source Total	Applied Pipeline	Total All Funding Sources and Applied Pipeline Amount
	GAP	GHP-State	GHP-USAID			
<b>State</b>		411,232		<b>411,232</b>	0	<b>411,232</b>
<b>USAID</b>		37,140,726		<b>37,140,726</b>	15,600,000	<b>52,740,726</b>
<b>HHS/CDC</b>	987,500	47,360,542		<b>48,348,042</b>	0	<b>48,348,042</b>
<b>Total</b>	<b>987,500</b>	<b>84,912,500</b>	<b>0</b>	<b>85,900,000</b>	<b>15,600,000</b>	<b>101,500,000</b>

### Summary of Planned Funding by Budget Code and Agency

Budget Code	Agency			On Hold Amount	Total
	State	HHS/CDC	USAID		
CIRC	0	0	0	0	<b>0</b>
HBHC	41,124	3,678,647	996,288	0	<b>4,716,059</b>
HKID	16,758	3,192,213	7,627,467	0	<b>10,836,438</b>
HLAB	0	1,580,255	305,731	0	<b>1,885,986</b>
HMBL	0	0	0	0	<b>0</b>
HMIN	0	0	0	0	<b>0</b>
HTXD	0	1,780	11,920,374	0	<b>11,922,154</b>
HTXS	156,888	17,420,236	6,125,652	0	<b>23,702,776</b>
HVAB	0	42,500	562,500	0	<b>605,000</b>
HVCT	0	6,333,775	930,750	0	<b>7,264,525</b>
HVMS	16,758	4,585,038	2,588,036	0	<b>7,189,832</b>
HVOP	0	514,251	1,504,427	0	<b>2,018,678</b>
HVSI	24,364	2,549,617	443,803	0	<b>3,017,784</b>
HVTB	50,275	2,090,792	294,005	0	<b>2,435,072</b>
IDUP	0	0	0	0	<b>0</b>

Approved



MTCT	3,803	2,818,518	1,768,896	0	<b>4,591,217</b>
OHSS	0	1,638,363	1,361,388	0	<b>2,999,751</b>
PDCS	11,409	711,268	413,630	0	<b>1,136,307</b>
PDTX	89,853	1,190,789	297,779	0	<b>1,578,421</b>
	<b>411,232</b>	<b>48,348,042</b>	<b>37,140,726</b>	<b>0</b>	<b>85,900,000</b>



## Technical Areas

### Technical Area Summary

#### Technical Area: Care

Budget Code	Budget Code Planned Amount	On Hold Amount
HBHC	3,982,441	0
HKID	10,520,163	0
HVTB	2,202,441	0
PDCS	762,346	0
<b>Total Technical Area Planned Funding:</b>	<b>17,467,391</b>	<b>0</b>

#### Technical Area: Governance and Systems

Budget Code	Budget Code Planned Amount	On Hold Amount
HLAB	1,764,201	0
HVSI	2,778,208	0
OHSS	2,734,800	0
<b>Total Technical Area Planned Funding:</b>	<b>7,277,209</b>	<b>0</b>

#### Technical Area: Prevention

Budget Code	Budget Code Planned Amount	On Hold Amount
CIRC	0	0
HVAB	605,000	0
HVCT	7,100,490	0
HVOP	1,848,047	0
MTCT	4,440,529	0
<b>Total Technical Area Planned Funding:</b>	<b>13,994,066</b>	<b>0</b>

Approved



**Technical Area: Treatment**

<b>Budget Code</b>	<b>Budget Code Planned Amount</b>	<b>On Hold Amount</b>
HTXD	11,824,484	0
HTXS	22,477,713	0
PDTX	1,047,905	0
<b>Total Technical Area Planned Funding:</b>	<b>35,350,102</b>	<b>0</b>



### Technical Area Summary Indicators and Targets

Indicator Number	Label	2018
PMTCT_STAT_DSD	PMTCT_STAT_DSD Number and percentage of pregnant women with known status (includes women who were tested for HIV and received their results) (DSD)	n/a
	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	239,824
	Number of new ANC and L&D clients	
	By Age (Denominator): Unknown Age	247,231
	By Age (Denominator): <10	
	By Age (Denominator): 10-14	
	By Age (Denominator): <15-19	
	By Age (Denominator): 20-24	
	By Age (Denominator): 25-49	
	By Age (Denominator): 50+	
	By Number of known positives: Unknown Age	2,300
	By Number of known positives: <10	
	By Number of known positives: 10-14	
	By Number of known positives: 15-19	
	By Number of known positives: 20-24	
By Number of known positives: 25-		



	49	
	By Number of known positives: 50+	
	By Number of new positives: Unknown Age	2,748
	By Number of new positives: <10	
	By Number of new positives: 10-14	
	By Number of new positives: 15-19	
	By Number of new positives: 20-24	
	By Number of new positives: 25-49	
	By Number of new positives: 50+	
	By Number of new negative: Unknown Age	234,765
	By Number of new negative: <10	
	By Number of new negative: 10-14	
	By Number of new negative: 15-19	
	By Number of new negative: 20-24	
	By Number of new negative: 25-49	
	By Number of new negative: 50+	
	By Age (Numerator): Unknown Age	5,039
	By Age (Numerator): <10	
	By Age (Numerator): 10-14	
	By Age (Numerator): 15-19	
	By Age (Numerator): 20-24	
	By Age (Numerator): 25-49	
	By Age (Numerator): 50+	
PMTCT_ART_DSD	PMTCT_ART_DSD Percentage of HIV-positive pregnant women who received ART to reduce risk of mother-to-child-transmission (MTCT) during pregnancy	2 %
	Number of HIV-positive pregnant women who received ART to reduce risk of mother-to-child-	4,791



	transmission (MTCT) during pregnancy	
	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	239,824
	New on ART	2,752
	Already on ART at beginning of current pregnancy	2,039
PP_PREV_DSD	PP_PREV_DSD Percentage of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period (DSD)	n/a
	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	31,749
	Total number of people in the target population	
	Age/sex: 10-14 Male	0
	Age/sex: 15-19 Male	46
	Age/sex: 20-24 Male	3,118
	Age/sex: 25-49 Male	5,799
	Age/sex: 50+ Male	0
	Age/sex: 10-14 Female	7,926
	Age/sex: 15-19 Female	7,059
	Age/sex: 20-24 Female	1,709
	Age/sex: 25-49 Female	6,111
	Age/sex: 50+ Female	0
	Aggregated Age/sex: <15 Male	
Aggregated Age/sex: 15+ Male		



	Aggregated Age/sex: <15 Female	
	Aggregated Age/sex: 15+ Female	
KP_PREV_DSD	KP_PREV_DSD Percentage of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required (DSD)	n/a
	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	93,120
	Total estimated number of key population in the catchment area	
	By key population type: Men who have sex with men who are sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	1,056
	By key population type: Men who have sex with men who are NOT sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	24,091
	By key population type: Transgender who are sex workers (Numerator: Number of key populations reached with individual	0



	and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	
	By key population type: Transgender who are NOT sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	0
	By key population type: Female sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	63,373
	By key population type: Males who inject drugs ( Male PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	0
	By key population type: Females who inject drugs (Female PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	0



	By key population type: People in prisons and enclosed settings (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	4,600
	By key population type: Female sex workers (FSW) (Denominator: Total estimated number of key population in the catchment area)	
	By key population type: People in prisons and enclosed settings (Denominator: Total estimated number of key population in the catchment area)	
	By key population type: Men who have sex with men who are sex workers (Denominator: Total estimated number of key population in the catchment area)	
	By key population type: Men who have sex with men who are NOT sex workers (Denominator: Total estimated number of key population in the catchment area)	
	By key population type: Transgender who are sex workers (Denominator: Total estimated number of key population in the catchment area)	
	By key population type: Transgender who are NOT sex workers (Denominator: Total estimated number of key	



	population in the catchment area)	
	By key population type: Males who inject drugs ( Male PWID) (Denominator: Total estimated number of key population in the catchment area)	
	By key population type: Females who inject drugs (Female PWID) (Denominator: Total estimated number of key population in the catchment area)	
	By key population type: Men who have sex with men/Transgender (MSM/TG) (Denominator: Total estimated number of key population in the catchment area)	
	By key population type: MSM/TG who are male sex workers (subset MSM/TG) (Denominator: Total estimated number of key population in the catchment area)	
	By Service: KP known status	
	By Service: KP was tested as part of the program and/or KP was referred for testing as part of the program	
	By New Client Status: New beneficiary	
	By New Client Status: Returning beneficiary within the current report period	
TB_STAT_DSD	TB_STAT_DSD Percentage of registered new and relapsed TB cases with documented HIV status.	92 %



	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	11,475
	Total number of registered new and relapsed TB cases, during the reporting period.	12,410
	Age/Sex: <1 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: 1-9 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: Male 10-14 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: Male 15-19 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: Male 20-24 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: Male 25-49 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	



	reporting period)	
	Age/Sex: Male 50+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: Female 10-14 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: Female 15-19 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: Female 20-24 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: Female 25-49 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: Female 50+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	251



	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	4,336
	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	384
	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	6,504
	Result: Known HIV positive at service entry	
	Result: New HIV positive	
	Result: HIV Negative	
	Age/Sex: <1 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period.)	
	Age/Sex: 1-9 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period.)	
	Age/Sex: Male 10-14 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period.)	
	Age/Sex: Male 15-19 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period.)	



	Age/Sex: Male 20-24 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period.)	
	Age/Sex: Male 25-49 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period.)	
	Age/Sex: Male 50+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period.)	
	Age/Sex: Female 10-14 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period.)	
	Age/Sex: Female 15-19 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period.)	
	Age/Sex: Female 20-24 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period.)	
	Age/Sex: Female 25-49 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period.)	
	Age/Sex: Female 50+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period.)	
	Aggregated Age/Sex: Male <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period.)	267



	cases, during the reporting period)	
	Aggregated Age/Sex: Male 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	4,701
	Aggregated Age/Sex: Female <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	415
	Aggregated Age/Sex: Female 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	7,027
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	905,852
	By Test Result: Positive	26,969
	Service Delivery Point (Community) Homebased testing: 10-14, Female, Negative	
	Service Delivery Point (Community) Homebased testing: 10-14, Female, Positive	
	Service Delivery Point (Community) Homebased testing: 10-14, Male, Negative	
	Service Delivery Point (Community) Homebased testing: 10-14, Male, Positive	
	Service Delivery Point (Community) Homebased testing: 15-19, Female, Negative	
	Service Delivery Point (Community) Homebased testing: 15-19,	



	Female, Positive	
	Service Delivery Point (Community) Homebased testing: 15-19, Male, Negative	
	Service Delivery Point (Community) Homebased testing: 15-19, Male, Positive	
	Service Delivery Point (Community) Homebased testing: 20-24, Female, Negative	
	Service Delivery Point (Community) Homebased testing: 20-24, Female, Positive	
	Service Delivery Point (Community) Homebased testing: 20-24, Male, Negative	
	Service Delivery Point (Community) Homebased testing: 20-24, Male, Positive	
	Service Delivery Point (Community) Homebased testing: 25-49, Female, Negative	
	Service Delivery Point (Community) Homebased testing: 25-49, Female, Positive	
	Service Delivery Point (Community) Homebased testing: 25-49, Male, Negative	
	Service Delivery Point (Community) Homebased testing: 25-49, Male, Positive	
	Service Delivery Point (Community) Homebased testing: 50+, Female, Negative	
	Service Delivery Point (Community)	



	Homebased testing: 50+, Female, Positive	
	Service Delivery Point (Community) Homebased testing: 50+, Male, Negative	
	Service Delivery Point (Community) Homebased testing: 50+, Male, Positive	
	Service Delivery Point (Community) Homebased testing: Unknown Age, Female, Negative	
	Service Delivery Point (Community) Homebased testing: Unknown Age, Female, Positive	
	Service Delivery Point (Community) Homebased testing: Unknown Age, Male, Negative	
	Service Delivery Point (Community) Homebased testing: Unknown Age, Male, Positive	
	Service Delivery Point (Community) Homebased testing: <1, Negative	
	Service Delivery Point (Community) Homebased testing: <1, Positive	
	Service Delivery Point (Community) Homebased testing: 1-9, Negative	
	Service Delivery Point (Community) Homebased testing: 1-9, Positive	
	Service Delivery Point by Agg Age (Community) Homebased testing: <15, Female, Negative	
	Service Delivery Point by Agg Age (Community) Homebased testing: <15, Female, Positive	
	Service Delivery Point by Agg Age	



	(Community) Homebased testing: <15, Male, Negative	
	Service Delivery Point by Agg Age (Community) Homebased testing: <15, Male, Positive	
	Service Delivery Point by Agg Age (Community) Homebased testing: 15+, Female, Negative	289
	Service Delivery Point by Agg Age (Community) Homebased testing: 15+, Female, Positive	7
	Service Delivery Point by Agg Age (Community) Homebased testing: 15+, Male, Negative	193
	Service Delivery Point by Agg Age (Community) Homebased testing: 15+, Male, Positive	4
	Service Delivery Point by Agg Age (Community) Homebased testing: Unknown Age, Female, Negative	
	Service Delivery Point by Agg Age (Community) Homebased testing: Unknown Age, Female, Positive	
	Service Delivery Point by Agg Age (Community) Homebased testing: Unknown Age, Male, Negative	
	Service Delivery Point by Agg Age (Community) by Aggregated Age: Homebased testing: Unknown Age, Male, Positive	
	Service Delivery Point (Facility) Inpatient: 10-14, Female, Negative	
	Service Delivery Point (Facility) Inpatient: 10-14, Female, Positive	
	Service Delivery Point (Facility)	



	Inpatient: 10-14, Male, Negative	
	Service Delivery Point (Facility) Inpatient: 10-14, Male, Positive	
	Service Delivery Point (Facility) Inpatient: 15-19, Female, Negative	
	Service Delivery Point (Facility) Inpatient: 15-19, Female, Positive	
	Service Delivery Point (Facility) Inpatient: 15-19, Male, Negative	
	Service Delivery Point (Facility) Inpatient: 15-19, Male, Positive	
	Service Delivery Point (Facility) Inpatient: 20-24, Female, Negative	
	Service Delivery Point (Facility) Inpatient: 20-24, Female, Positive	
	Service Delivery Point (Facility) Inpatient: 20-24, Male, Negative	
	Service Delivery Point (Facility) Inpatient: 20-24, Male, Positive	
	Service Delivery Point (Facility) Inpatient: 25-49, Female, Negative	
	Service Delivery Point (Facility) Inpatient: 25-49, Female, Positive	
	Service Delivery Point (Facility) Inpatient: 25-49, Male, Negative	
	Service Delivery Point (Facility) Inpatient: 25-49, Male, Positive	
	Service Delivery Point (Facility) Inpatient: 50+, Female, Negative	
	Service Delivery Point (Facility) Inpatient: 50+, Female, Positive	
	Service Delivery Point (Facility) Inpatient: 50+, Male, Negative	
	Service Delivery Point (Facility)	



	Inpatient: 50+, Male, Positive	
	Service Delivery Point (Facility) Inpatient: Unknown Age, Female, Negative	
	Service Delivery Point (Facility) Inpatient: Unknown Age, Female, Positive	
	Service Delivery Point (Facility) Inpatient: Unknown Age, Male, Negative	
	Service Delivery Point (Facility) Inpatient: Unknown Age, Male, Positive	
	Service Delivery Point (Facility) Inpatient: <1, Negative	
	Service Delivery Point (Facility) Inpatient: <1, Positive	
	Service Delivery Point (Facility) Inpatient: 1-9, Negative	
	Service Delivery Point (Facility) Inpatient: 1-9, Positive	
	Service Delivery Point by Agg Age (Facility) Inpatient: <15, Female, Negative	
	Service Delivery Point by Agg Age (Facility) Inpatient: <15, Female, Positive	
	Service Delivery Point by Agg Age (Facility) Inpatient: <15, Male, Negative	
	Service Delivery Point by Agg Age (Facility) Inpatient: <15, Male, Positive	
	Service Delivery Point by Agg Age (Facility) Inpatient: 15+, Female,	154



	Negative	
	Service Delivery Point by Agg Age (Facility) Inpatient: 15+, Female, Positive	8
	Service Delivery Point by Agg Age (Facility) Inpatient: 15+, Male, Negative	103
	Service Delivery Point by Agg Age (Facility) Inpatient: 15+, Male, Positive	4
	Service Delivery Point by Agg Age (Facility) Inpatient: Unknown Age, Female, Negative	
	Service Delivery Point by Agg Age (Facility) Inpatient: Unknown Age, Female, Positive	
	Service Delivery Point by Agg Age (Facility) Inpatient: Unknown Age, Male, Negative	
	Service Delivery Point by Agg Age (Facility) Inpatient: Unknown Age, Male, Positive	
	Service Delivery Point (Community) Mobile Testing: 10-14, Female, Negative	
	Service Delivery Point (Community) Mobile Testing: 10-14, Female, Positive	
	Service Delivery Point (Community) Mobile Testing: 10-14, Male, Negative	
	Service Delivery Point (Community) Mobile Testing: 10-14, Male, Positive	
	Service Delivery Point (Community)	



	Mobile Testing: 15-19, Female, Negative	
	Service Delivery Point (Community) Mobile Testing: 15-19, Female, Positive	
	Service Delivery Point (Community) Mobile Testing: 15-19, Male, Negative	
	Service Delivery Point (Community) Mobile Testing: 15-19, Male, Positive	
	Service Delivery Point (Community) Mobile Testing: 20-24, Female, Negative	
	Service Delivery Point (Community) Mobile Testing: 20-24, Female, Positive	
	Service Delivery Point (Community) Mobile Testing: 20-24, Male, Negative	
	Service Delivery Point (Community) Mobile Testing: 20-24, Male, Positive	
	Service Delivery Point (Community) Mobile Testing: 25-49, Female, Negative	
	Service Delivery Point (Community) Mobile Testing: 25-49, Female, Positive	
	Service Delivery Point (Community) Mobile Testing: 25-49, Male, Negative	
	Service Delivery Point (Community) Mobile Testing: 25-49, Male, Positive	



	Service Delivery Point (Community) Mobile Testing: 50+, Female, Negative	
	Service Delivery Point (Community) Mobile Testing: 50+, Female, Positive	
	Service Delivery Point (Community) Mobile Testing: 50+, Male, Negative	
	Service Delivery Point (Community) Mobile Testing: 50+, Male, Positive	
	Service Delivery Point (Community) Mobile Testing: Unknown Age, Female, Negative	
	Service Delivery Point (Community) Mobile Testing: Unknown Age, Female, Positive	
	Service Delivery Point (Community) Mobile Testing: Unknown Age, Male, Negative	
	Service Delivery Point (Community) Mobile Testing: Unknown Age, Male, Positive	
	Service Delivery Point (Community) Mobile Testing: <1, Negative	
	Service Delivery Point (Community) Mobile Testing: <1, Positive	
	Service Delivery Point (Community) Mobile Testing: 1-9, Negative	
	Service Delivery Point (Community) Mobile Testing: 1-9, Positive	
	Service Delivery Point by Agg Age(Community) Mobile Testing: <15, Female, Negative	
	Service Delivery Point by Agg	



	Age(Community) Mobile Testing: <15, Female, Positive	
	Service Delivery Point by Agg Age(Community) Mobile Testing: <15, Male, Negative	
	Service Delivery Point by Agg Age(Community) Mobile Testing: <15, Male, Positive	
	Service Delivery Point by Agg Age(Community) Mobile Testing: 15+, Female, Negative	1,700
	Service Delivery Point by Agg Age(Community) Mobile Testing: 15+, Female, Positive	35
	Service Delivery Point by Agg Age(Community) Mobile Testing: 15+, Male, Negative	1,188
	Service Delivery Point by Agg Age(Community) Mobile Testing: 15+, Male, Positive	23
	Service Delivery Point by Agg Age(Community) Mobile Testing: Unknown Age, Female, Negative	
	Service Delivery Point by Agg Age(Community) Mobile Testing: Unknown Age, Female, Positive	
	Service Delivery Point by Agg Age(Community) Mobile Testing: Unknown Age, Male, Negative	
	Service Delivery Point by Agg Age(Community) Mobile Testing: Unknown Age, Male, Positive	
	Service Delivery Point (Facility) Other PITC: 10-14, Female, Negative	



	Service Delivery Point (Facility) Other PITC: 10-14, Female, Positive	
	Service Delivery Point (Facility) Other PITC: 10-14, Male, Negative	
	Service Delivery Point (Facility) Other PITC: 10-14, Male, Positive	
	Service Delivery Point (Facility) Other PITC: 15-19, Female, Negative	
	Service Delivery Point (Facility) Other PITC: 15-19, Female, Positive	
	Service Delivery Point (Facility) Other PITC: 15-19, Male, Negative	
	Service Delivery Point (Facility) Other PITC: 15-19, Male, Positive	
	Service Delivery Point (Facility) Other PITC: 20-24, Female, Negative	
	Service Delivery Point (Facility) Other PITC: 20-24, Female, Positive	
	Service Delivery Point (Facility) Other PITC: 20-24, Male, Negative	
	Service Delivery Point (Facility) Other PITC: 20-24, Male, Positive	
	Service Delivery Point (Facility) Other PITC: 25-49, Female, Negative	
	Service Delivery Point (Facility) Other PITC: 25-49, Female, Positive	
	Service Delivery Point (Facility) Other PITC: 25-49, Male, Negative	



	Service Delivery Point (Facility) Other PITC: 25-49, Male, Positive	
	Service Delivery Point (Facility) Other PITC: 50+, Female, Negative	
	Service Delivery Point (Facility) Other PITC: 50+, Female, Positive	
	Service Delivery Point (Facility) Other PITC: 50+, Male, Negative	
	Service Delivery Point (Facility) Other PITC: 50+, Male, Positive	
	Service Delivery Point (Facility) Other PITC: Unknown Age, Female, Negative	
	Service Delivery Point (Facility) Other PITC: Unknown Age, Female, Positive	
	Service Delivery Point (Facility) Other PITC: Unknown Age, Male, Negative	
	Service Delivery Point (Facility) Other PITC: Unknown Age, Male, Positive	
	Service Delivery Point (Facility) Other PITC: <1, Negative	
	Service Delivery Point (Facility) Other PITC: <1, Positive	
	Service Delivery Point (Facility) Other PITC: 1-9, Negative	
	Service Delivery Point (Facility) Other PITC: 1-9, Positive	
	Service Delivery Point by Agg Age (Facility) Other PITC: <15, Female, Negative	0
	Service Delivery Point by Agg Age	0



	(Facility) Other PITC: <15, Female, Positive	
	Service Delivery Point by Agg Age (Facility) Other PITC: <15, Male, Negative	0
	Service Delivery Point by Agg Age (Facility) Other PITC: <15, Male, Positive	0
	Service Delivery Point by Agg Age (Facility) Other PITC: 15+, Female, Negative	92,046
	Service Delivery Point by Agg Age (Facility) Other PITC: 15+, Female, Positive	2,314
	Service Delivery Point by Agg Age (Facility) Other PITC: 15+, Male, Negative	62,091
	Service Delivery Point by Agg Age (Facility) Other PITC: 15+, Male, Positive	1,548
	Service Delivery Point (Facility) Other PITC: Unknown Age, Female, Negative	
	Service Delivery Point by Agg Age (Facility) Other PITC: Unknown Age, Female, Positive	
	Service Delivery Point by Agg Age (Facility) Other PITC: Unknown Age, Male, Negative	
	Service Delivery Point by Agg Age (Facility) Other PITC: Unknown Age, Male, Positive	
	Service Delivery Point (Facility) Other PITC: 10-14, Female, Negative	



	Service Delivery Point (Community) Other: 10-14, Female, Positive	
	Service Delivery Point (Community) Other: 10-14, Male, Negative	
	Service Delivery Point (Community) Other: 10-14, Male, Positive	
	Service Delivery Point (Community) Other: 15-19, Female, Negative	
	Service Delivery Point (Community) Other: 15-19, Female, Positive	
	Service Delivery Point (Community) Other: 15-19, Male, Negative	
	Service Delivery Point (Community) Other: 15-19, Male, Positive	
	Service Delivery Point (Community) Other: 20-24, Female, Negative	
	Service Delivery Point (Community) Other: 20-24, Female, Positive	
	Service Delivery Point (Community) Other: 20-24, Male, Negative	
	Service Delivery Point (Community) Other: 20-24, Male, Positive	
	Service Delivery Point (Community) Other: 25-49, Female, Negative	
	Service Delivery Point (Community) Other: 25-49, Female, Positive	
	Service Delivery Point (Community) Other: 25-49, Male, Negative	
	Service Delivery Point (Community) Other: 25-49, Male, Positive	
	Service Delivery Point (Community) Other: 50+, Female, Negative	
	Service Delivery Point (Community) Other: 50+, Female, Positive	



	Service Delivery Point (Community) Other: 50+, Male, Negative	
	Service Delivery Point (Community) Other: 50+, Male, Positive	
	Service Delivery Point (Community) Other: Unknown Age, Female, Negative	
	Service Delivery Point (Community) Other: Unknown Age, Female, Positive	
	Service Delivery Point (Community) Other: Unknown Age, Male, Negative	
	Service Delivery Point (Community) Other: Unknown Age, Male, Positive	
	Service Delivery Point (Community) Other: <1, Negative	
	Service Delivery Point (Community) Other: <1, Positive	
	Service Delivery Point (Community) Other: 1-9, Negative	
	Service Delivery Point (Community) Other: 1-9, Positive	
	Service Delivery Point by Agg Age (Community) Other: <15, Female, Negative	
	Service Delivery Point by Agg Age (Community) Other: <15, Female, Positive	
	Service Delivery Point by Agg Age (Community) Other: <15, Male, Negative	
	Service Delivery Point by Agg Age (Community) Other: <15, Male,	



	Positive	
	Service Delivery Point by Agg Age (Community) Other: 15+, Female, Negative	465
	Service Delivery Point by Agg Age (Community) Other: 15+, Female, Positive	12
	Service Delivery Point by Agg Age (Community) Other: 15+, Male, Negative	309
	Service Delivery Point by Agg Age (Community) Other: 15+, Male, Positive	8
	Service Delivery Point by Agg Age (Community) Other: Unknown Age, Female, Negative	
	Service Delivery Point by Agg Age (Community) Other: Unknown Age, Female, Positive	
	Service Delivery Point by Agg Age (Community) Other: Unknown Age, Male, Negative	
	Service Delivery Point by Agg Age (Community) Other: Unknown Age, Male, Positive	
	Service Delivery Point (Facility) Pediatric : <5 Negative	
	Service Delivery Point (Facility) Pediatric : <5 Positive	
	Service Delivery Point (Facility) TB: 10-14, Female, Negative	
	Service Delivery Point (Facility) TB: 10-14, Female, Positive	
	Service Delivery Point (Facility) TB: 10-14, Male, Negative	



	Service Delivery Point (Facility) TB: 10-14, Male, Positive	
	Service Delivery Point (Facility) TB: 15-19, Female, Negative	
	Service Delivery Point (Facility) TB: 15-19, Female, Positive	
	Service Delivery Point (Facility) TB: 15-19, Male, Negative	
	Service Delivery Point (Facility) TB: 15-19, Male, Positive	
	Service Delivery Point (Facility) TB: 20-24, Female, Negative	
	Service Delivery Point (Facility) TB: 20-24, Female, Positive	
	Service Delivery Point (Facility) TB: 20-24, Male, Negative	
	Service Delivery Point (Facility) TB: 20-24, Male, Positive	
	Service Delivery Point (Facility) TB: 25-49, Female, Negative	
	Service Delivery Point (Facility) TB: 25-49, Female, Positive	
	Service Delivery Point (Facility) TB: 25-49, Male, Negative	
	Service Delivery Point (Facility) TB: 25-49, Male, Positive	
	Service Delivery Point (Facility) TB: 50+, Female, Negative	
	Service Delivery Point (Facility) TB: 50+, Female, Positive	
	Service Delivery Point (Facility) TB: 50+, Male, Negative	
	Service Delivery Point (Facility) TB: 50+, Male, Positive	



	Service Delivery Point (Facility) TB: Unknown Age, Female, Negative	
	Service Delivery Point (Facility) TB: Unknown Age, Female, Positive	
	Service Delivery Point (Facility) TB: Unknown Age, Male, Negative	
	Service Delivery Point (Facility) TB: Unknown Age, Male, Positive	
	Service Delivery Point (Facility) TB: <1, Negative	
	Service Delivery Point (Facility) TB: <1, Positive	
	Service Delivery Point (Facility) TB: 1-9, Negative	
	Service Delivery Point (Facility) TB: 1-9, Positive	
	Service Delivery Point by Agg Age (Facility) TB: <15, Female, Negative	0
	Service Delivery Point by Agg Age (Facility) TB: <15, Female, Positive	0
	Service Delivery Point by Agg Age (Facility) TB: <15, Male, Negative	0
	Service Delivery Point by Agg Age (Facility) TB: <15, Male, Positive	0
	Service Delivery Point by Agg Age (Facility) TB: 15+, Female, Negative	3,574
	Service Delivery Point by Agg Age (Facility) TB: 15+, Female, Positive	413
	Service Delivery Point by Agg Age (Facility) TB: 15+, Male, Negative	2,417
	Service Delivery Point by Agg Age (Facility) TB: 15+, Male, Positive	277



	Service Delivery Point by Agg Age (Facility) TB: Unknown Age, Female, Negative	
	Service Delivery Point by Agg Age (Facility) TB: Unknown Age, Female, Positive	
	Service Delivery Point by Agg Age (Facility) TB: Unknown Age, Male, Negative	
	Service Delivery Point by Agg Age (Facility) TB: Unknown Age, Male, Positive	
	Service Delivery Point (Facility) VMMC: <1, Negative	
	Service Delivery Point (Facility) VMMC: <1, Positive	
	Service Delivery Point (Facility) VMMC: 10-14, Negative	
	Service Delivery Point (Facility) VMMC: 10-14, Positive	
	Service Delivery Point (Facility) VMMC: 15-19, Negative	
	Service Delivery Point (Facility) VMMC: 15-19, Positive	
	Service Delivery Point (Facility) VMMC: 1-9, Negative	
	Service Delivery Point (Facility) VMMC: 1-9, Positive	
	Service Delivery Point (Facility) VMMC: 20-24, Negative	
	Service Delivery Point (Facility) VMMC: 20-24, Positive	
	Service Delivery Point (Facility) VMMC: 25-49, Negative	



	Service Delivery Point (Facility) VMMC: 25-49, Positive	
	Service Delivery Point (Facility) VMMC: 50+, Negative	
	Service Delivery Point (Facility) VMMC: 50+, Positive	
	Service Delivery Point (Facility) VMMC: Unknown Age, Negative	
	Service Delivery Point (Facility) VMMC: Unknown Age, Positive	
	Service Delivery Point (Facility) VMMC: <15, Negative	
	Service Delivery Point by Agg Age (Facility) VMMC: <15, Positive	
	Service Delivery Point by Agg Age (Facility) VMMC: 15+, Negative	
	Service Delivery Point by Agg Age (Facility) VMMC: 15+, Positive	
	Service Delivery Point by Agg Age (Facility) VMMC: Unknown Age, Negative	
	Service Delivery Point by Agg Age (Facility) VMMC: Unknown Age, Positive	
	Service Delivery Point (Facility) Index: 10-14, Female, Negative	
	Service Delivery Point (Facility) Index: 10-14, Female, Positive	
	Service Delivery Point (Facility) Index: 10-14, Male, Negative	
	Service Delivery Point (Facility) Index: 10-14, Male, Positive	
	Service Delivery Point (Facility) Index: 15-19, Female, Negative	



	Service Delivery Point (Facility) Index: 15-19, Female, Positive	
	Service Delivery Point (Facility) Index: 15-19, Male, Negative	
	Service Delivery Point (Facility) Index: 15-19, Male, Positive	
	Service Delivery Point (Facility) Index: 20-24, Female, Negative	
	Service Delivery Point (Facility) Index: 20-24, Female, Positive	
	Service Delivery Point (Facility) Index: 20-24, Male, Negative	
	Service Delivery Point (Facility) Index: 20-24, Male, Positive	
	Service Delivery Point (Facility) Index: 25-49, Female, Negative	
	Service Delivery Point (Facility) Index: 25-49, Female, Positive	
	Service Delivery Point (Facility) Index: 25-49, Male, Negative	
	Service Delivery Point (Facility) Index: 25-49, Male, Positive	
	Service Delivery Point (Facility) Index: 50+, Female, Negative	
	Service Delivery Point (Facility) Index: 50+, Female, Positive	
	Service Delivery Point (Facility) Index: 50+, Male, Negative	
	Service Delivery Point (Facility) Index: 50+, Male, Positive	
	Service Delivery Point (Facility) Index: Unknown Age, Female, Negative	
	Service Delivery Point (Facility)	



	Index: Unknown Age, Female, Positive	
	Service Delivery Point (Facility) Index: Unknown Age, Male, Negative	
	Service Delivery Point (Facility) Index: Unknown Age, Male, Positive	
	Service Delivery Point (Facility) Index: <1, Negative	
	Service Delivery Point (Facility) Index: <1, Positive	
	Service Delivery Point (Facility) Index: 1-9, Negative	
	Service Delivery Point (Facility) Index: 1-9, Positive	
	Service Delivery Point Agg Age (Facility) Index: <15, Female, Negative	0
	Service Delivery Point Agg Age (Facility) Index: <15, Female, Positive	0
	Service Delivery Point Agg Age (Facility) Index: <15, Male, Negative	0
	Service Delivery Point Agg Age (Facility) Index: <15, Male, Positive	0
	Service Delivery Point Agg Age (Facility) Index: 15+, Female, Negative	25,667
	Service Delivery Point Agg Age (Facility) Index: 15+, Female, Positive	2,147
	Service Delivery Point Agg Age (Facility) Index: 15+, Male,	17,317



	Negative	
	Service Delivery Point Agg Age (Facility) Index: 15+, Male, Positive	1,449
	Service Delivery Point Agg Age (Facility) Index: Unknown Age, Female, Negative	
	Service Delivery Point Agg Age (Facility) Index: Unknown Age, Female, Positive	
	Service Delivery Point Agg Age (Facility) Index: Unknown Age, Male, Negative	
	Service Delivery Point Agg Age (Facility) Index: Unknown Age, Male, Positive	
	By Key Population: FSW, Negative	
	By Key Population: FSW, Positive	
	By Key Population: MSM, Negative	
	By Key Population: MSM, Positive	
	By Key Population: People in prisons and other enclosed settings, Negative	
	By Key Population: People in prisons and other enclosed settings, Positive	214
	By Key Population: PWID, Negative	
	By Key Population: PWID, Positive	
	By Key Population: TG, Negative	
	By Key Population: TG, Positive	
	Service Delivery Point (Facility) Malnutrition: Negative	
	Service Delivery Point (Facility) Malnutrition: Positive	



	Service Delivery Point (Community) Index Mod: 10-14, Female, Negative	
	Service Delivery Point (Community) Index Mod: 10-14, Female, Positive	
	Service Delivery Point (Community) Index Mod: 10-14, Male, Negative	
	Service Delivery Point (Community) Index Mod: 10-14, Male, Positive	
	Service Delivery Point (Community) Index Mod: 15-19, Female, Negative	
	Service Delivery Point (Community) Index Mod: 15-19, Female, Positive	
	Service Delivery Point (Community) Index Mod: 15-19, Male, Negative	
	Service Delivery Point (Community) Index Mod: 15-19, Male, Positive	
	Service Delivery Point (Community) Index Mod: 20-24, Female, Negative	
	Service Delivery Point (Community) Index Mod: 20-24, Female, Positive	
	Service Delivery Point (Community) Index Mod: 20-24, Male, Negative	
	Service Delivery Point (Community) Index Mod: 20-24, Male, Positive	
	Service Delivery Point (Community) Index Mod: 25-49, Female, Negative	
	Service Delivery Point (Community) Index Mod: 25-49, Female, Positive	
	Service Delivery Point (Community) Index Mod: 25-49, Male, Negative	



	Service Delivery Point (Community) Index Mod: 25-49, Male, Positive	
	Service Delivery Point (Community) Index Mod: 50+, Female, Negative	
	Service Delivery Point (Community) Index Mod: 50+, Female, Positive	
	Service Delivery Point (Community) Index Mod: 50+, Male, Negative	
	Service Delivery Point (Community) Index Mod: 50+, Male, Positive	
	Service Delivery Point (Community) Index Mod: Unknown Age, Female, Negative	
	Service Delivery Point (Community) Index Mod: Unknown Age, Female, Positive	
	Service Delivery Point (Community) Index Mod: Unknown Age, Male, Negative	
	Service Delivery Point (Community) Index Mod: Unknown Age, Male, Positive	
	Service Delivery Point (Community) Index Mod: <1, Negative	
	Service Delivery Point (Community) Index Mod: <1, Positive	
	Service Delivery Point (Community) Index Mod: 1-9, Negative	
	Service Delivery Point (Community) Index Mod: 1-9, Positive	
	Service Delivery Point by Agg Age (Community) Index Mod: <15, Female, Negative	
	Service Delivery Point by Agg Age	



	(Community) Index Mod: <15, Female, Positive	
	Service Delivery Point by Agg Age (Community) Index Mod: <15, Male, Negative	
	Service Delivery Point by Agg Age (Community) Index Mod: <15, Male, Positive	
	Service Delivery Point by Agg Age (Community) Index Mod: 15+, Female, Negative	
	Service Delivery Point by Agg Age (Community) Index Mod: 15+, Female, Positive	
	Service Delivery Point by Agg Age (Community) Index Mod: 15+, Male, Negative	
	Service Delivery Point by Agg Age (Community) Index Mod: 15+, Male, Positive	
	Service Delivery Point by Agg Age (Community) Index Mod: Unknown Age, Female, Negative	
	Service Delivery Point by Agg Age (Community) Index Mod: Unknown Age, Female, Positive	
	Service Delivery Point by Agg Age (Community) Index Mod: Unknown Age, Male, Negative	
	Service Delivery Point by Agg Age (Community) Index Mod: Unknown Age, Male, Positive	
	Service Delivery Point (Facility) ANC: <1, Negative	
	Service Delivery Point (Facility)	



	ANC: <1, Positive	
	Service Delivery Point (Facility) ANC: 10-14, Negative	
	Service Delivery Point (Facility) ANC: 10-14, Positive	
	Service Delivery Point (Facility) ANC: 15-19, Negative	
	Service Delivery Point (Facility) ANC: 15-19, Positive	
	Service Delivery Point (Facility) ANC: 1-9, Negative	
	Service Delivery Point (Facility) ANC: 1-9, Positive	
	Service Delivery Point (Facility) ANC: 20-24, Negative	
	Service Delivery Point (Facility) ANC: 20-24, Positive	
	Service Delivery Point (Facility) ANC: 25-49, Negative	
	Service Delivery Point (Facility) ANC: 25-49, Positive	
	Service Delivery Point (Facility) ANC: 50+, Negative	
	Service Delivery Point (Facility) ANC: 50+, Positive	
	Service Delivery Point (Facility) ANC: Unknown Age, Negative	
	Service Delivery Point (Facility) ANC: Unknown Age, Positive	
	Service Delivery Point by Agg Age (Facility) ANC: <15, Negative	
	Service Delivery Point by Agg Age (Facility) ANC: <15, Positive	
	Service Delivery Point by Agg Age	



	(Facility) ANC: 15+, Negative	
	Service Delivery Point by Agg Age (Facility) ANC: 15+, Positive	
	Service Delivery Point by Agg Age (Facility) ANC: Unknown Age, Negative	
	Service Delivery Point by Agg Age (Facility) ANC: Unknown Age, Positive	
	Service Delivery Point (Facility) VCT: 10-14, Female, Negative	
	Service Delivery Point (Facility) VCT: 10-14, Female, Positive	
	Service Delivery Point (Facility) VCT: 10-14, Male, Negative	
	Service Delivery Point (Facility) VCT: 10-14, Male, Positive	
	Service Delivery Point (Facility) VCT: 15-19, Female, Negative	
	Service Delivery Point (Facility) VCT: 15-19, Female, Positive	
	Service Delivery Point (Facility) VCT: 15-19, Male, Negative	
	Service Delivery Point (Facility) VCT: 15-19, Male, Positive	
	Service Delivery Point (Facility) VCT: 20-24, Female, Negative	
	Service Delivery Point (Facility) VCT: 20-24, Female, Positive	
	Service Delivery Point (Facility) VCT: 20-24, Male, Negative	
	Service Delivery Point (Facility) VCT: 20-24, Male, Positive	
	Service Delivery Point (Facility)	



	VCT: 25-49, Female, Negative	
	Service Delivery Point (Facility)	
	VCT: 25-49, Female, Positive	
	Service Delivery Point (Facility)	
	VCT: 25-49, Male, Negative	
	Service Delivery Point (Facility)	
	VCT: 25-49, Male, Positive	
	Service Delivery Point (Facility)	
	VCT: 50+, Female, Negative	
	Service Delivery Point (Facility)	
	VCT: 50+, Female, Positive	
	Service Delivery Point (Facility)	
	VCT: 50+, Male, Negative	
	Service Delivery Point (Facility)	
	VCT: 50+, Male, Positive	
	Service Delivery Point (Facility)	
	VCT: Unknown Age, Female, Negative	
	Service Delivery Point (Facility)	
	VCT: Unknown Age, Female, Positive	
	Service Delivery Point (Facility)	
	VCT:	
	Service Delivery Point (Facility)	
	VCT: Unknown Age, Male, Positive	
	Service Delivery Point (Facility)	
	VCT: <1, Negative	
	Service Delivery Point (Facility)	
	VCT: <1, Positive	
	Service Delivery Point (Facility)	
	VCT: 1-9, Negative	
	Service Delivery Point (Facility)	
	VCT: 1-9, Positive	
	Service Delivery Point by Agg Age	77,562



	(Facility) VCT: <15, Female, Negative	
	Service Delivery Point by Agg Age (Facility) VCT: <15, Female, Positive	827
	Service Delivery Point by Agg Age (Facility) VCT: <15, Male, Negative	52,328
	Service Delivery Point by Agg Age (Facility) VCT: <15, Male, Positive	558
	Service Delivery Point by Agg Age (Facility) VCT: 15+, Female, Negative	179,947
	Service Delivery Point by Agg Age (Facility) VCT: 15+, Female, Positive	7,557
	Service Delivery Point by Agg Age (Facility) VCT: 15+, Male, Negative	120,899
	Service Delivery Point by Agg Age (Facility) VCT: 15+, Male, Positive	5,082
	Service Delivery Point by Agg Age (Facility) VCT: Unknown Age, Female, Negative	
	Service Delivery Point by Agg Age (Facility) VCT: Unknown Age, Female, Positive	
	Service Delivery Point by Agg Age (Facility) VCT: Unknown Age, Male, Negative	
	Service Delivery Point by Agg Age (Facility) VCT: Unknown Age, Male, Positive	
	Service Delivery Point (Community) VCT Mod: 10-14, Female, Negative	
	Service Delivery Point (Community) VCT Mod: 10-14, Female, Positive	



	Service Delivery Point (Community) VCT Mod: 10-14, Male, Negative	
	Service Delivery Point (Community) VCT Mod: 10-14, Male, Positive	
	Service Delivery Point (Community) VCT Mod: 15-19, Female, Negative	
	Service Delivery Point (Community) VCT Mod: 15-19, Female, Positive	
	Service Delivery Point (Community) VCT Mod: 15-19, Male, Negative	
	Service Delivery Point (Community) VCT Mod: 15-19, Male, Positive	
	Service Delivery Point (Community) VCT Mod: 20-24, Female, Negative	
	Service Delivery Point (Community) VCT Mod: 20-24, Female, Positive	
	Service Delivery Point (Community) VCT Mod: 20-24, Male, Negative	
	Service Delivery Point (Community) VCT Mod: 20-24, Male, Positive	
	Service Delivery Point (Community) VCT Mod: 25-49, Female, Negative	
	Service Delivery Point (Community) VCT Mod: 25-49, Female, Positive	
	Service Delivery Point (Community) VCT Mod: 25-49, Male, Negative	
	Service Delivery Point (Community) VCT Mod: 25-49, Male, Positive	
	Service Delivery Point (Community) VCT Mod: 50+, Female, Negative	
	Service Delivery Point (Community) VCT Mod: 50+, Female, Positive	
	Service Delivery Point (Community) VCT Mod: 50+, Male, Negative	



	Service Delivery Point (Community) VCT Mod: 50+, Male, Positive	
	Service Delivery Point (Community) VCT Mod: Unknown Age, Female, Negative	
	Service Delivery Point (Community) VCT Mod: Unknown Age, Female, Positive	
	Service Delivery Point (Community) VCT Mod: Unknown Age, Male, Negative	
	Service Delivery Point (Community) VCT Mod: Unknown Age, Male, Positive	
	Service Delivery Point (Community) VCT Mod: <1, Negative	
	Service Delivery Point (Community) VCT Mod: <1, Positive	
	Service Delivery Point (Community) VCT Mod: 1-9, Negative	
	Service Delivery Point (Community) VCT Mod: 1-9, Positive	
	Service Delivery Point by Agg Age (Community) VCT Mod: <15, Female, Negative	
	Service Delivery Point by Agg Age (Community) VCT Mod: <15, Female, Positive	
	Service Delivery Point by Agg Age (Community) VCT Mod: <15, Male, Negative	
	Service Delivery Point by Agg Age (Community) VCT Mod: <15, Male, Positive	
	Service Delivery Point by Agg Age	



	(Community) VCT Mod: 15+, Female, Negative	
	Service Delivery Point by Agg Age (Community) VCT Mod: 15+, Female, Positive	
	Service Delivery Point by Agg Age (Community) VCT Mod: 15+, Male, Negative	
	Service Delivery Point by Agg Age (Community) VCT Mod: 15+, Male, Positive	
	Service Delivery Point by Agg Age (Community) VCT Mod: Unknown Age, Female, Negative	
	Service Delivery Point by Agg Age (Community) VCT Mod: Unknown Age, Female, Positive	
	Service Delivery Point by Agg Age (Community) VCT Mod: Unknown Age, Male, Negative	
	Service Delivery Point by Agg Age (Community) VCT Mod: Unknown Age, Male, Positive	
GEND_GBV_DSD	Number of people receiving post-GBV care	1,526
	By type of service: Physical and/or Emotional Violence (Other Post-GBV Care)	151
	By type of service: Sexual Violence (Post-Rape Care)	1,375
	By PEP service provision (related to sexual violence services provided)	883
	<10, Female, Physical and/or Emotional Violence	0



	<10, Female, Sexual Violence (Post-Rape Care)	0
	<10, Male, Physical and/or Emotional Violence	0
	<10, Male, Sexual Violence (Post-Rape Care)	0
	10-14, Female, Physical and/or Emotional Violence	0
	10-14, Female, Sexual Violence (Post-Rape Care)	0
	10-14, Male, Physical and/or Emotional Violence	0
	10-14, Male, Sexual Violence (Post-Rape Care)	0
	15-19, Female, Physical and/or Emotional Violence	0
	15-19, Female, Sexual Violence (Post-Rape Care)	0
	15-19, Male, Physical and/or Emotional Violence	0
	15-19, Male, Sexual Violence (Post-Rape Care)	0
	20-24, Female, Physical and/or Emotional Violence	0
	20-24, Female, Sexual Violence (Post-Rape Care)	0
	20-24, Male, Physical and/or Emotional Violence	0
	20-24, Male, Sexual Violence (Post-Rape Care)	0
	25-49, Female, Physical and/or Emotional Violence	0
	25-49, Female, Sexual Violence (Post-Rape Care)	0



	25-49, Male, Physical and/or Emotional Violence	0
	25-49, Male, Sexual Violence (Post-Rape Care)	0
	50+, Female, Physical and/or Emotional Violence	0
	50+, Female, Sexual Violence (Post-Rape Care)	0
	50+, Male, Physical and/or Emotional Violence	0
	50+, Male, Sexual Violence (Post-Rape Care)	0
	Unknown Age, Female, Physical and/or Emotional Violence	6
	Unknown Age, Female, Sexual Violence (Post-Rape Care)	93
	Unknown Age, Male, Physical and/or Emotional Violence	4
	Unknown Age, Male, Sexual Violence (Post-Rape Care)	3
OVC_SERV_DSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	98,923
	Age/Sex: 10-14 Male	7,384
	Age/Sex: 15-17 Male	5,366
	By: Age/sex: Male 18-24	4,034
	By: Age/sex: Male 25+	10,065
	Age/Sex: 18+ Male	
	Age/Sex: 10-14 Female	18,352
	Age/Sex: 15-17 Female	12,710
	By: Age/sex: 18-24 Female	7,349
	By: Age/sex: 25+ Female	16,870
	Age/Sex: 18+ Female	



	Sum of Age/Sex disaggregates	43,812
	Required only for DREAMS countries - By service, age and sex: Education Support Female <1	
	Required only for DREAMS countries - By service, age and sex: Education Support Female 10-14	5,742
	Required only for DREAMS countries - By service, age and sex: Education Support Female 15-17	1,609
	Required only for DREAMS countries - By service, age and sex: Education Support Female 18-24	
	Required only for DREAMS countries - By service, age and sex: Education Support Female 25+	
	Required only for DREAMS countries - By service, age and sex: Education Support Male <1	
	Required only for DREAMS countries - By service, age and sex: Education Support Male 10-14	
	Required only for DREAMS countries - By service, age and sex: Education Support Male 15-17	
	Required only for DREAMS countries - By service, age and sex: Education Support Male 18-24	
	Required only for DREAMS countries - By service, age and sex: Education Support Male 25+	



	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female <1	
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 10-14	180
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 15-17	
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 18-24	86
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 25+	1,575
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male <1	
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male 10-14	
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male 15-17	
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs	38



	Male 18-24	
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male 25+	302
	Required only for DREAMS countries - By service, age and sex: Social Protection Female <1	
	Required only for DREAMS countries - By service, age and sex: Social Protection Female 10-14	4,435
	Required only for DREAMS countries - By service, age and sex: Social Protection Female 15-17	2,104
	Required only for DREAMS countries - By service, age and sex: Social Protection Female 18-24	171
	Required only for DREAMS countries - By service, age and sex: Social Protection Female 25+	
	Required only for DREAMS countries - By service, age and sex: Social Protection Male <1	
	Required only for DREAMS countries - By service, age and sex: Social Protection Male 10-14	
	Required only for DREAMS countries - By service, age and sex: Social Protection Male 15-17	
	Required only for DREAMS countries - By service, age and sex: Social Protection Male 18-24	



	Required only for DREAMS countries - By service, age and sex: Social Protection Male 25+	
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female <1	
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 10-14	
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 15-17	
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 18-24	187
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 25+	2,668
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Male <1	
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Male 10-14	
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Male 15-17	



	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Male 18-24	32
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Male 25+	712
	Required only for DREAMS countries - By service, age and sex: Other Services Female <1	
	Required only for DREAMS countries - By service, age and sex: Other Services Female 10-14	
	Required only for DREAMS countries - By service, age and sex: Other Services Female 15-17	
	Required only for DREAMS countries - By service, age and sex: Other Services Female 18-24	4
	Required only for DREAMS countries - By service, age and sex: Other Services Female 25+	81
	Required only for DREAMS countries - By service, age and sex: Other Services Male <1	
	Required only for DREAMS countries - By service, age and sex: Other Services Male 10-14	
	Required only for DREAMS countries - By service, age and sex: Other Services Male 15-17	
	Required only for DREAMS countries - By service, age and sex: Other Services Male 18-24	2



	Required only for DREAMS countries - By service, age and sex: Other Services Male 25+	54
	Age/Sex: <1	3,358
	Age/Sex: 1-9	13,427
	Required only for DREAMS countries - By service, age and sex: Education Support 1-9 Male	
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male 1-9	
	Required only for DREAMS countries - By service, age and sex: Social Protection Programs Male 1-9	
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Male 1-9	
	Required only for DREAMS countries - By service, age and sex: Other Services Male 1-9	
	Program Completion: Active	73,308
	Program Completion: Graduation	2,036
	Program Completion: Transferred	20,029
	Program Completion: Exited without graduation	3,550
	By Aggregated Age/Sex: <18 Male	
	By Aggregated Age/Sex: 18+ Male	
	By Aggregated Age/Sex: <18 Female	
	By Aggregated Age/Sex: 18+ Female	



	Required only for DREAMS countries - By service, age and sex: Education Support Female 1-9	
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 1-9	
	Required only for DREAMS countries - By service, age and sex: Social Protection Programs Female 1-9	
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 1-9	
	Required only for DREAMS countries - By service, age and sex: Other Services Female 1-9	
TB_ART_DSD	TB_ART_DSD Percentage of HIV-positive new and relapsed registered TB cases on ART during TB treatment	100 %
	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	1,658
	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	1,658
	Age/Sex: <1 (Numerator: The number of registered new and relapse TB cases with documented	



	HIV-positive status who are on ART during TB treatment during the reporting period)	
	Age/Sex: 1-9 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Age/Sex: Male 10-14 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Age/Sex: Male 15-19 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Age/Sex: Male 20-24 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Age/Sex: Male 25-49 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Age/Sex: Male 50+ (Numerator: The number of registered new and relapse TB cases with documented	



	HIV-positive status who are on ART during TB treatment during the reporting period)	
	Age/Sex: Female 10-14 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Age/Sex: Female 15-19 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Age/Sex: Female 20-24 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Age/Sex: Female 25-49 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Age/Sex: Female 50+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during	



	the reporting period)	
	Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	26
	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	717
	Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	47
	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	866
	On ART: Already on ART	
	On ART: New on ART	
	Age/Sex: >1 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting	



	period)	
	Age/Sex: 1-9 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Age/Sex: Male 10-14 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Age/Sex: Male 15-19 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Age/Sex: Male 20-24 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Age/Sex: Male 25-49 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Age/Sex: Male 50+ (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting	



	period)	
	Age/Sex: Female 10-14 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Age/Sex: Female 15-19 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Age/Sex: Female 20-24 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Age/Sex: Female 25-49 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Age/Sex: Female 50+ (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Aggregated Age/Sex: Male <15 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment	26



	during the reporting period)	
	Aggregated Age/Sex: Male 15+ (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	721
	Aggregated Age/Sex: Female <15 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	47
	Aggregated Age/Sex: Female 15+ (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	864
TB_PREV_DSD	TB_PREV_DSD TB_PREV_DSD	90 %
	The number of ART patients who completed a course of TB preventive therapy or at least 6 months of Isoniazid Preventive Therapy (IPT) during the reporting period	19,878
	The number of ART patients who were newly started on TB preventive therapy (including those who newly started on TB preventive therapy in this reporting period and those who started in the previous reporting period but had not been reported as they did not fulfill the minimum requirements for the previous reporting period).	22,070



	By Age/Sex (Denominator): <15, Female	707
	By Age/Sex (Denominator): <15, Male	472
	By Age/Sex (Denominator): 15+, Female	13,187
	By Age/Sex (Denominator): 15+, Male	7,699
	By Therapy type (Denominator): 6-12 Month IPT	
	By Therapy type (Denominator): Alternative Regimen	
	By Therapy type (Denominator): Continuous IPT	
	By Age/Sex (Numerator): <15, Female	643
	By Age/Sex (Numerator): <15, Male	485
	By Age/Sex (Numerator): 15+, Female	11,783
	By Age/Sex (Numerator): 15+, Male	6,962
	By Therapy type (Numerator): 6-12 Month IPT	
	By Therapy type (Numerator): Alternative Regimen	
	By Therapy type (Numerator): Continuous IPT	
TX_TB_DSD	TX_TB_DSD The proportion of ART patients who were screened who are receiving TB treatment	2 %
	Number of ART patients who were started on TB treatment during the reporting period.	1,442



	Number of ART patients who were screened for TB at least once during the reporting period	93,464
	Numerator: By Aggregated Age/Sex: <15, Female	19
	Numerator: By Aggregated Age/Sex: <15, Male	31
	Numerator: By Aggregated Age/Sex: 15+, Female	865
	Numerator: By Aggregated Age/Sex: 15+, Male	526
	Denominator: By Aggregated Age/Sex: <15, Female	3,113
	Denominator: By Aggregated Age/Sex: <15, Male	2,066
	Denominator: By Aggregated Age/Sex: 15+, Female	55,552
	Denominator: By Aggregated Age/Sex: 15+, Male	32,730
	Denominator: By Screen Result: Negative	86,929
	Denominator: By Screen Result: Positive	6,531
	Denominator: Number of ART patients who had a specimen sent for bacteriologic diagnosis of active TB disease	18,694
	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Other (No Xpert)	0
	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Smear Only	9,350
	Denominator: By Diagnostic Test	9,348



	[Subdisagg of Specimen Sent]: Gene Xpert MTB / R if Assay	
PMTCT_EID_DSD	PMTCT_EID_DSD Percent of infants born to HIV-positive women that receive a virological HIV test within 12 months of birth (DSD)	n/a
	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	4,785
	Number of HIV- positive pregnant women identified during the reporting period (include known HIV-positive women at entry into PMTCT)	
	By infants who received a virologic test within 2 months of birth	
	By infants who received their first virologic HIV test between 2 and 12 months of age	
	Sum of Infant Age disaggregates	
	By infants with a positive virologic test result within 12 months of birth	
	Number of infants with a positive virological test result within 2 months of birth	53
	Number of infants with a positive virological test result within 12 months of birth	
	Unknown, <= 2 months	
	Unknown, 2 - 12 months	
	Number of infants with a negative virological test result within 2 months of birth	2,546
	Number of infants with a positive virological test result between 2	83



	and 12 months of birth	
	Number of infants with a negative virological test result between 2 and 12 months of birth	2,103
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	107,524
	Age/Sex: 15-19 Male	
	Age/Sex: 15-19 Female	
	Age/Sex: 20+ Female	
	Aggregated Age/Sex: <1 Male	
	Aggregated Age/Sex: <1 Female	
	Aggregated Age/Sex: <15 Male	2,216
	Aggregated Age/Sex: 15+ Male	40,935
	Aggregated Age/Sex: <15 Female	3,286
	Aggregated Age/Sex: 1-14 Female	
	Aggregated Age/Sex: 15+ Female	60,907
	Sum of Aggregated Age/Sex <15	5,502
	Sum of Aggregated Age/Sex 15+	101,842
	Sum of Aggregated Age/Sex disaggregates	107,344
	Age/Sex: <1	
	Age/Sex: <1-9	
	Age/Sex: 10-14 Male	
	Age/Sex: 10-14 Female	
	Aggregated Age/Sex: 1-14 Male	
	Age/Sex: 20-24 Male	
	Age/Sex: 25-49 Male	
	Age/Sex: 50+ Male	
Age/Sex: 20-24 Female		
Age/Sex: 25-49 Female		
Age/Sex: 50+ Female		



TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	25,364
	By Age/Sex: <1	
	By Age/Sex: 1-9	
	By Age/Sex: 10-14 Male	
	By Age/Sex: 15-19 Male	
	By Age/Sex: 20-24 Male	
	By Age/Sex: 25-49 Male	
	By Age/Sex: 50+ Male	
	By Age/Sex: 10-14 Female	
	By Age/Sex: 15-19 Female	
	By Age/Sex: 20-24 Female	
	By Age/Sex: 25-49 Female	
	By Age/Sex: 50+ Female	
	Aggregated Grouping by Age: <1	
	Aggregated Grouping by Age: <1 Male	
	Aggregated Grouping by Age/Sex: <15 Male	641
	Aggregated Grouping by Age/Sex: 1-14 Male	
	Aggregated Grouping by Age/Sex: 15+ Male	10,148
	Aggregated Grouping by Age/Sex: <1 Female	
	Aggregated Grouping by Age/Sex: <15 Female	639
Aggregated Grouping by Age/Sex: 15+ Female	13,932	
Pregnancy status	2,750	
Breastfeeding status	0	
FSW		



	MSM	
	People in prisons and other enclosed settings	165
	TG	
	Aggregated Grouping by Age/Sex: 1-14 Female	
	By Key populations: People who inject drugs (PWID)	
TX_PVLS_DSD	TX_PVLS_DSD Percentage of ART patients with a viral load result documented in the medical record and/or laboratory information systems (LIS) within the past 12 months with a suppressed viral load (<1000 copies/ml)	75 %
	Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months.	80,572
	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	107,442
	Numerator: Indication: Routine	72,513
	Numerator: Indication: Targeted	8,059
	Numerator: Preg/BF by Indication: Pregnant Routine	4,115
	Numerator: Preg/BF by Indication: Breastfeeding Routine	0
	Numerator: Preg/BF by Indication: Pregnant Targeted	0
	Numerator: Preg/BF by Indication:	0



	Breastfeeding Targeted	
	Numerator: Age/Sex by Indication: <1 Routine	
	Numerator: Age/Sex by Indication: 1-9 Routine	
	Numerator: Age/Sex by Indication: 10-14 Male Routine	
	Numerator: Age/Sex by Indication: 15-19 Male Routine	
	Numerator: Age/Sex by Indication: 20-24 Male Routine	
	Numerator: Age/Sex by Indication: 25-49 Male Routine	
	Numerator: Age/Sex by Indication: 50+ Male Routine	
	Numerator: Age/Sex by Indication: 10-14 Female Routine	
	Numerator: Age/Sex by Indication: 15-19 Female Routine	
	Numerator: Age/Sex by Indication: 20-24 Female Routine	
	Numerator: Age/Sex by Indication: 25-49 Female Routine	
	Numerator: Age/Sex by Indication: 50+ Female Routine	
	Numerator: Age/Sex by Indication: <1 Targeted	
	Numerator: Age/Sex by Indication: 1-9 Targeted	
	Numerator: Age/Sex by Indication: 10-14 Male Targeted	
	Numerator: Age/Sex by Indication: 15-19 Male Targeted	
	Numerator: Age/Sex by Indication:	



	20-24 Male Targeted	
	Numerator: Age/Sex by Indication: 25-49 Male Targeted	
	Numerator: Age/Sex by Indication: 50+ Male Targeted	
	Numerator: Age/Sex by Indication: 10-14 Female Targeted	
	Numerator: Age/Sex by Indication: 15-19 Female Targeted	
	Numerator: Age/Sex by Indication: 20-24 Female Targeted	
	Numerator: Age/Sex by Indication: 25-49 Female Targeted	
	Numerator: Age/Sex by Indication: 50+ Female Targeted	
	Numerator: Aggregate Age/Sex by Indication: <15 Male Targeted	172
	Numerator: Aggregate Age/Sex by Indication: 15+ Male Targeted	2,809
	Numerator: Aggregate Age/Sex by Indication: <15 Female Targeted	257
	Numerator: Aggregate Age/Sex by Indication: 15+ Female Targeted	4,804
	Numerator: Aggregate Age/Sex by Indication: <15 Male Routine	1,590
	Numerator: Aggregate Age/Sex by Indication: 15+ Male Routine	25,248
	Numerator: Aggregate Age/Sex by Indication: <15 Female Routine	2,405
	Numerator: Aggregate Age/Sex by Indication: 15+ Female Routine	43,270
	Denominator: Indication: Routine	94,838
	Denominator: Indication: Targeted	10,633
	Denominator: Preg/BF by	4,076



	Indication: Pregnant Routine	
	Denominator: Preg/BF by Indication: Breastfeeding Routine	0
	Denominator: Preg/BF by Indication: Pregnant Targeted	0
	Denominator: Preg/BF by Indication: Breastfeeding Targeted	0
	Denominator: Age/Sex by Indication: <1 Routine	
	Denominator: Age/Sex by Indication: 1-9 Routine	
	Denominator: Age/Sex by Indication: 10-14 Male Routine	
	Denominator: Age/Sex by Indication: 15-19 Male Routine	
	Denominator: Age/Sex by Indication: 20-24 Male Routine	
	Denominator: Age/Sex by Indication: 25-49 Male Routine	
	Denominator: Age/Sex by Indication: 50+ Male Routine	
	Denominator: Age/Sex by Indication: 10-14 Female Routine	
	Denominator: Age/Sex by Indication: 15-19 Female Routine	
	Denominator: Age/Sex by Indication: 20-24 Female Routine	
	Denominator: Age/Sex by Indication: 25-49 Female Routine	
	Denominator: Age/Sex by Indication: 50+ Female Routine	
	Denominator: Age/Sex by Indication: <1 Targeted	
	Denominator: Age/Sex by	



	Indication: 1-9 Targeted	
	Denominator: Age/Sex by Indication: 10-14 Male Targeted	
	Denominator: Age/Sex by Indication: 15-19 Male Targeted	
	Denominator: Age/Sex by Indication: 20-24 Male Targeted	
	Denominator: Age/Sex by Indication: 25-49 Male Targeted	
	Denominator: Age/Sex by Indication: 50+ Male Targeted	
	Denominator: Age/Sex by Indication: 10-14 Female Targeted	
	Denominator: Age/Sex by Indication: 15-19 Female Targeted	
	Denominator: Age/Sex by Indication: 20-24 Female Targeted	
	Denominator: Age/Sex by Indication: 25-49 Female Targeted	
	Denominator: Age/Sex by Indication: 50+ Female Targeted	
	Denominator: Aggregate Age/Sex by Indication: <15 Male Targeted	225
	Denominator: Aggregate Age/Sex by Indication: 15+ Male Targeted	3,754
	Denominator: Aggregate Age/Sex by Indication: <15 Female Targeted	350
	Denominator: Aggregate Age/Sex by Indication: 15+ Female Targeted	6,407
	Denominator: Aggregate Age/Sex by Indication: <15 Male Routine	2,114
	Denominator: Aggregate Age/Sex by Indication: 15+ Male Routine	33,667
	Denominator: Aggregate Age/Sex	3,209



	by Indication: <15 Female Routine	
	Denominator: Aggregate Age/Sex by Indication: 15+ Female Routine	57,693
	Numerator Aggregated Age/Sex: <15 Male	
	Numerator Aggregated Age/Sex: 15+ Male	
	Numerator Aggregated Age/Sex: <15 Female	
	Numerator Aggregated Age/Sex: 15+ Female	
	Denominator Aggregated Age/Sex: <15 Male	
	Denominator Aggregated Age/Sex: 15+ Male	
	Denominator Aggregated Age/Sex: <15 Female	
	Denominator Aggregated Age/Sex: 15+ Female	
	<15, Routine, Unknown Sex	
	<15, Targeted, Unknown Sex	
	<15, Undocumented Test Indication, Female	0
	<15, Undocumented Test Indication, Male	0
	<15, Undocumented Test Indication, Unknown Sex	
	15+, Routine, Unknown Sex	
	15+, Targeted, Unknown Sex	
	15+, Undocumented Test Indication, Female	0
	15+, Undocumented Test Indication, Male	0
	15+, Undocumented Test	



	Indication, Unknown Sex	
	Unknown Age, Routine, Female	
	Unknown Age, Routine, Male	
	Unknown Age, Routine, Unknown Sex	
	Unknown Age, Targeted, Female	
	Unknown Age, Targeted, Male	
	Unknown Age, Targeted, Unknown Sex	
	Unknown Age, Undocumented Test Indication, Female	
	Unknown Age, Undocumented Test Indication, Male	
	Unknown Age, Undocumented Test Indication, Unknown Sex	
	Breastfeeding, Undocumented Test Indication	0
	Pregnant, Undocumented Test Indication	0
	Undocumented Test Indication	0
	<15, Routine, Unknown Sex	0
	<15, Targeted, Unknown Sex	
	<15, Undocumented Test Indication, Female	0
	<15, Undocumented Test Indication, Male	0
	<15, Undocumented Test Indication, Unknown Sex	
	15+, Routine, Unknown Sex	0
	15+, Targeted, Unknown Sex	
	15+, Undocumented Test Indication, Female	0
	15+, Undocumented Test	0



	Indication, Male	
	15+, Undocumented Test Indication, Unknown Sex	
	Unknown Age, Routine, Female	
	Unknown Age, Routine, Male	
	Unknown Age, Routine, Unknown Sex	
	Unknown Age, Targeted, Female	
	Unknown Age, Targeted, Male	
	Unknown Age, Targeted, Unknown Sex	
	Unknown Age, Undocumented Test Indication, Female	
	Unknown Age, Undocumented Test Indication, Male	
	Unknown Age, Undocumented Test Indication, Unknown Sex	
	Breastfeeding, Undocumented Test Indication	0
	Pregnant, Undocumented Test Indication	0
	Undocumented Test Indication	0
TX_RET_DSD	TX_RET_DSD Percent of adults and children known to be alive and on treatment 12 months after initiation of antiretroviral therapy	76 %
	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	17,085
	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have	22,357



	stopped ART, and those lost to follow-up	
	Age/Sex: <1 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Age/Sex: 1-9 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Age/Sex: 10-14 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Age/Sex: 15-19 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Age/Sex: 20-24 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Age/Sex: 25-49 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Age/Sex: 50+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Age/Sex: 10-14 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	



	Age/Sex: 15-19 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Age/Sex: 20-24 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Age/Sex: 25-49 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Age/Sex: 50+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Age/Sex: >1 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Age/Sex: 1-9 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Age/Sex: 10-14 Male (Denominator: Total number of adults and children who initiated	



	ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Age/Sex: 15-19 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Age/Sex: 20-24 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Age/Sex: 25-49 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Age/Sex: 50+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to	



	follow-up)	
	Age/Sex: 10-14 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Age/Sex: 15-19 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Age/Sex: 20-24 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Age/Sex: 25-49 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Age/Sex: 50+ Female (Denominator: Total number of adults and children who initiated	



	ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Aggregated Age: <15 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Aggregated Age: 15+ (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Aggregated Age: <15 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Aggregated Age: 15+ (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Numerator by Status: Pregnant	2,379
	Numerator by Status: Breastfeeding	0
	Denominator by Status: Pregnant	2,379
	Denominator by Status: Breastfeeding	0



	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	341
	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	6,369
	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	495
	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	9,877
	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	446
	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	7,882



	<p>Aggregated Age/Sex: &lt;15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)</p>	<p>663</p>
	<p>Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)</p>	<p>13,361</p>



## Partners and Implementing Mechanisms

### Partner List

Mech ID	Partner Name	Organization Type	Agency	Funding Source	Planned Funding
10639	Global Health Supply Chain Program	Private Contractor	U.S. Agency for International Development	GHP-State	12,429,765
12608	Ministre de la Sante Publique et Population, Haiti	Host Country Government Agency	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	0
12692	Ministre de la Sante Publique et Population, Haiti	Host Country Government Agency	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	14,882,542
12708	Promoteurs Objectif Zéro Sida (Promoteurs de l'Objectif Zéro Sida)	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	0
13569	University of Miami School of Medicine	University	U.S. Department of Health and Human Services/Centers	GHP-State	0



			for Disease Control and Prevention		
13620	Groupe Haitien d'Etude du Sarcome de Kaposi et des Infections Opportunistes	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	0
13621	Palladium Group	NGO	U.S. Agency for International Development	GHP-State	0
13744	Groupe Haitien d'Etude du Sarcome de Kaposi et des Infections Opportunistes	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	0
14564	Management Sciences for Health	NGO	U.S. Agency for International Development	GHP-State	0
14624	University of Maryland	University	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	0
14627	Catholic Medical Mission Board	FBO	U.S. Department of Health and Human Services/Centers for Disease Control and	GHP-State	0



			Prevention		
14706	Foundation for Reproductive Health and Family Education	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	0
14710	University of Washington	University	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	0
14761	Health Through Walls	NGO	U.S. Agency for International Development	GHP-State	800,000
14766	JHPIEGO	University	U.S. Agency for International Development	GHP-State	0
16722	Abt Associates	Private Contractor	U.S. Agency for International Development	GHP-State	500,000
16801	Caris Foundation	NGO	U.S. Agency for International Development	GHP-State	4,585,119
16856	University of Washington	University	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	2,425,500
17691	Ministre de la	Host Country	U.S. Department	GHP-State	0



	Sante Publique et Population, Haiti	Government Agency	of Health and Human Services/Centers for Disease Control and Prevention		
17692	Pathfinder International	NGO	U.S. Agency for International Development	GHP-State	0
18018	FHI 360	NGO	U.S. Agency for International Development	GHP-State	2,616,452
18047	National Alliance of State and Territorial AIDS Directors	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	1,320,000
18050	Center for Development and Health	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	1,125,000
18086	Measure Evaluation	NGO	U.S. Agency for International Development	GHP-State	300,000
18266	Groupe Haitien d'Etude du Sarcome de Kaposi et des Infections Opportunistes	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	3,000,000



18267	Partners in Health	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	6,900,000
18268	Catholic Medical Mission Board	FBO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	5,600,000
18269	Groupe Haitien d'Etude du Sarcome de Kaposi et des Infections Opportunistes	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	4,895,000
18270	Foundation for Reproductive Health and Family Education	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	1,300,000
18425	Right To Care, South Africa	NGO	U.S. Agency for International Development	GHP-State	2,400,000
18443	JHPIEGO	University	U.S. Agency for International Development	GHP-State	0
18623	Catholic Relief Services	FBO	U.S. Agency for International	GHP-State	2,275,680

Approved



			Development		
18624	US Bureau of the Census	Other USG Agency	U.S. Agency for International Development	GHP-State	250,000
18625	TBD	TBD	Redacted	Redacted	Redacted
18626	Ministry of Health, Haiti	Host Country Government Agency	U.S. Agency for International Development	GHP-State	250,000
18631	TBD	TBD	Redacted	Redacted	Redacted



## Implementing Mechanism(s)

### Implementing Mechanism Details

<b>Mechanism ID: 10639</b>	<b>Mechanism Name: Global Health Supply Chain Program</b>
Funding Agency: USAID	Procurement Type: Contract
Prime Partner Name: Global Health Supply Chain Program	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:
<b>Total All Funding Sources: 12,429,765</b>	
<b>Total Mechanism Pipeline: N/A</b>	
<b>Applied Pipeline Amount: 15,600,000</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 28,029,765</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	12,429,765

### Cross-Cutting Budget Attribution(s)

Water	477,684
-------	---------

### Budget Code Information

<b>Mechanism ID:</b>	10639		
<b>Mechanism Name:</b>	Global Health Supply Chain Program		
<b>Prime Partner Name:</b>	Global Health Supply Chain Program		
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	HBHC	0	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>



Care	HKID	605,281	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	HVTB	0	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	PDCS	0	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Governance and Systems	HLAB	0	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Governance and Systems	HVSI	0	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Governance and Systems	OHSS	0	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	HVCT	0	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	HVOP	0	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	MTCT	0	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Treatment	HTXD	11,824,484	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Treatment	HTXS	0	0



Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	0	0

### Implementing Mechanism Indicator Information

(No data provided.)

### Implementing Mechanism Details

<b>Mechanism ID: 12608</b>	<b>Mechanism Name: Blood Safety</b>
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Ministre de la Sante Publique et Population, Haiti	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

<b>Total All Funding Sources: 0</b>	<b>Total Mechanism Pipeline: N/A</b>
<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 0</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	0

### Cross-Cutting Budget Attribution(s)

(No data provided.)

### Budget Code Information

<b>Mechanism ID:</b>	12608
<b>Mechanism Name:</b>	Blood Safety
<b>Prime Partner Name:</b>	Ministre de la Sante Publique et Population, Haiti



Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	0	0

### Implementing Mechanism Indicator Information

(No data provided.)

### Implementing Mechanism Details

<b>Mechanism ID: 12692</b>	<b>Mechanism Name: MSPP/UGP (National AIDS Strategic Plan)</b>
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Ministre de la Sante Publique et Population, Haiti	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: Yes	Managing Agency: HHS/CDC

<b>Total All Funding Sources: 14,882,542</b>	<b>Total Mechanism Pipeline: N/A</b>
<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 14,882,542</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	14,882,542

### Cross-Cutting Budget Attribution(s)

Key Populations: MSM and TG	500,000
Focus Area:	Training of health workers and community outreach workers
Focus Area:	Collection and use of strategic information
Focus Area:	Implementation of core HIV prevention interventions for MSM/TG that are consistent with the current PEPFAR technical guidance



Focus Area:	Monitoring and evaluation of MSM/TG programs
Key Populations: FSW	500,000
Focus Area:	Implementation of core HIV prevention interventions for SWs consistent with PEPFAR guidance on sexual prevention
Focus Area:	Training of health workers and community outreach workers
Focus Area:	Collection and use of strategic information on SWs and clients
Focus Area:	Monitoring and evaluation of SW programs
Gender: GBV	750,000
Focus Area:	GBV Prevention
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Focus Area:	Post GBV Care
Sub Area:	Capacity building
Gender: Gender Equality	450,000
Focus Area:	Promoting gender-related policies and laws that increase legal protection
Sub Area:	Monitoring and Evaluation
Focus Area:	Changing harmful gender norms and promoting positive gender norms
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Human Resources for Health	500,000
Construction	135,000
Motor Vehicles: Purchased	240,000

### Budget Code Information

<b>Mechanism ID:</b>	<b>12692</b>
----------------------	--------------



<b>Mechanism Name:</b> MSPP/UGP (National AIDS Strategic Plan)			
<b>Prime Partner Name:</b> Ministre de la Sante Publique et Population, Haiti			
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	HBHC	637,665	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	HKID	1,296,688	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	HVTB	582,098	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	PDCS	180,127	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Governance and Systems	HLAB	1,214,201	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Governance and Systems	HVSI	1,743,109	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Governance and Systems	OHSS	1,349,800	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	HVCT	1,822,745	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	MTCT	980,091	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Treatment	HTXS	4,874,169	0



Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	201,849	0

### Implementing Mechanism Indicator Information

Indicator Number	Label	2018
PMTCT_ART_DSD	Number of HIV-positive pregnant women who received ART to reduce risk of mother-to-child-transmission (MTCT) during pregnancy	1,215
PMTCT_ART_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	67,970
PMTCT_ART_DSD	New on ART	699
PMTCT_ART_DSD	Already on ART at beginning of current pregnancy	516
PMTCT_STAT_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	67,970
PMTCT_STAT_DSD	By Age (Denominator): Unknown Age	70,068
PMTCT_STAT_DSD	By Number of known positives: Unknown Age	587
PMTCT_STAT_DSD	By Number of new positives: Unknown Age	683
PMTCT_STAT_DSD	By Number of new negative: Unknown Age	66,695
PMTCT_STAT_DSD	By Age (Numerator): Unknown Age	1,275
PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	1,275
PP_PREV_DSD	Age/sex: 10-14 Female	738
PP_PREV_DSD	Age/sex: 15-19 Female	537
PP_PREV_DSD	Sum of Age/Sex disaggregates	1,275
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	211,396
HTC_TST_DSD	By Test Result: Positive	5,362



HTC_TST_DSD	Sum of Test Result disaggregates	5,362
HTC_TST_DSD	Service Delivery Point by Agg Age (Community) Homebased testing: 15+, Female, Negative	108
HTC_TST_DSD	Service Delivery Point by Agg Age (Community) Homebased testing: 15+, Female, Positive	3
HTC_TST_DSD	Service Delivery Point by Agg Age (Community) Homebased testing: 15+, Male, Negative	72
HTC_TST_DSD	Service Delivery Point by Agg Age (Community) Homebased testing: 15+, Male, Positive	2
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Inpatient: 15+, Female, Negative	33
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Inpatient: 15+, Female, Positive	2
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Inpatient: 15+, Male, Negative	23
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Inpatient: 15+, Male, Positive	1
HTC_TST_DSD	Service Delivery Point by Agg Age(Community) Mobile Testing: 15+, Female, Negative	113
HTC_TST_DSD	Service Delivery Point by Agg Age(Community) Mobile Testing: 15+, Female, Positive	3
HTC_TST_DSD	Service Delivery Point by Agg Age(Community) Mobile Testing: 15+, Male, Negative	76
HTC_TST_DSD	Service Delivery Point by Agg Age(Community) Mobile Testing: 15+, Male, Positive	2
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Other PITC: 15+, Female, Negative	20,906
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Other PITC: 15+, Female, Positive	471
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Other PITC: 15+, Male, Negative	13,959
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Other PITC: 15+, Male, Positive	313
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) TB: 15+,	961



	Female, Negative	
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) TB: 15+, Female, Positive	87
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) TB: 15+, Male, Negative	641
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) TB: 15+, Male, Positive	57
HTC_TST_DSD	Service Delivery Point Agg Age (Facility) Index: 15+, Female, Negative	5,848
HTC_TST_DSD	Service Delivery Point Agg Age (Facility) Index: 15+, Female, Positive	449
HTC_TST_DSD	Service Delivery Point Agg Age (Facility) Index: 15+, Male, Negative	3,898
HTC_TST_DSD	Service Delivery Point Agg Age (Facility) Index: 15+, Male, Positive	299
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) VCT: <15, Female, Negative	20,266
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) VCT: <15, Female, Positive	212
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) VCT: <15, Male, Negative	13,512
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) VCT: <15, Male, Positive	141
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) VCT: 15+, Female, Negative	37,686
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) VCT: 15+, Female, Positive	1,205
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) VCT: 15+, Male, Negative	25,125
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) VCT: 15+, Male, Positive	802
TB_STAT_DSD	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	2,661
TB_STAT_DSD	Total number of registered new and relapsed TB cases,	2,844



	during the reporting period.	
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	53
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	1,013
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	78
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	1,517
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	55
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	1,087
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	82
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	1,620
GEND_GBV_DSD	Number of people receiving post-GBV care	863
GEND_GBV_DSD	By type of service: Physical and/or Emotional Violence (Other Post-GBV Care)	85
GEND_GBV_DSD	By type of service: Sexual Violence (Post-Rape Care)	778
GEND_GBV_DSD	By PEP service provision (related to sexual violence services provided)	287
GEND_GBV_DSD	Unknown Age, Female, Sexual Violence (Post-Rape Care)	1
OVC_SERV_DSD	Number of active beneficiaries served by PEPFAR	12,430



	OVC programs for children and families affected by HIV/AIDS	
OVC_SERV_DSD	Age/Sex: 10-14 Male	1,093
OVC_SERV_DSD	Age/Sex: 15-17 Male	795
OVC_SERV_DSD	By: Age/sex: Male 18-24	598
OVC_SERV_DSD	By: Age/sex: Male 25+	1,493
OVC_SERV_DSD	Age/Sex: 10-14 Female	1,640
OVC_SERV_DSD	Age/Sex: 15-17 Female	1,192
OVC_SERV_DSD	By: Age/sex: 18-24 Female	894
OVC_SERV_DSD	By: Age/sex: 25+ Female	2,235
OVC_SERV_DSD	Sum of Age/Sex disaggregates	4,720
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support Female 10-14	210
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support Female 15-17	75
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 25+	246
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male 25+	110
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Social Protection Female 10-14	275
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Social Protection Female 15-17	177
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Social Protection Female 18-24	17
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 18-24	17
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 25+	371
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Male 18-24	11
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Male 25+	248



OVC_SERV_DSD	Age/Sex: <1	499
OVC_SERV_DSD	Age/Sex: 1-9	1,989
OVC_SERV_DSD	Program Completion: Active	9,656
OVC_SERV_DSD	Program Completion: Graduation	364
OVC_SERV_DSD	Program Completion: Transferred	2,042
OVC_SERV_DSD	Program Completion: Exited without graduation	368
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	316
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	316
TB_ART_DSD	Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	3
TB_ART_DSD	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	128
TB_ART_DSD	Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	8
TB_ART_DSD	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	177
TB_ART_DSD	Aggregated Age/Sex: Male <15 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	3
TB_ART_DSD	Aggregated Age/Sex: Male 15+ (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment)	130



	during the reporting period)	
TB_ART_DSD	Aggregated Age/Sex: Female <15 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	8
TB_ART_DSD	Aggregated Age/Sex: Female 15+ (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	175
PMTCT_EID_DSD	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	1,211
PMTCT_EID_DSD	Number of infants with a positive virological test result within 2 months of birth	11
PMTCT_EID_DSD	Number of infants with a negative virological test result within 2 months of birth	645
PMTCT_EID_DSD	Number of infants with a positive virological test result between 2 and 12 months of birth	18
PMTCT_EID_DSD	Number of infants with a negative virological test result between 2 and 12 months of birth	537
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	24,585
TX_CURR_DSD	Aggregated Age/Sex: <15 Male	485
TX_CURR_DSD	Aggregated Age/Sex: 15+ Male	9,347
TX_CURR_DSD	Aggregated Age/Sex: <15 Female	729
TX_CURR_DSD	Aggregated Age/Sex: 15+ Female	14,020
TX_CURR_DSD	Sum of Aggregated Age/Sex <15	1,214
TX_CURR_DSD	Sum of Aggregated Age/Sex 15+	23,367
TX_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	24,581
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	5,188
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Male	159
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Male	2,047
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Female	162
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Female	2,817



TX_NEW_DSD	Sum of Aggregated Age/Sex disaggregates	5,185
TX_NEW_DSD	Pregnancy status	697
TX_PVLS_DSD	Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months.	18,441
TX_PVLS_DSD	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	24,587
TX_PVLS_DSD	Numerator: Indication: Routine	16,594
TX_PVLS_DSD	Numerator: Indication: Targeted	1,847
TX_PVLS_DSD	Numerator: Preg/BF by Indication: Pregnant Routine	928
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: <15 Male Targeted	36
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: 15+ Male Targeted	646
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: <15 Female Targeted	54
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: 15+ Female Targeted	1,106
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: <15 Male Routine	333
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: 15+ Male Routine	5,807
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: <15 Female Routine	500
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: 15+ Female Routine	9,953
TX_PVLS_DSD	Denominator: Indication: Routine	22,124
TX_PVLS_DSD	Denominator: Indication: Targeted	2,459
TX_PVLS_DSD	Denominator: Preg/BF by Indication: Pregnant Routine	928
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Male Targeted	48
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+	863



	Male Targeted	
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Female Targeted	72
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Female Targeted	1,476
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Male Routine	443
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Male Routine	7,745
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Female Routine	663
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Female Routine	13,271
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	3,361
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	4,441
TX_RET_DSD	Numerator by Status: Pregnant	478
TX_RET_DSD	Denominator by Status: Pregnant	478
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	64
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	1,246
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	91
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	1,960
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Denominator: Total	89



	number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	1,555
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	134
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	2,661
TB_PREV_DSD	The number of ART patients who completed a course of TB preventive therapy or at least 6 months of Isoniazid Preventive Therapy (IPT) during the reporting period	4,001
TB_PREV_DSD	The number of ART patients who were newly started on TB preventive therapy (including those who newly started on TB preventive therapy in this reporting period and those who started in the previous reporting period but had not been reported as they did not fulfill the minimum requirements for the previous reporting period).	4,440
TB_PREV_DSD	By Age/Sex (Denominator): <15, Female	133
TB_PREV_DSD	By Age/Sex (Denominator): <15, Male	89
TB_PREV_DSD	By Age/Sex (Denominator): 15+, Female	2,663
TB_PREV_DSD	By Age/Sex (Denominator): 15+, Male	1,554
TB_PREV_DSD	By Age/Sex (Numerator): <15, Female	119



TB_PREV_DSD	By Age/Sex (Numerator): <15, Male	82
TB_PREV_DSD	By Age/Sex (Numerator): 15+, Female	2,396
TB_PREV_DSD	By Age/Sex (Numerator): 15+, Male	1,400
TX_TB_DSD	Number of ART patients who were started on TB treatment during the reporting period.	452
TX_TB_DSD	Number of ART patients who were screened for TB at least once during the reporting period	22,602
TX_TB_DSD	Numerator: By Aggregated Age/Sex: <15, Female	6
TX_TB_DSD	Numerator: By Aggregated Age/Sex: <15, Male	10
TX_TB_DSD	Numerator: By Aggregated Age/Sex: 15+, Female	273
TX_TB_DSD	Numerator: By Aggregated Age/Sex: 15+, Male	163
TX_TB_DSD	Denominator: By Aggregated Age/Sex: <15, Female	678
TX_TB_DSD	Denominator: By Aggregated Age/Sex: <15, Male	452
TX_TB_DSD	Denominator: By Aggregated Age/Sex: 15+, Female	13,558
TX_TB_DSD	Denominator: By Aggregated Age/Sex: 15+, Male	7,912
TX_TB_DSD	Denominator: By Screen Result: Negative	22,147
TX_TB_DSD	Denominator: By Screen Result: Positive	452
TX_TB_DSD	Denominator: Number of ART patients who had a specimen sent for bacteriologic diagnosis of active TB disease	4,520
TX_TB_DSD	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Other (No Xpert)	0
TX_TB_DSD	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Smear Only	2,260
TX_TB_DSD	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Gene Xpert MTB / R if Assay	2,258

### Implementing Mechanism Details

<b>Mechanism ID: 12708</b>	<b>Mechanism Name: POZ</b>
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Promoteurs Objectif Zéro Sida (Promoteurs de l'Objectif Zéro Sida)	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No

Approved



Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:
<b>Total All Funding Sources: 0</b>	<b>Total Mechanism Pipeline: N/A</b>
<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 0</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	0

### Cross-Cutting Budget Attribution(s)

(No data provided.)

### Budget Code Information

<b>Mechanism ID:</b>	12708		
<b>Mechanism Name:</b>	POZ		
<b>Prime Partner Name:</b>	Promoteurs Objectif Zéro Sida (Promoteurs de l'Objectif Zéro Sida)		
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	HBHC	0	0

### Implementing Mechanism Indicator Information

(No data provided.)

### Implementing Mechanism Details

<b>Mechanism ID: 13569</b>	<b>Mechanism Name: University of Miami</b>
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: University of Miami School of Medicine	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No



Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:
<b>Total All Funding Sources: 0</b>	<b>Total Mechanism Pipeline: N/A</b>
<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 0</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	0

**Cross-Cutting Budget Attribution(s)**

(No data provided.)

**Budget Code Information**

<b>Mechanism ID:</b> 13569			
<b>Mechanism Name:</b> University of Miami			
<b>Prime Partner Name:</b> University of Miami School of Medicine			
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	HBHC	0	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	HVTB	0	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	PDCS	0	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Governance and Systems	HVSI	0	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>



Governance and Systems	OHSS	0	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	HVCT	0	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	MTCT	0	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Treatment	HTXS	0	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Treatment	PDTX	0	0

### Implementing Mechanism Indicator Information

(No data provided.)

### Implementing Mechanism Details

<b>Mechanism ID: 13620</b>	<b>Mechanism Name: GHESKIO 0545</b>
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Groupe Haitien d'Etude du Sarcome de Kaposi et des Infections Opportunistes	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

<b>Total All Funding Sources: 0</b>	<b>Total Mechanism Pipeline: N/A</b>
<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 0</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	0



**Cross-Cutting Budget Attribution(s)**

(No data provided.)

**Budget Code Information**

<b>Mechanism ID:</b>	13620		
<b>Mechanism Name:</b>	GHESKIO 0545		
<b>Prime Partner Name:</b>	Groupe Haitien d'Etude du Sarcome de Kaposi et des Infections Opportunistes		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	0	0



Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	0	0

**Implementing Mechanism Indicator Information**

(No data provided.)

**Implementing Mechanism Details**

<b>Mechanism ID: 13621</b>	<b>Mechanism Name: Support to UPE</b>
Funding Agency: USAID	Procurement Type: Contract
Prime Partner Name: Palladium Group	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:
<b>Total All Funding Sources: 0</b>	<b>Total Mechanism Pipeline: N/A</b>
<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 0</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	0

**Cross-Cutting Budget Attribution(s)**

(No data provided.)

**Budget Code Information**

<b>Mechanism ID:</b>	13621
<b>Mechanism Name:</b>	Support to UPE
<b>Prime Partner Name:</b>	Palladium Group



Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HKID	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	0	0

### Implementing Mechanism Indicator Information

(No data provided.)

### Implementing Mechanism Details

<b>Mechanism ID: 13744</b>	<b>Mechanism Name: GHESKIO 541</b>
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Groupe Haitien d'Etude du Sarcome de Kaposi et des Infections Opportunistes	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

<b>Total All Funding Sources: 0</b>	<b>Total Mechanism Pipeline: N/A</b>
<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 0</b>	
Funding Source	Funding Amount
GHP-State	0

### Cross-Cutting Budget Attribution(s)

(No data provided.)



**Budget Code Information**

<b>Mechanism ID:</b>	13744		
<b>Mechanism Name:</b>	GHESKIO 541		
<b>Prime Partner Name:</b>	Groupe Haitien d'Etude du Sarcome de Kaposi et des Infections Opportunistes		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HKID	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount



Treatment	PDTX	0	0
-----------	------	---	---

### Implementing Mechanism Indicator Information

(No data provided.)

### Implementing Mechanism Details

<b>Mechanism ID: 14564</b>	<b>Mechanism Name: LMG (Leadership, Management and Governance)</b>
Funding Agency: USAID	Procurement Type: Contract
Prime Partner Name: Management Sciences for Health	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

<b>Total All Funding Sources: 0</b>	<b>Total Mechanism Pipeline: N/A</b>
<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 0</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	0

### Cross-Cutting Budget Attribution(s)

(No data provided.)

### Budget Code Information

<b>Mechanism ID:</b>	14564		
<b>Mechanism Name:</b>	LMG (Leadership, Management and Governance)		
<b>Prime Partner Name:</b>	Management Sciences for Health		
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>



Governance and Systems	OHSS	0	0

### Implementing Mechanism Indicator Information

(No data provided.)

### Implementing Mechanism Details

<b>Mechanism ID: 14624</b>	<b>Mechanism Name: University of Maryland</b>
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: University of Maryland	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

<b>Total All Funding Sources: 0</b>	<b>Total Mechanism Pipeline: N/A</b>
<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 0</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	0

### Cross-Cutting Budget Attribution(s)

(No data provided.)

### Budget Code Information

<b>Mechanism ID:</b>	14624
<b>Mechanism Name:</b>	University of Maryland
<b>Prime Partner Name:</b>	University of Maryland



Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	0	0

### Implementing Mechanism Indicator Information

(No data provided.)

### Implementing Mechanism Details

<b>Mechanism ID: 14627</b>	<b>Mechanism Name: Catholic Medical Mission Board</b>
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Catholic Medical Mission Board	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

<b>Total All Funding Sources: 0</b>	<b>Total Mechanism Pipeline: N/A</b>
<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 0</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	0

### Cross-Cutting Budget Attribution(s)

(No data provided.)

### Budget Code Information

<b>Mechanism ID: 14627</b>
----------------------------



<b>Mechanism Name:</b> Catholic Medical Mission Board			
<b>Prime Partner Name:</b> Catholic Medical Mission Board			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	0	0

### Implementing Mechanism Indicator Information

(No data provided.)

### Implementing Mechanism Details

<b>Mechanism ID:</b> 14706	<b>Mechanism Name:</b> FOSREF
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Foundation for Reproductive Health and Family Education	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

<b>Total All Funding Sources:</b> 0	<b>Total Mechanism Pipeline:</b> N/A
<b>Applied Pipeline Amount:</b> 0	
<b>Total All Funding Sources and Applied Pipeline Amount:</b> 0	
Funding Source	Funding Amount
GHP-State	0

### Cross-Cutting Budget Attribution(s)

(No data provided.)

### Budget Code Information

<b>Mechanism ID:</b> 14706
----------------------------



<b>Mechanism Name:</b> FOSREF			
<b>Prime Partner Name:</b> Foundation for Reproductive Health and Family Education			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	0	0

### Implementing Mechanism Indicator Information

(No data provided.)

### Implementing Mechanism Details

<b>Mechanism ID:</b> 14710	<b>Mechanism Name:</b> ITECH 549
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: University of Washington	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

<b>Total All Funding Sources:</b> 0	<b>Total Mechanism Pipeline:</b> N/A
<b>Applied Pipeline Amount:</b> 0	
<b>Total All Funding Sources and Applied Pipeline Amount:</b> 0	
Funding Source	Funding Amount
GHP-State	0

### Cross-Cutting Budget Attribution(s)

(No data provided.)

### Budget Code Information

<b>Mechanism ID:</b> 14710
----------------------------



<b>Mechanism Name:</b> ITECH 549			
<b>Prime Partner Name:</b> University of Washington			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	0	0

### Implementing Mechanism Indicator Information

(No data provided.)

### Implementing Mechanism Details

<b>Mechanism ID:</b> 14761	<b>Mechanism Name:</b> HTW (Health Through Walls)
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Health Through Walls	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

<b>Total All Funding Sources:</b> 800,000	<b>Total Mechanism Pipeline:</b> N/A
<b>Applied Pipeline Amount:</b> 0	
<b>Total All Funding Sources and Applied Pipeline Amount:</b> 800,000	
Funding Source	Funding Amount
GHP-State	800,000

### Cross-Cutting Budget Attribution(s)

Human Resources for Health	24,000
Education	8,000
Water	8,000



### Budget Code Information

<b>Mechanism ID:</b> 14761			
<b>Mechanism Name:</b> HTW (Health Through Walls)			
<b>Prime Partner Name:</b> Health Through Walls			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	255,676	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	28,266	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	207,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	306,100	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	2,958	0

### Implementing Mechanism Indicator Information

Indicator Number	Label	2018
KP_PREV_DSD	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	4,600
KP_PREV_DSD	By key population type: People in prisons and enclosed settings (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	4,600
HTC_TST_DSD	Number of individuals who received T&C services for	9,510



	HIV and received their test results during the past 12 months	
HTC_TST_DSD	By Test Result: Positive	214
HTC_TST_DSD	Sum of Test Result disaggregates	214
HTC_TST_DSD	Service Delivery Point by Agg Age(Community) Mobile Testing: 15+, Female, Negative	2
HTC_TST_DSD	Service Delivery Point by Agg Age(Community) Mobile Testing: 15+, Male, Negative	59
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Other PITC: 15+, Female, Negative	751
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Other PITC: 15+, Female, Positive	16
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Other PITC: 15+, Male, Negative	1,208
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Other PITC: 15+, Male, Positive	24
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) TB: 15+, Female, Negative	41
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) TB: 15+, Female, Positive	3
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) TB: 15+, Male, Negative	68
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) TB: 15+, Male, Positive	7
HTC_TST_DSD	Service Delivery Point Agg Age (Facility) Index: 15+, Female, Negative	234
HTC_TST_DSD	Service Delivery Point Agg Age (Facility) Index: 15+, Female, Positive	17
HTC_TST_DSD	Service Delivery Point Agg Age (Facility) Index: 15+, Male, Negative	363
HTC_TST_DSD	Service Delivery Point Agg Age (Facility) Index: 15+, Male, Positive	26
HTC_TST_DSD	By Key Population: People in prisons and other enclosed settings, Positive	214



HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) VCT: <15, Female, Negative	73
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) VCT: <15, Female, Positive	1
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) VCT: <15, Male, Negative	667
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) VCT: <15, Male, Positive	6
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) VCT: 15+, Female, Negative	1,136
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) VCT: 15+, Female, Positive	45
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) VCT: 15+, Male, Negative	1,686
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) VCT: 15+, Male, Positive	71
TB_STAT_DSD	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	44
TB_STAT_DSD	Total number of registered new and relapsed TB cases, during the reporting period.	52
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	18
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	26
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	22
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	30
GEND_GBV_DSD	Number of people receiving post-GBV care	0
GEND_GBV_DSD	By type of service: Physical and/or Emotional Violence	0



	(Other Post-GBV Care)	
GEND_GBVDSD	By type of service: Sexual Violence (Post-Rape Care)	0
GEND_GBVDSD	By PEP service provision (related to sexual violence services provided)	0
OVC_SERV_DSD	Age/Sex: 10-14 Male	0
OVC_SERV_DSD	Age/Sex: 15-17 Male	0
OVC_SERV_DSD	By: Age/sex: Male 18-24	0
OVC_SERV_DSD	By: Age/sex: Male 25+	0
OVC_SERV_DSD	Age/Sex: 10-14 Female	0
OVC_SERV_DSD	Age/Sex: 15-17 Female	0
OVC_SERV_DSD	By: Age/sex: 18-24 Female	0
OVC_SERV_DSD	By: Age/sex: 25+ Female	0
OVC_SERV_DSD	Sum of Age/Sex disaggregates	0
OVC_SERV_DSD	Age/Sex: <1	0
OVC_SERV_DSD	Age/Sex: 1-9	0
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	12
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	12
TB_ART_DSD	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	12
TB_ART_DSD	Aggregated Age/Sex: Male 15+ (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	11
TB_ART_DSD	Aggregated Age/Sex: Female 15+ (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	1
TX_CURR_DSD	Number of adults and children receiving antiretroviral	832



	therapy (ART)	
TX_CURR_DSD	Aggregated Age/Sex: <15 Male	22
TX_CURR_DSD	Aggregated Age/Sex: 15+ Male	516
TX_CURR_DSD	Aggregated Age/Sex: <15 Female	3
TX_CURR_DSD	Aggregated Age/Sex: 15+ Female	291
TX_CURR_DSD	Sum of Aggregated Age/Sex <15	25
TX_CURR_DSD	Sum of Aggregated Age/Sex 15+	807
TX_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	832
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	165
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Male	7
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Male	104
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Female	1
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Female	53
TX_NEW_DSD	Sum of Aggregated Age/Sex disaggregates	165
TX_NEW_DSD	People in prisons and other enclosed settings	165
TX_PVLS_DSD	Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months.	623
TX_PVLS_DSD	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	832
TX_PVLS_DSD	Numerator: Indication: Routine	562
TX_PVLS_DSD	Numerator: Indication: Targeted	61
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: <15 Male Targeted	1
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: 15+ Male Targeted	21
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: <15 Female Targeted	2
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: 15+ Female Targeted	36



TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: <15 Male Routine	11
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: 15+ Male Routine	197
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: <15 Female Routine	16
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: 15+ Female Routine	337
TX_PVLS_DSD	Denominator: Indication: Routine	748
TX_PVLS_DSD	Denominator: Indication: Targeted	84
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Male Targeted	1
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Male Targeted	30
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Female Targeted	2
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Female Targeted	50
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Male Routine	14
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Male Routine	263
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Female Routine	20
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Female Routine	452
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	362
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	481
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment	7



	at 12 months after initiating ART)	
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	129
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	9
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	217
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	8
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	171
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	12
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	290
TB_PREV_DSD	The number of ART patients who completed a course of TB preventive therapy or at least 6 months of Isoniazid Preventive Therapy (IPT) during the reporting period	435
TB_PREV_DSD	The number of ART patients who were newly started on	480



	TB preventive therapy (including those who newly started on TB preventive therapy in this reporting period and those who started in the previous reporting period but had not been reported as they did not fulfill the minimum requirements for the previous reporting period).	
TB_PREV_DSD	By Age/Sex (Denominator): <15, Female	12
TB_PREV_DSD	By Age/Sex (Denominator): <15, Male	8
TB_PREV_DSD	By Age/Sex (Denominator): 15+, Female	290
TB_PREV_DSD	By Age/Sex (Denominator): 15+, Male	170
TB_PREV_DSD	By Age/Sex (Numerator): <15, Female	11
TB_PREV_DSD	By Age/Sex (Numerator): <15, Male	7
TB_PREV_DSD	By Age/Sex (Numerator): 15+, Female	262
TB_PREV_DSD	By Age/Sex (Numerator): 15+, Male	155
TX_TB_DSD	Number of ART patients who were started on TB treatment during the reporting period.	14
TX_TB_DSD	Number of ART patients who were screened for TB at least once during the reporting period	624
TX_TB_DSD	Numerator: By Aggregated Age/Sex: 15+, Female	4
TX_TB_DSD	Numerator: By Aggregated Age/Sex: 15+, Male	10
TX_TB_DSD	Denominator: By Aggregated Age/Sex: <15, Female	9
TX_TB_DSD	Denominator: By Aggregated Age/Sex: <15, Male	22
TX_TB_DSD	Denominator: By Aggregated Age/Sex: 15+, Female	200
TX_TB_DSD	Denominator: By Aggregated Age/Sex: 15+, Male	393
TX_TB_DSD	Denominator: By Screen Result: Negative	610
TX_TB_DSD	Denominator: By Screen Result: Positive	14
TX_TB_DSD	Denominator: Number of ART patients who had a specimen sent for bacteriologic diagnosis of active TB disease	123
TX_TB_DSD	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Smear Only	64
TX_TB_DSD	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Gene Xpert MTB / R if Assay	64



### Implementing Mechanism Details

<b>Mechanism ID: 14766</b>	<b>Mechanism Name: SSQH Nord (Services de Santé de Qualité pour Haïti)</b>		
Funding Agency: USAID	Procurement Type: Contract		
Prime Partner Name: JHPIEGO			
Agreement Start Date: Redacted	Agreement End Date: Redacted		
TBD: No	New Mechanism: No		
Global Fund / Multilateral Engagement: N/A			
G2G: No	Managing Agency:		
<b>Total All Funding Sources: 0</b>		<b>Total Mechanism Pipeline: N/A</b>	
<b>Applied Pipeline Amount: 0</b>			
<b>Total All Funding Sources and Applied Pipeline Amount: 0</b>			
<b>Funding Source</b>	<b>Funding Amount</b>		
GHP-State	0		

### Cross-Cutting Budget Attribution(s)

(No data provided.)

### Budget Code Information

<b>Mechanism ID: 14766</b>			
<b>Mechanism Name: SSQH Nord (Services de Santé de Qualité pour Haïti)</b>			
<b>Prime Partner Name: JHPIEGO</b>			
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	HBHC	0	0

### Implementing Mechanism Indicator Information

(No data provided.)



### Implementing Mechanism Details

<b>Mechanism ID: 16722</b>	<b>Mechanism Name: HFG (Health Financing and Governance)</b>
Funding Agency: USAID	Procurement Type: Contract
Prime Partner Name: Abt Associates	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

<b>Total All Funding Sources: 500,000</b>	<b>Total Mechanism Pipeline: N/A</b>
<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 500,000</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	500,000

### Cross-Cutting Budget Attribution(s)

(No data provided.)

### Budget Code Information

<b>Mechanism ID:</b>	16722		
<b>Mechanism Name:</b>	HFG (Health Financing and Governance)		
<b>Prime Partner Name:</b>	Abt Associates		
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Governance and Systems	OHSS	500,000	0

### Implementing Mechanism Indicator Information



(No data provided.)

**Implementing Mechanism Details**

<b>Mechanism ID: 16801</b>	<b>Mechanism Name: BEST (Byen en ak Sante Timoun)</b>
Funding Agency: USAID	Procurement Type: Contract
Prime Partner Name: Caris Foundation	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

<b>Total All Funding Sources: 4,585,119</b>	<b>Total Mechanism Pipeline: N/A</b>
<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 4,585,119</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	4,585,119

**Cross-Cutting Budget Attribution(s)**

Gender: GBV	50,000
Focus Area:	GBV Prevention
Sub Area:	Collection and Use of Gender-related Strategic Information
Focus Area:	Post GBV Care
Economic Strengthening	584,144
Education	584,144
Water	25,000
Food and Nutrition: Policy, Tools, and Service Delivery	23,843



### Budget Code Information

<b>Mechanism ID:</b> 16801			
<b>Mechanism Name:</b> BEST (Byen en ak Sante Timoun)			
<b>Prime Partner Name:</b> Caris Foundation			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HKID	4,085,119	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	250,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	250,000	0

### Implementing Mechanism Indicator Information

Indicator Number	Label	2018
PMTCT_ART_DSD	Number of HIV-positive pregnant women who received ART to reduce risk of mother-to-child-transmission (MTCT) during pregnancy	0
PMTCT_ART_DSD	New on ART	0
PMTCT_ART_DSD	Already on ART at beginning of current pregnancy	0
PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	4,910
PP_PREV_DSD	Age/sex: 10-14 Female	2,855
PP_PREV_DSD	Age/sex: 15-19 Female	2,077
PP_PREV_DSD	Sum of Age/Sex disaggregates	4,932
KP_PREV_DSD	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum	2,310



	standards required	
KP_PREV_DSD	By key population type: Female sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	2,310
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	1,846
HTC_TST_DSD	By Test Result: Positive	155
HTC_TST_DSD	Sum of Test Result disaggregates	155
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Other PITC: 15+, Female, Negative	94
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Other PITC: 15+, Female, Positive	14
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Other PITC: 15+, Male, Negative	62
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Other PITC: 15+, Male, Positive	9
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) TB: <15, Female, Negative	0
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) TB: <15, Female, Positive	0
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) TB: <15, Male, Negative	0
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) TB: <15, Male, Positive	0
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) TB: 15+, Female, Negative	10
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) TB: 15+, Female, Positive	3
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) TB: 15+, Male, Negative	7
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) TB: 15+, Male, Positive	2



	Male, Positive	
HTC_TST_DSD	Service Delivery Point Agg Age (Facility) Index: 15+, Female, Negative	22
HTC_TST_DSD	Service Delivery Point Agg Age (Facility) Index: 15+, Female, Positive	19
HTC_TST_DSD	Service Delivery Point Agg Age (Facility) Index: 15+, Male, Negative	15
HTC_TST_DSD	Service Delivery Point Agg Age (Facility) Index: 15+, Male, Positive	12
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) VCT: 15+, Female, Negative	350
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) VCT: 15+, Female, Positive	57
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) VCT: 15+, Male, Negative	234
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) VCT: 15+, Male, Positive	38
TB_STAT_DSD	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	0
TB_STAT_DSD	Total number of registered new and relapsed TB cases, during the reporting period.	0
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	0
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	0
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	0
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	0
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Denominator: Total	0



	number of registered new and relapsed TB cases, during the reporting period)	
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	0
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	0
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	0
GEND_GBV_DSD	Number of people receiving post-GBV care	0
GEND_GBV_DSD	By type of service: Physical and/or Emotional Violence (Other Post-GBV Care)	0
GEND_GBV_DSD	By type of service: Sexual Violence (Post-Rape Care)	0
GEND_GBV_DSD	By PEP service provision (related to sexual violence services provided)	0
OVC_SERV_DSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	48,173
OVC_SERV_DSD	Age/Sex: 10-14 Male	4,240
OVC_SERV_DSD	Age/Sex: 15-17 Male	3,080
OVC_SERV_DSD	By: Age/sex: Male 18-24	2,314
OVC_SERV_DSD	By: Age/sex: Male 25+	5,774
OVC_SERV_DSD	Age/Sex: 10-14 Female	6,364
OVC_SERV_DSD	Age/Sex: 15-17 Female	4,631
OVC_SERV_DSD	By: Age/sex: 18-24 Female	3,468
OVC_SERV_DSD	By: Age/sex: 25+ Female	8,663
OVC_SERV_DSD	Sum of Age/Sex disaggregates	18,315
OVC_SERV_DSD	Age/Sex: <1	1,926
OVC_SERV_DSD	Age/Sex: 1-9	7,709
OVC_SERV_DSD	Program Completion: Active	32,930
OVC_SERV_DSD	Program Completion: Graduation	860



OVC_SERV_DSD	Program Completion: Transferred	12,240
OVC_SERV_DSD	Program Completion: Exited without graduation	2,143
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	1
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	1
TB_ART_DSD	Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	0
TB_ART_DSD	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	1
TB_ART_DSD	Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	0
TB_ART_DSD	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	0
TB_ART_DSD	Aggregated Age/Sex: Male <15 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	0
TB_ART_DSD	Aggregated Age/Sex: Male 15+ (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	1
TB_ART_DSD	Aggregated Age/Sex: Female <15 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment	0



	during the reporting period)	
TB_ART_DSD	Aggregated Age/Sex: Female 15+ (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	0
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	152
TX_CURR_DSD	Aggregated Age/Sex: 15+ Male	61
TX_CURR_DSD	Aggregated Age/Sex: 15+ Female	91
TX_CURR_DSD	Sum of Aggregated Age/Sex 15+	152
TX_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	152
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	144
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Male	0
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Male	60
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Female	0
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Female	84
TX_NEW_DSD	Sum of Aggregated Age/Sex disaggregates	144
TX_PVLS_DSD	Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months.	114
TX_PVLS_DSD	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	152
TX_PVLS_DSD	Numerator: Indication: Routine	103
TX_PVLS_DSD	Numerator: Indication: Targeted	11
TX_PVLS_DSD	Numerator: Preg/BF by Indication: Pregnant Routine	0
TX_PVLS_DSD	Numerator: Preg/BF by Indication: Breastfeeding Routine	0
TX_PVLS_DSD	Numerator: Preg/BF by Indication: Pregnant Targeted	0
TX_PVLS_DSD	Numerator: Preg/BF by Indication: Breastfeeding Targeted	0



TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: <15 Male Targeted	0
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: 15+ Male Targeted	4
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: <15 Female Targeted	0
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: 15+ Female Targeted	7
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: <15 Male Routine	2
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: 15+ Male Routine	36
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: <15 Female Routine	3
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: 15+ Female Routine	62
TX_PVLS_DSD	Denominator: Indication: Routine	137
TX_PVLS_DSD	Denominator: Indication: Targeted	15
TX_PVLS_DSD	Denominator: Preg/BF by Indication: Pregnant Routine	0
TX_PVLS_DSD	Denominator: Preg/BF by Indication: Breastfeeding Routine	0
TX_PVLS_DSD	Denominator: Preg/BF by Indication: Pregnant Targeted	0
TX_PVLS_DSD	Denominator: Preg/BF by Indication: Breastfeeding Targeted	0
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Male Targeted	0
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Male Targeted	6
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Female Targeted	0
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Female Targeted	9
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Male Routine	3



TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Male Routine	48
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Female Routine	4
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Female Routine	82
TX_PVLS_DSD	<15, Undocumented Test Indication, Female	0
TX_PVLS_DSD	<15, Undocumented Test Indication, Male	0
TX_PVLS_DSD	15+, Undocumented Test Indication, Female	0
TX_PVLS_DSD	15+, Undocumented Test Indication, Male	0
TX_PVLS_DSD	Breastfeeding, Undocumented Test Indication	0
TX_PVLS_DSD	Pregnant, Undocumented Test Indication	0
TX_PVLS_DSD	Undocumented Test Indication	0
TX_PVLS_DSD	<15, Undocumented Test Indication, Female	0
TX_PVLS_DSD	<15, Undocumented Test Indication, Male	0
TX_PVLS_DSD	15+, Undocumented Test Indication, Female	0
TX_PVLS_DSD	15+, Undocumented Test Indication, Male	0
TX_PVLS_DSD	Breastfeeding, Undocumented Test Indication	0
TX_PVLS_DSD	Pregnant, Undocumented Test Indication	0
TX_PVLS_DSD	Undocumented Test Indication	0
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	0
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	0
TX_RET_DSD	Numerator by Status: Pregnant	0
TX_RET_DSD	Numerator by Status: Breastfeeding	0
TX_RET_DSD	Denominator by Status: Pregnant	0
TX_RET_DSD	Denominator by Status: Breastfeeding	0
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	0



TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	0
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	0
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	0
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	0
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	0
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	0
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	0
TB_PREV_DSD	The number of ART patients who completed a course of TB preventive therapy or at least 6 months of Isoniazid Preventive Therapy (IPT) during the reporting period	0
TB_PREV_DSD	The number of ART patients who were newly started on TB preventive therapy (including those who newly	0



	started on TB preventive therapy in this reporting period and those who started in the previous reporting period but had not been reported as they did not fulfill the minimum requirements for the previous reporting period).	
TB_PREV_DSD	By Age/Sex (Denominator): <15, Female	0
TB_PREV_DSD	By Age/Sex (Denominator): <15, Male	0
TB_PREV_DSD	By Age/Sex (Denominator): 15+, Female	0
TB_PREV_DSD	By Age/Sex (Denominator): 15+, Male	0
TB_PREV_DSD	By Age/Sex (Numerator): <15, Female	0
TB_PREV_DSD	By Age/Sex (Numerator): <15, Male	0
TB_PREV_DSD	By Age/Sex (Numerator): 15+, Female	0
TB_PREV_DSD	By Age/Sex (Numerator): 15+, Male	0

### Implementing Mechanism Details

<b>Mechanism ID: 16856</b>	<b>Mechanism Name: ITECH 1331</b>
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: University of Washington	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

<b>Total All Funding Sources: 2,425,500</b>	<b>Total Mechanism Pipeline: N/A</b>
<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 2,425,500</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	2,425,500

### Cross-Cutting Budget Attribution(s)

Key Populations: MSM and TG	20,000
Focus Area:	Training of health workers and community outreach



	workers
Key Populations: FSW	30,000
Gender: GBV	10,000
Focus Area:	GBV Prevention
Sub Area:	Collection and Use of Gender-related Strategic Information
Education	200,000
Human Resources for Health	150,000

**Budget Code Information**

<b>Mechanism ID:</b> 16856			
<b>Mechanism Name:</b> ITECH 1331			
<b>Prime Partner Name:</b> University of Washington			
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	HBHC	520,454	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Governance and Systems	HLAB	175,000	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Governance and Systems	HVSI	350,000	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Governance and Systems	OHSS	285,000	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	HVCT	75,000	0



Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	25,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	970,046	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	25,000	0

### Implementing Mechanism Indicator Information

(No data provided.)

### Implementing Mechanism Details

<b>Mechanism ID: 17691</b>	<b>Mechanism Name: MSPP Research</b>
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Ministre de la Sante Publique et Population, Haiti	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

<b>Total All Funding Sources: 0</b>	<b>Total Mechanism Pipeline: N/A</b>
<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 0</b>	
Funding Source	Funding Amount
GHP-State	0

### Cross-Cutting Budget Attribution(s)

(No data provided.)



### Budget Code Information

<b>Mechanism ID:</b> 17691			
<b>Mechanism Name:</b> MSPP Research			
<b>Prime Partner Name:</b> Ministre de la Sante Publique et Population, Haiti			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	0	0

### Implementing Mechanism Indicator Information

(No data provided.)

### Implementing Mechanism Details

<b>Mechanism ID:</b> 17692	<b>Mechanism Name:</b> SSQH Centre/Sud (Services de Santé de Qualité pour Haïti)
Funding Agency: USAID	Procurement Type: Contract
Prime Partner Name: Pathfinder International	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

<b>Total All Funding Sources:</b> 0	<b>Total Mechanism Pipeline:</b> N/A
<b>Applied Pipeline Amount:</b> 0	
<b>Total All Funding Sources and Applied Pipeline Amount:</b> 0	
Funding Source	Funding Amount
GHP-State	0

### Cross-Cutting Budget Attribution(s)

(No data provided.)



**Budget Code Information**

<b>Mechanism ID:</b> 17692			
<b>Mechanism Name:</b> SSQH Centre/Sud (Services de Santé de Qualité pour Haïti)			
<b>Prime Partner Name:</b> Pathfinder International			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	0	0

**Implementing Mechanism Indicator Information**

(No data provided.)

**Implementing Mechanism Details**

<b>Mechanism ID:</b> 18018		<b>Mechanism Name:</b> Linkages	
Funding Agency: USAID		Procurement Type: Contract	
Prime Partner Name: FHI 360			
Agreement Start Date: Redacted		Agreement End Date: Redacted	
TBD: No		New Mechanism: No	
Global Fund / Multilateral Engagement: N/A			
G2G: No		Managing Agency:	

<b>Total All Funding Sources:</b> 2,616,452		<b>Total Mechanism Pipeline:</b> N/A	
<b>Applied Pipeline Amount:</b> 0			
<b>Total All Funding Sources and Applied Pipeline Amount:</b> 2,616,452			
Funding Source	Funding Amount		
GHP-State	2,616,452		

**Cross-Cutting Budget Attribution(s)**

Key Populations: FSW	654,169
Focus Area:	Implementation of core HIV prevention interventions



	for SWs consistent with PEPFAR guidance on sexual prevention
Gender: GBV	100,000
Focus Area:	Post GBV Care
Sub Area:	Collection and Use of Gender-related Strategic Information
Key Populations: MSM and TG	1,962,283
Focus Area:	GBV Prevention
Focus Area:	Post GBV Care
Sub Area:	Implementation

**Budget Code Information**

<b>Mechanism ID:</b> 18018 <b>Mechanism Name:</b> Linkages <b>Prime Partner Name:</b> FHI 360			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	400,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	41	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	245,996	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	1,126,796	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	224	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount



Treatment	HTXS	843,395	0
-----------	------	---------	---

### Implementing Mechanism Indicator Information

Indicator Number	Label	2018
PMTCT_ART_DSD	Number of HIV-positive pregnant women who received ART to reduce risk of mother-to-child-transmission (MTCT) during pregnancy	0
PMTCT_ART_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	16
PMTCT_ART_DSD	New on ART	0
PMTCT_ART_DSD	Already on ART at beginning of current pregnancy	0
PMTCT_STAT_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	16
PMTCT_STAT_DSD	By Age (Denominator): Unknown Age	17
PMTCT_STAT_DSD	By Number of new negative: Unknown Age	16
PMTCT_STAT_DSD	By Age (Numerator): Unknown Age	14
PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	9,467
PP_PREV_DSD	Age/sex: 10-14 Male	0
PP_PREV_DSD	Age/sex: 15-19 Male	46
PP_PREV_DSD	Age/sex: 20-24 Male	100
PP_PREV_DSD	Age/sex: 25-49 Male	272
PP_PREV_DSD	Age/sex: 50+ Male	0
PP_PREV_DSD	Age/sex: 10-14 Female	0
PP_PREV_DSD	Age/sex: 15-19 Female	1,580
PP_PREV_DSD	Age/sex: 20-24 Female	1,586
PP_PREV_DSD	Age/sex: 25-49 Female	5,883



PP_PREV_DSD	Age/sex: 50+ Female	0
PP_PREV_DSD	Sum of Age/Sex disaggregates	9,467
KP_PREV_DSD	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	53,738
KP_PREV_DSD	By key population type: Men who have sex with men who are sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	550
KP_PREV_DSD	By key population type: Men who have sex with men who are NOT sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	14,520
KP_PREV_DSD	By key population type: Transgender who are sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	0
KP_PREV_DSD	By key population type: Transgender who are NOT sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	0
KP_PREV_DSD	By key population type: Female sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	38,668
KP_PREV_DSD	By key population type: Males who inject drugs ( Male PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet	0



	the minimum standards required)	
KP_PREV_DSD	By key population type: Females who inject drugs (Female PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	0
KP_PREV_DSD	By key population type: People in prisons and enclosed settings (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	0
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	28,371
HTC_TST_DSD	By Test Result: Positive	2,371
HTC_TST_DSD	Sum of Test Result disaggregates	2,371
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Other PITC: 15+, Female, Negative	2,018
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Other PITC: 15+, Female, Positive	205
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Other PITC: 15+, Male, Negative	1,346
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Other PITC: 15+, Male, Positive	135
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) TB: <15, Female, Negative	0
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) TB: <15, Female, Positive	0
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) TB: <15, Male, Negative	0
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) TB: <15, Male, Positive	0
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) TB: 15+, Female, Negative	29



HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) TB: 15+, Female, Positive	32
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) TB: 15+, Male, Negative	19
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) TB: 15+, Male, Positive	21
HTC_TST_DSD	Service Delivery Point Agg Age (Facility) Index: 15+, Female, Negative	341
HTC_TST_DSD	Service Delivery Point Agg Age (Facility) Index: 15+, Female, Positive	129
HTC_TST_DSD	Service Delivery Point Agg Age (Facility) Index: 15+, Male, Negative	227
HTC_TST_DSD	Service Delivery Point Agg Age (Facility) Index: 15+, Male, Positive	86
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) VCT: 15+, Female, Negative	11,972
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) VCT: 15+, Female, Positive	1,229
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) VCT: 15+, Male, Negative	7,983
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) VCT: 15+, Male, Positive	820
GEND_GBV_DSD	Number of people receiving post-GBV care	0
GEND_GBV_DSD	By type of service: Physical and/or Emotional Violence (Other Post-GBV Care)	0
GEND_GBV_DSD	By type of service: Sexual Violence (Post-Rape Care)	0
GEND_GBV_DSD	By PEP service provision (related to sexual violence services provided)	0
GEND_GBV_DSD	<10, Female, Physical and/or Emotional Violence	0
GEND_GBV_DSD	<10, Female, Sexual Violence (Post-Rape Care)	0
GEND_GBV_DSD	<10, Male, Physical and/or Emotional Violence	0
GEND_GBV_DSD	<10, Male, Sexual Violence (Post-Rape Care)	0
GEND_GBV_DSD	10-14, Female, Physical and/or Emotional Violence	0
GEND_GBV_DSD	10-14, Female, Sexual Violence (Post-Rape Care)	0



GEND_GBV_DSD	10-14, Male, Physical and/or Emotional Violence	0
GEND_GBV_DSD	10-14, Male, Sexual Violence (Post-Rape Care)	0
GEND_GBV_DSD	15-19, Female, Physical and/or Emotional Violence	0
GEND_GBV_DSD	15-19, Female, Sexual Violence (Post-Rape Care)	0
GEND_GBV_DSD	15-19, Male, Physical and/or Emotional Violence	0
GEND_GBV_DSD	15-19, Male, Sexual Violence (Post-Rape Care)	0
GEND_GBV_DSD	20-24, Female, Physical and/or Emotional Violence	0
GEND_GBV_DSD	20-24, Female, Sexual Violence (Post-Rape Care)	0
GEND_GBV_DSD	20-24, Male, Physical and/or Emotional Violence	0
GEND_GBV_DSD	20-24, Male, Sexual Violence (Post-Rape Care)	0
GEND_GBV_DSD	25-49, Female, Physical and/or Emotional Violence	0
GEND_GBV_DSD	25-49, Female, Sexual Violence (Post-Rape Care)	0
GEND_GBV_DSD	25-49, Male, Physical and/or Emotional Violence	0
GEND_GBV_DSD	25-49, Male, Sexual Violence (Post-Rape Care)	0
GEND_GBV_DSD	50+, Female, Physical and/or Emotional Violence	0
GEND_GBV_DSD	50+, Female, Sexual Violence (Post-Rape Care)	0
GEND_GBV_DSD	50+, Male, Physical and/or Emotional Violence	0
GEND_GBV_DSD	50+, Male, Sexual Violence (Post-Rape Care)	0
GEND_GBV_DSD	Unknown Age, Female, Physical and/or Emotional Violence	0
GEND_GBV_DSD	Unknown Age, Female, Sexual Violence (Post-Rape Care)	0
GEND_GBV_DSD	Unknown Age, Male, Physical and/or Emotional Violence	0
GEND_GBV_DSD	Unknown Age, Male, Sexual Violence (Post-Rape Care)	0
OVC_SERV_DSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	0
OVC_SERV_DSD	Age/Sex: 10-14 Male	0
OVC_SERV_DSD	Age/Sex: 15-17 Male	0
OVC_SERV_DSD	By: Age/sex: Male 18-24	0
OVC_SERV_DSD	By: Age/sex: Male 25+	0



OVC_SERV_DSD	Age/Sex: 10-14 Female	0
OVC_SERV_DSD	Age/Sex: 15-17 Female	0
OVC_SERV_DSD	By: Age/sex: 18-24 Female	0
OVC_SERV_DSD	By: Age/sex: 25+ Female	0
OVC_SERV_DSD	Sum of Age/Sex disaggregates	0
OVC_SERV_DSD	Age/Sex: <1	0
OVC_SERV_DSD	Age/Sex: 1-9	0
OVC_SERV_DSD	Program Completion: Active	0
OVC_SERV_DSD	Program Completion: Graduation	0
OVC_SERV_DSD	Program Completion: Transferred	0
OVC_SERV_DSD	Program Completion: Exited without graduation	0
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	33
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	33
TB_ART_DSD	Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	0
TB_ART_DSD	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	33
TB_ART_DSD	Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	0
TB_ART_DSD	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	0
TB_ART_DSD	Aggregated Age/Sex: Male <15 (Denominator: The	0



	number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
TB_ART_DSD	Aggregated Age/Sex: Male 15+ (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	33
TB_ART_DSD	Aggregated Age/Sex: Female <15 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	0
TB_ART_DSD	Aggregated Age/Sex: Female 15+ (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	0
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	2,317
TX_CURR_DSD	Aggregated Age/Sex: <15 Male	0
TX_CURR_DSD	Aggregated Age/Sex: 15+ Male	927
TX_CURR_DSD	Aggregated Age/Sex: <15 Female	0
TX_CURR_DSD	Aggregated Age/Sex: 15+ Female	1,390
TX_CURR_DSD	Sum of Aggregated Age/Sex <15	0
TX_CURR_DSD	Sum of Aggregated Age/Sex 15+	2,317
TX_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	2,317
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	2,154
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Male	0
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Male	927
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Female	0
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Female	1,227
TX_NEW_DSD	Sum of Aggregated Age/Sex disaggregates	2,154
TX_PVLS_DSD	Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting	1,741



	laboratory results within the past 12 months.	
TX_PVLS_DSD	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	2,317
TX_PVLS_DSD	Numerator: Indication: Routine	1,567
TX_PVLS_DSD	Numerator: Indication: Targeted	174
TX_PVLS_DSD	Numerator: Preg/BF by Indication: Pregnant Routine	0
TX_PVLS_DSD	Numerator: Preg/BF by Indication: Breastfeeding Routine	0
TX_PVLS_DSD	Numerator: Preg/BF by Indication: Pregnant Targeted	0
TX_PVLS_DSD	Numerator: Preg/BF by Indication: Breastfeeding Targeted	0
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: <15 Male Targeted	1
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: 15+ Male Targeted	61
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: <15 Female Targeted	3
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: 15+ Female Targeted	106
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: <15 Male Routine	34
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: 15+ Male Routine	549
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: <15 Female Routine	48
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: 15+ Female Routine	939
TX_PVLS_DSD	Denominator: Indication: Routine	2,085
TX_PVLS_DSD	Denominator: Indication: Targeted	232
TX_PVLS_DSD	Denominator: Preg/BF by Indication: Pregnant Routine	0
TX_PVLS_DSD	Denominator: Preg/BF by Indication: Breastfeeding Routine	0
TX_PVLS_DSD	Denominator: Preg/BF by Indication: Pregnant Targeted	0



TX_PVLS_DSD	Denominator: Preg/BF by Indication: Breastfeeding Targeted	0
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Male Targeted	2
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Male Targeted	85
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Female Targeted	6
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Female Targeted	140
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Male Routine	42
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Male Routine	729
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Female Routine	63
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Female Routine	1,251
TX_PVLS_DSD	<15, Undocumented Test Indication, Female	0
TX_PVLS_DSD	<15, Undocumented Test Indication, Male	0
TX_PVLS_DSD	15+, Undocumented Test Indication, Female	0
TX_PVLS_DSD	15+, Undocumented Test Indication, Male	0
TX_PVLS_DSD	Breastfeeding, Undocumented Test Indication	0
TX_PVLS_DSD	Pregnant, Undocumented Test Indication	0
TX_PVLS_DSD	Undocumented Test Indication	0
TX_PVLS_DSD	<15, Undocumented Test Indication, Female	0
TX_PVLS_DSD	<15, Undocumented Test Indication, Male	0
TX_PVLS_DSD	15+, Undocumented Test Indication, Female	0
TX_PVLS_DSD	15+, Undocumented Test Indication, Male	0
TX_PVLS_DSD	Breastfeeding, Undocumented Test Indication	0
TX_PVLS_DSD	Pregnant, Undocumented Test Indication	0
TX_PVLS_DSD	Undocumented Test Indication	0
TX_RET_DSD	Number of adults and children who are still alive and on	11



	treatment at 12 months after initiating ART	
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	15
TX_RET_DSD	Numerator by Status: Pregnant	0
TX_RET_DSD	Numerator by Status: Breastfeeding	0
TX_RET_DSD	Denominator by Status: Pregnant	0
TX_RET_DSD	Denominator by Status: Breastfeeding	0
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	0
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	4
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	0
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	7
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	0
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	5
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have	0



	stopped ART, and those lost to follow-up)	
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	9
TB_PREV_DSD	The number of ART patients who completed a course of TB preventive therapy or at least 6 months of Isoniazid Preventive Therapy (IPT) during the reporting period	14
TB_PREV_DSD	The number of ART patients who were newly started on TB preventive therapy (including those who newly started on TB preventive therapy in this reporting period and those who started in the previous reporting period but had not been reported as they did not fulfill the minimum requirements for the previous reporting period).	15
TB_PREV_DSD	By Age/Sex (Denominator): 15+, Female	9
TB_PREV_DSD	By Age/Sex (Denominator): 15+, Male	6
TB_PREV_DSD	By Age/Sex (Numerator): 15+, Female	8
TB_PREV_DSD	By Age/Sex (Numerator): 15+, Male	6
TX_TB_DSD	Number of ART patients who were started on TB treatment during the reporting period.	12
TX_TB_DSD	Number of ART patients who were screened for TB at least once during the reporting period	554
TX_TB_DSD	Numerator: By Aggregated Age/Sex: <15, Female	0
TX_TB_DSD	Numerator: By Aggregated Age/Sex: <15, Male	0
TX_TB_DSD	Numerator: By Aggregated Age/Sex: 15+, Female	6
TX_TB_DSD	Numerator: By Aggregated Age/Sex: 15+, Male	6
TX_TB_DSD	Denominator: By Aggregated Age/Sex: <15, Female	17
TX_TB_DSD	Denominator: By Aggregated Age/Sex: <15, Male	12
TX_TB_DSD	Denominator: By Aggregated Age/Sex: 15+, Female	331
TX_TB_DSD	Denominator: By Aggregated Age/Sex: 15+, Male	194
TX_TB_DSD	Denominator: By Screen Result: Negative	542



TX_TB_DSD	Denominator: By Screen Result: Positive	12
TX_TB_DSD	Denominator: Number of ART patients who had a specimen sent for bacteriologic diagnosis of active TB disease	110
TX_TB_DSD	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Other (No Xpert)	0
TX_TB_DSD	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Smear Only	56
TX_TB_DSD	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Gene Xpert MTB / R if Assay	56

### Implementing Mechanism Details

<b>Mechanism ID: 18047</b>	<b>Mechanism Name: NASTAD 1525</b>
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: National Alliance of State and Territorial AIDS Directors	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

<b>Total All Funding Sources: 1,320,000</b>	<b>Total Mechanism Pipeline: N/A</b>
<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 1,320,000</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	1,320,000

### Cross-Cutting Budget Attribution(s)

Motor Vehicles: Purchased	35,000
Human Resources for Health	90,000



### Budget Code Information

<b>Mechanism ID:</b>	18047		
<b>Mechanism Name:</b>	NASTAD 1525		
<b>Prime Partner Name:</b>	National Alliance of State and Territorial AIDS Directors		
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	HBHC	50,000	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Governance and Systems	HVSI	150,000	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	HVCT	370,000	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	MTCT	300,000	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Treatment	HTXS	450,000	0

### Implementing Mechanism Indicator Information

(No data provided.)

### Implementing Mechanism Details

<b>Mechanism ID: 18050</b>	<b>Mechanism Name: CDS 1528</b>
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Center for Development and Health	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:



<b>Total All Funding Sources: 1,125,000</b>	<b>Total Mechanism Pipeline: N/A</b>
<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 1,125,000</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	1,125,000

**Cross-Cutting Budget Attribution(s)**

Gender: GBV	30,000
Focus Area:	GBV Prevention
Sub Area:	Collection and Use of Gender-related Strategic Information
Human Resources for Health	50,000
Food and Nutrition: Commodities	20,000
Motor Vehicles: Purchased	55,000

**Budget Code Information**

<b>Mechanism ID:</b>	18050		
<b>Mechanism Name:</b>	CDS 1528		
<b>Prime Partner Name:</b>	Center for Development and Health		
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	HBHC	130,340	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	HVTB	206,461	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	PDCS	9,596	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>



Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	163,351	0
Prevention	MTCT	93,850	0
Treatment	HTXS	504,234	0
Treatment	PDTX	17,168	0

### Implementing Mechanism Indicator Information

Indicator Number	Label	2018
PMTCT_ART_DSD	Number of HIV-positive pregnant women who received ART to reduce risk of mother-to-child-transmission (MTCT) during pregnancy	137
PMTCT_ART_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	6,526
PMTCT_ART_DSD	New on ART	87
PMTCT_ART_DSD	Already on ART at beginning of current pregnancy	50
PMTCT_STAT_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	6,526
PMTCT_STAT_DSD	By Age (Denominator): Unknown Age	6,728
PMTCT_STAT_DSD	By Number of known positives: Unknown Age	57
PMTCT_STAT_DSD	By Number of new positives: Unknown Age	86
PMTCT_STAT_DSD	By Number of new negative: Unknown Age	6,381
PMTCT_STAT_DSD	By Age (Numerator): Unknown Age	144
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12	16,823



	months	
HTC_TST_DSD	By Test Result: Positive	552
HTC_TST_DSD	Sum of Test Result disaggregates	552
HTC_TST_DSD	Service Delivery Point by Agg Age(Community) Mobile Testing: 15+, Female, Negative	20
HTC_TST_DSD	Service Delivery Point by Agg Age(Community) Mobile Testing: 15+, Female, Positive	0
HTC_TST_DSD	Service Delivery Point by Agg Age(Community) Mobile Testing: 15+, Male, Negative	13
HTC_TST_DSD	Service Delivery Point by Agg Age(Community) Mobile Testing: 15+, Male, Positive	0
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Other PITC: 15+, Female, Negative	652
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Other PITC: 15+, Female, Positive	11
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Other PITC: 15+, Male, Negative	435
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Other PITC: 15+, Male, Positive	8
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) TB: 15+, Female, Negative	34
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) TB: 15+, Female, Positive	4
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) TB: 15+, Male, Negative	23
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) TB: 15+, Male, Positive	2
HTC_TST_DSD	Service Delivery Point Agg Age (Facility) Index: 15+, Female, Negative	550
HTC_TST_DSD	Service Delivery Point Agg Age (Facility) Index: 15+, Female, Positive	47
HTC_TST_DSD	Service Delivery Point Agg Age (Facility) Index: 15+, Male, Negative	366
HTC_TST_DSD	Service Delivery Point Agg Age (Facility) Index: 15+,	32



	Male, Positive	
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) VCT: <15, Female, Negative	609
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) VCT: <15, Female, Positive	9
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) VCT: <15, Male, Negative	407
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) VCT: <15, Male, Positive	6
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) VCT: 15+, Female, Negative	5,086
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) VCT: 15+, Female, Positive	172
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) VCT: 15+, Male, Negative	3,391
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) VCT: 15+, Male, Positive	114
TB_STAT_DSD	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	144
TB_STAT_DSD	Total number of registered new and relapsed TB cases, during the reporting period.	150
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	2
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	55
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	4
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	83
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Denominator: Total	2



	number of registered new and relapsed TB cases, during the reporting period)	
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	57
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	4
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	87
GEND_GBV_DSD	Number of people receiving post-GBV care	10
GEND_GBV_DSD	By type of service: Physical and/or Emotional Violence (Other Post-GBV Care)	1
GEND_GBV_DSD	By type of service: Sexual Violence (Post-Rape Care)	9
GEND_GBV_DSD	By PEP service provision (related to sexual violence services provided)	9
GEND_GBV_DSD	Unknown Age, Female, Physical and/or Emotional Violence	1
GEND_GBV_DSD	Unknown Age, Female, Sexual Violence (Post-Rape Care)	9
GEND_GBV_DSD	Unknown Age, Male, Physical and/or Emotional Violence	0
GEND_GBV_DSD	Unknown Age, Male, Sexual Violence (Post-Rape Care)	0
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	33
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	33
TB_ART_DSD	Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during	0



	TB treatment during the reporting period)	
TB_ART_DSD	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	14
TB_ART_DSD	Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	0
TB_ART_DSD	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	17
TB_ART_DSD	Aggregated Age/Sex: Male <15 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	0
TB_ART_DSD	Aggregated Age/Sex: Male 15+ (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	16
TB_ART_DSD	Aggregated Age/Sex: Female <15 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	0
TB_ART_DSD	Aggregated Age/Sex: Female 15+ (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	17
PMTCT_EID_DSD	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	135
PMTCT_EID_DSD	Number of infants with a positive virological test result within 2 months of birth	1
PMTCT_EID_DSD	Number of infants with a negative virological test result within 2 months of birth	73



PMTCT_EID_DSD	Number of infants with a positive virological test result between 2 and 12 months of birth	1
PMTCT_EID_DSD	Number of infants with a negative virological test result between 2 and 12 months of birth	60
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	1,771
TX_CURR_DSD	Aggregated Age/Sex: <15 Male	21
TX_CURR_DSD	Aggregated Age/Sex: 15+ Male	687
TX_CURR_DSD	Aggregated Age/Sex: <15 Female	30
TX_CURR_DSD	Aggregated Age/Sex: 15+ Female	1,032
TX_CURR_DSD	Sum of Aggregated Age/Sex <15	51
TX_CURR_DSD	Sum of Aggregated Age/Sex 15+	1,719
TX_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	1,770
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	485
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Male	8
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Male	197
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Female	8
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Female	272
TX_NEW_DSD	Sum of Aggregated Age/Sex disaggregates	485
TX_NEW_DSD	Pregnancy status	87
TX_PVLS_DSD	Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months.	1,257
TX_PVLS_DSD	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	1,678
TX_PVLS_DSD	Numerator: Indication: Routine	1,132
TX_PVLS_DSD	Numerator: Indication: Targeted	125
TX_PVLS_DSD	Numerator: Preg/BF by Indication: Pregnant Routine	129
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: <15 Male Targeted	3



TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: 15+ Male Targeted	44
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: <15 Female Targeted	3
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: 15+ Female Targeted	74
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: <15 Male Routine	24
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: 15+ Male Routine	395
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: <15 Female Routine	34
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: 15+ Female Routine	680
TX_PVLS_DSD	Denominator: Indication: Routine	1,510
TX_PVLS_DSD	Denominator: Indication: Targeted	168
TX_PVLS_DSD	Denominator: Preg/BF by Indication: Pregnant Routine	129
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Male Targeted	4
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Male Targeted	60
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Female Targeted	5
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Female Targeted	100
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Male Routine	30
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Male Routine	528
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Female Routine	45
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Female Routine	905
TX_RET_DSD	Number of adults and children who are still alive and on	424



	treatment at 12 months after initiating ART	
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	546
TX_RET_DSD	Numerator by Status: Pregnant	95
TX_RET_DSD	Denominator by Status: Pregnant	95
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	8
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	156
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	12
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	248
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	11
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	193
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	15
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Denominator: Total	327



	number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
TB_PREV_DSD	The number of ART patients who completed a course of TB preventive therapy or at least 6 months of Isoniazid Preventive Therapy (IPT) during the reporting period	492
TB_PREV_DSD	The number of ART patients who were newly started on TB preventive therapy (including those who newly started on TB preventive therapy in this reporting period and those who started in the previous reporting period but had not been reported as they did not fulfill the minimum requirements for the previous reporting period).	546
TB_PREV_DSD	By Age/Sex (Denominator): <15, Female	15
TB_PREV_DSD	By Age/Sex (Denominator): <15, Male	11
TB_PREV_DSD	By Age/Sex (Denominator): 15+, Female	327
TB_PREV_DSD	By Age/Sex (Denominator): 15+, Male	191
TB_PREV_DSD	By Age/Sex (Numerator): <15, Female	15
TB_PREV_DSD	By Age/Sex (Numerator): <15, Male	10
TB_PREV_DSD	By Age/Sex (Numerator): 15+, Female	295
TB_PREV_DSD	By Age/Sex (Numerator): 15+, Male	172
TX_TB_DSD	Number of ART patients who were started on TB treatment during the reporting period.	26
TX_TB_DSD	Number of ART patients who were screened for TB at least once during the reporting period	1,271
TX_TB_DSD	Numerator: By Aggregated Age/Sex: <15, Female	0
TX_TB_DSD	Numerator: By Aggregated Age/Sex: <15, Male	0
TX_TB_DSD	Numerator: By Aggregated Age/Sex: 15+, Female	15
TX_TB_DSD	Numerator: By Aggregated Age/Sex: 15+, Male	11
TX_TB_DSD	Denominator: By Aggregated Age/Sex: <15, Female	38
TX_TB_DSD	Denominator: By Aggregated Age/Sex: <15, Male	25
TX_TB_DSD	Denominator: By Aggregated Age/Sex: 15+, Female	763



TX_TB_DSD	Denominator: By Aggregated Age/Sex:15+, Male	445
TX_TB_DSD	Denominator: By Screen Result: Negative	1,245
TX_TB_DSD	Denominator: By Screen Result: Positive	26
TX_TB_DSD	Denominator: Number of ART patients who had a specimen sent for bacteriologic diagnosis of active TB disease	254
TX_TB_DSD	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Smear Only	127
TX_TB_DSD	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Gene Xpert MTB / R if Assay	127

### Implementing Mechanism Details

<b>Mechanism ID: 18086</b>	<b>Mechanism Name: MEASURE Evaluation Phase IV</b>
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Measure Evaluation	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

<b>Total All Funding Sources: 300,000</b>	<b>Total Mechanism Pipeline: N/A</b>
<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 300,000</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	300,000

### Cross-Cutting Budget Attribution(s)

(No data provided.)



### Budget Code Information

<b>Mechanism ID: 18086</b>			
<b>Mechanism Name: MEASURE Evaluation Phase IV</b>			
<b>Prime Partner Name: Measure Evaluation</b>			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HKID	300,000	0

### Implementing Mechanism Indicator Information

(No data provided.)

### Implementing Mechanism Details

<b>Mechanism ID: 18266</b>	<b>Mechanism Name: GHESKIO 1924</b>
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Groupe Haitien d'Etude du Sarcome de Kaposi et des Infections Opportunistes	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

<b>Total All Funding Sources: 3,000,000</b>	<b>Total Mechanism Pipeline: N/A</b>
<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 3,000,000</b>	
Funding Source	Funding Amount
GHP-State	3,000,000

### Cross-Cutting Budget Attribution(s)

Key Populations: FSW	35,000
Focus Area:	Implementation of core HIV prevention interventions for SWs consistent with PEPFAR guidance on sexual prevention



Gender: GBV	150,000
Focus Area:	GBV Prevention
Sub Area:	Collection and Use of Gender-related Strategic Information
Food and Nutrition: Commodities	50,000
Human Resources for Health	800,000

**Budget Code Information**

<b>Mechanism ID:</b>	18266		
<b>Mechanism Name:</b>	GHESKIO 1924		
<b>Prime Partner Name:</b>	Groupe Haitien d'Etude du Sarcome de Kaposi et des Infections Opportunistes		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	134,120	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HKID	569,797	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	86,400	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	15,763	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HLAB	100,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and	HVSI	60,000	0



Systems			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVAB	42,500	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	441,723	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	86,591	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	1,353,613	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	109,493	0

### Implementing Mechanism Indicator Information

Indicator Number	Label	2018
PMTCT_ART_DSD	Number of HIV-positive pregnant women who received ART to reduce risk of mother-to-child-transmission (MTCT) during pregnancy	109
PMTCT_ART_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	6,244
PMTCT_ART_DSD	New on ART	64
PMTCT_ART_DSD	Already on ART at beginning of current pregnancy	45
PMTCT_STAT_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	6,244
PMTCT_STAT_DSD	By Age (Denominator): Unknown Age	13,217
PMTCT_STAT_DSD	By Number of known positives: Unknown Age	51



PMTCT_STAT_DSD	By Number of new positives: Unknown Age	64
PMTCT_STAT_DSD	By Number of new negative: Unknown Age	6,129
PMTCT_STAT_DSD	By Age (Numerator): Unknown Age	114
PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	616
PP_PREV_DSD	Age/sex: 10-14 Female	357
PP_PREV_DSD	Age/sex: 15-19 Female	259
PP_PREV_DSD	Sum of Age/Sex disaggregates	616
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	84,162
HTC_TST_DSD	By Test Result: Positive	1,762
HTC_TST_DSD	Sum of Test Result disaggregates	1,762
HTC_TST_DSD	Service Delivery Point by Agg Age(Community) Mobile Testing: 15+, Female, Negative	54
HTC_TST_DSD	Service Delivery Point by Agg Age(Community) Mobile Testing: 15+, Female, Positive	1
HTC_TST_DSD	Service Delivery Point by Agg Age(Community) Mobile Testing: 15+, Male, Negative	36
HTC_TST_DSD	Service Delivery Point by Agg Age(Community) Mobile Testing: 15+, Male, Positive	1
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Other PITC: 15+, Female, Negative	8,045
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Other PITC: 15+, Female, Positive	150
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Other PITC: 15+, Male, Negative	5,364
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Other PITC: 15+, Male, Positive	100
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) TB: 15+, Female, Negative	441
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) TB: 15+, Female, Positive	55



HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) TB: 15+, Male, Negative	293
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) TB: 15+, Male, Positive	37
HTC_TST_DSD	Service Delivery Point Agg Age (Facility) Index: 15+, Female, Negative	2,347
HTC_TST_DSD	Service Delivery Point Agg Age (Facility) Index: 15+, Female, Positive	166
HTC_TST_DSD	Service Delivery Point Agg Age (Facility) Index: 15+, Male, Negative	1,565
HTC_TST_DSD	Service Delivery Point Agg Age (Facility) Index: 15+, Male, Positive	111
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) VCT: <15, Female, Negative	15,598
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) VCT: <15, Female, Positive	157
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) VCT: <15, Male, Negative	10,399
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) VCT: <15, Male, Positive	105
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) VCT: 15+, Female, Negative	9,361
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) VCT: 15+, Female, Positive	450
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) VCT: 15+, Male, Negative	6,241
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) VCT: 15+, Male, Positive	300
TB_STAT_DSD	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	1,661
TB_STAT_DSD	Total number of registered new and relapsed TB cases, during the reporting period.	1,910
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with	37



	documented HIV status, during the reporting period)	
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	627
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	56
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	941
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	43
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	720
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	64
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	1,083
GEND_GBV_DSD	Number of people receiving post-GBV care	322
GEND_GBV_DSD	By type of service: Physical and/or Emotional Violence (Other Post-GBV Care)	33
GEND_GBV_DSD	By type of service: Sexual Violence (Post-Rape Care)	289
GEND_GBV_DSD	By PEP service provision (related to sexual violence services provided)	289
OVC_SERV_DSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	6,000
OVC_SERV_DSD	Age/Sex: 10-14 Male	528
OVC_SERV_DSD	Age/Sex: 15-17 Male	384
OVC_SERV_DSD	By: Age/sex: Male 18-24	288



OVC_SERV_DSD	By: Age/sex: Male 25+	720
OVC_SERV_DSD	Age/Sex: 10-14 Female	792
OVC_SERV_DSD	Age/Sex: 15-17 Female	576
OVC_SERV_DSD	By: Age/sex: 18-24 Female	432
OVC_SERV_DSD	By: Age/sex: 25+ Female	1,080
OVC_SERV_DSD	Sum of Age/Sex disaggregates	2,280
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support Female 10-14	277
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support Female 15-17	86
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 25+	334
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male 25+	144
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Social Protection Female 10-14	396
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Social Protection Female 15-17	230
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Social Protection Female 18-24	22
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 18-24	22
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 25+	486
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Male 18-24	14
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Male 25+	324
OVC_SERV_DSD	Age/Sex: <1	240
OVC_SERV_DSD	Age/Sex: 1-9	960
OVC_SERV_DSD	Program Completion: Active	4,092
OVC_SERV_DSD	Program Completion: Graduation	108
OVC_SERV_DSD	Program Completion: Transferred	1,530



OVC_SERV_DSD	Program Completion: Exited without graduation	270
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	231
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	231
TB_ART_DSD	Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	5
TB_ART_DSD	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	87
TB_ART_DSD	Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	8
TB_ART_DSD	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	131
TB_ART_DSD	Aggregated Age/Sex: Male <15 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	5
TB_ART_DSD	Aggregated Age/Sex: Male 15+ (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	87
TB_ART_DSD	Aggregated Age/Sex: Female <15 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	8



TB_ART_DSD	Aggregated Age/Sex: Female 15+ (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	131
PMTCT_EID_DSD	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	109
PMTCT_EID_DSD	Number of infants with a positive virological test result within 2 months of birth	1
PMTCT_EID_DSD	Number of infants with a negative virological test result within 2 months of birth	58
PMTCT_EID_DSD	Number of infants with a positive virological test result between 2 and 12 months of birth	2
PMTCT_EID_DSD	Number of infants with a negative virological test result between 2 and 12 months of birth	48
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	14,977
TX_CURR_DSD	Aggregated Age/Sex: <15 Male	336
TX_CURR_DSD	Aggregated Age/Sex: 15+ Male	5,655
TX_CURR_DSD	Aggregated Age/Sex: <15 Female	504
TX_CURR_DSD	Aggregated Age/Sex: 15+ Female	8,482
TX_CURR_DSD	Sum of Aggregated Age/Sex <15	840
TX_CURR_DSD	Sum of Aggregated Age/Sex 15+	14,137
TX_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	14,977
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	3,162
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Male	118
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Male	1,229
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Female	118
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Female	1,697
TX_NEW_DSD	Sum of Aggregated Age/Sex disaggregates	3,162
TX_NEW_DSD	Pregnancy status	64
TX_PVLS_DSD	Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml)	11,232



	documented in the medical records and /or supporting laboratory results within the past 12 months.	
TX_PVLS_DSD	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	14,976
TX_PVLS_DSD	Numerator: Indication: Routine	10,109
TX_PVLS_DSD	Numerator: Indication: Targeted	1,123
TX_PVLS_DSD	Numerator: Preg/BF by Indication: Pregnant Routine	386
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: <15 Male Targeted	23
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: 15+ Male Targeted	393
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: <15 Female Targeted	34
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: 15+ Female Targeted	674
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: <15 Male Routine	202
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: 15+ Male Routine	3,538
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: <15 Female Routine	303
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: 15+ Female Routine	6,065
TX_PVLS_DSD	Denominator: Indication: Routine	13,478
TX_PVLS_DSD	Denominator: Indication: Targeted	1,497
TX_PVLS_DSD	Denominator: Preg/BF by Indication: Pregnant Routine	386
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Male Targeted	30
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Male Targeted	524
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Female Targeted	45
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+	899



	Female Targeted	
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Male Routine	269
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Male Routine	4,717
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Female Routine	404
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Female Routine	8,087
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	2,148
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	2,864
TX_RET_DSD	Numerator by Status: Pregnant	181
TX_RET_DSD	Denominator by Status: Pregnant	181
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	42
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	817
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	63
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	1,226
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	57



TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	1,003
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	86
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	1,718
TB_PREV_DSD	The number of ART patients who completed a course of TB preventive therapy or at least 6 months of Isoniazid Preventive Therapy (IPT) during the reporting period	2,659
TB_PREV_DSD	The number of ART patients who were newly started on TB preventive therapy (including those who newly started on TB preventive therapy in this reporting period and those who started in the previous reporting period but had not been reported as they did not fulfill the minimum requirements for the previous reporting period).	2,956
TB_PREV_DSD	By Age/Sex (Denominator): <15, Female	86
TB_PREV_DSD	By Age/Sex (Denominator): <15, Male	57
TB_PREV_DSD	By Age/Sex (Denominator): 15+, Female	1,718
TB_PREV_DSD	By Age/Sex (Denominator): 15+, Male	1,003
TB_PREV_DSD	By Age/Sex (Numerator): <15, Female	77
TB_PREV_DSD	By Age/Sex (Numerator): <15, Male	52
TB_PREV_DSD	By Age/Sex (Numerator): 15+, Female	1,546
TB_PREV_DSD	By Age/Sex (Numerator): 15+, Male	901
TX_TB_DSD	Number of ART patients who were started on TB	27



	treatment during the reporting period.	
TX_TB_DSD	Number of ART patients who were screened for TB at least once during the reporting period	13,345
TX_TB_DSD	Numerator: By Aggregated Age/Sex: <15, Female	0
TX_TB_DSD	Numerator: By Aggregated Age/Sex: <15, Male	1
TX_TB_DSD	Numerator: By Aggregated Age/Sex: 15+, Female	16
TX_TB_DSD	Numerator: By Aggregated Age/Sex: 15+, Male	10
TX_TB_DSD	Denominator: By Aggregated Age/Sex: <15, Female	401
TX_TB_DSD	Denominator: By Aggregated Age/Sex: <15, Male	267
TX_TB_DSD	Denominator: By Aggregated Age/Sex: 15+, Female	8,007
TX_TB_DSD	Denominator: By Aggregated Age/Sex: 15+, Male	4,670
TX_TB_DSD	Denominator: By Screen Result: Negative	10,677
TX_TB_DSD	Denominator: By Screen Result: Positive	2,668
TX_TB_DSD	Denominator: Number of ART patients who had a specimen sent for bacteriologic diagnosis of active TB disease	2,668
TX_TB_DSD	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Smear Only	1,334
TX_TB_DSD	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Gene Xpert MTB / R if Assay	1,334

### Implementing Mechanism Details

<b>Mechanism ID: 18267</b>	<b>Mechanism Name: PIH 1926</b>
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Partners in Health	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

<b>Total All Funding Sources: 6,900,000</b>	<b>Total Mechanism Pipeline: N/A</b>
<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 6,900,000</b>	



Funding Source	Funding Amount
GHP-State	6,900,000

**Cross-Cutting Budget Attribution(s)**

Gender: GBV	50,000
Focus Area:	GBV Prevention
Sub Area:	Collection and Use of Gender-related Strategic Information
Motor Vehicles: Purchased	168,675
Human Resources for Health	350,000

**Budget Code Information**

<b>Mechanism ID:</b> 18267			
<b>Mechanism Name:</b> PIH 1926			
<b>Prime Partner Name:</b> Partners in Health			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	619,226	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HKID	1,270,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	497,075	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	98,854	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and	HVSI	150,099	0



Systems			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	922,948	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	502,399	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	2,723,968	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	115,431	0

### Implementing Mechanism Indicator Information

Indicator Number	Label	2018
PMTCT_ART_DSD	Number of HIV-positive pregnant women who received ART to reduce risk of mother-to-child-transmission (MTCT) during pregnancy	863
PMTCT_ART_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	33,907
PMTCT_ART_DSD	New on ART	487
PMTCT_ART_DSD	Already on ART at beginning of current pregnancy	376
PMTCT_STAT_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	33,907
PMTCT_STAT_DSD	By Age (Denominator): Unknown Age	34,957
PMTCT_STAT_DSD	By Number of known positives: Unknown Age	398
PMTCT_STAT_DSD	By Number of new positives: Unknown Age	511
PMTCT_STAT_DSD	By Number of new negative: Unknown Age	32,997
PMTCT_STAT_DSD	By Age (Numerator): Unknown Age	893



PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	1,220
PP_PREV_DSD	Age/sex: 10-14 Female	704
PP_PREV_DSD	Age/sex: 15-19 Female	513
PP_PREV_DSD	Sum of Age/Sex disaggregates	1,217
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	118,704
HTC_TST_DSD	By Test Result: Positive	3,560
HTC_TST_DSD	Sum of Test Result disaggregates	3,560
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Inpatient: 15+, Female, Negative	0
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Inpatient: 15+, Female, Positive	0
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Inpatient: 15+, Male, Negative	0
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Inpatient: 15+, Male, Positive	0
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Other PITC: 15+, Female, Negative	12,149
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Other PITC: 15+, Female, Positive	358
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Other PITC: 15+, Male, Negative	8,100
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Other PITC: 15+, Male, Positive	238
HTC_TST_DSD	Service Delivery Point by Agg Age (Community) Other: 15+, Female, Negative	465
HTC_TST_DSD	Service Delivery Point by Agg Age (Community) Other: 15+, Female, Positive	12
HTC_TST_DSD	Service Delivery Point by Agg Age (Community) Other: 15+, Male, Negative	309
HTC_TST_DSD	Service Delivery Point by Agg Age (Community) Other:	8



	15+, Male, Positive	
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) TB: 15+, Female, Negative	200
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) TB: 15+, Female, Positive	20
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) TB: 15+, Male, Negative	133
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) TB: 15+, Male, Positive	14
HTC_TST_DSD	Service Delivery Point Agg Age (Facility) Index: 15+, Female, Negative	3,633
HTC_TST_DSD	Service Delivery Point Agg Age (Facility) Index: 15+, Female, Positive	298
HTC_TST_DSD	Service Delivery Point Agg Age (Facility) Index: 15+, Male, Negative	2,422
HTC_TST_DSD	Service Delivery Point Agg Age (Facility) Index: 15+, Male, Positive	199
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) VCT: <15, Female, Negative	8,147
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) VCT: <15, Female, Positive	87
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) VCT: <15, Male, Negative	5,431
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) VCT: <15, Male, Positive	57
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) VCT: 15+, Female, Negative	24,170
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) VCT: 15+, Female, Positive	803
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) VCT: 15+, Male, Negative	16,113
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) VCT: 15+, Male, Positive	535
TB_STAT_DSD	Number of registered new and relapsed TB cases with	1,892



	documented HIV status, during the reporting period.	
TB_STAT_DSD	Total number of registered new and relapsed TB cases, during the reporting period.	1,936
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	33
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	724
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	50
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	1,085
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	33
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	741
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	50
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	1,112
GEND_GBV_DSD	Number of people receiving post-GBV care	74
GEND_GBV_DSD	By type of service: Physical and/or Emotional Violence (Other Post-GBV Care)	8
GEND_GBV_DSD	By type of service: Sexual Violence (Post-Rape Care)	66
GEND_GBV_DSD	By PEP service provision (related to sexual violence services provided)	65
OVC_SERV_DSD	Number of active beneficiaries served by PEPFAR	12,002



	OVC programs for children and families affected by HIV/AIDS	
OVC_SERV_DSD	Age/Sex: 10-14 Male	1,056
OVC_SERV_DSD	Age/Sex: 15-17 Male	767
OVC_SERV_DSD	By: Age/sex: Male 18-24	577
OVC_SERV_DSD	By: Age/sex: Male 25+	1,441
OVC_SERV_DSD	Age/Sex: 10-14 Female	1,584
OVC_SERV_DSD	Age/Sex: 15-17 Female	1,152
OVC_SERV_DSD	By: Age/sex: 18-24 Female	863
OVC_SERV_DSD	By: Age/sex: 25+ Female	2,158
OVC_SERV_DSD	Sum of Age/Sex disaggregates	4,559
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support Female 10-14	166
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support Female 15-17	53
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 18-24	86
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 25+	108
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male 18-24	38
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male 25+	48
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Social Protection Female 10-14	296
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Social Protection Female 15-17	137
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Social Protection Female 18-24	14
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 18-24	10
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 25+	210



OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Male 18-24	7
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Male 25+	140
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Other Services Female 18-24	4
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Other Services Female 25+	81
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Other Services Male 18-24	2
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Other Services Male 25+	54
OVC_SERV_DSD	Age/Sex: <1	480
OVC_SERV_DSD	Age/Sex: 1-9	1,920
OVC_SERV_DSD	Program Completion: Active	8,713
OVC_SERV_DSD	Program Completion: Graduation	484
OVC_SERV_DSD	Program Completion: Transferred	2,362
OVC_SERV_DSD	Program Completion: Exited without graduation	443
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	286
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	286
TB_ART_DSD	Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	6
TB_ART_DSD	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	109
TB_ART_DSD	Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with	7



	documented HIV-positive status who are on ART during TB treatment during the reporting period)	
TB_ART_DSD	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	164
TB_ART_DSD	Aggregated Age/Sex: Male <15 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	6
TB_ART_DSD	Aggregated Age/Sex: Male 15+ (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	110
TB_ART_DSD	Aggregated Age/Sex: Female <15 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	7
TB_ART_DSD	Aggregated Age/Sex: Female 15+ (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	163
PMTCT_EID_DSD	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	867
PMTCT_EID_DSD	Number of infants with a positive virological test result within 2 months of birth	15
PMTCT_EID_DSD	Number of infants with a negative virological test result within 2 months of birth	452
PMTCT_EID_DSD	Number of infants with a positive virological test result between 2 and 12 months of birth	24
PMTCT_EID_DSD	Number of infants with a negative virological test result between 2 and 12 months of birth	376
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	15,226
TX_CURR_DSD	Aggregated Age/Sex: <15 Male	268



TX_CURR_DSD	Aggregated Age/Sex: 15+ Male	5,822
TX_CURR_DSD	Aggregated Age/Sex: <15 Female	402
TX_CURR_DSD	Aggregated Age/Sex: 15+ Female	8,734
TX_CURR_DSD	Sum of Aggregated Age/Sex <15	670
TX_CURR_DSD	Sum of Aggregated Age/Sex 15+	14,556
TX_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	15,226
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	3,419
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Male	68
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Male	1,350
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Female	68
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Female	1,932
TX_NEW_DSD	Sum of Aggregated Age/Sex disaggregates	3,418
TX_NEW_DSD	Pregnancy status	487
TX_PVLS_DSD	Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months.	11,416
TX_PVLS_DSD	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	15,229
TX_PVLS_DSD	Numerator: Indication: Routine	10,274
TX_PVLS_DSD	Numerator: Indication: Targeted	1,142
TX_PVLS_DSD	Numerator: Preg/BF by Indication: Pregnant Routine	767
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: <15 Male Targeted	25
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: 15+ Male Targeted	399
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: <15 Female Targeted	34
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: 15+ Female Targeted	684
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: <15 Male	207



	Routine	
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: 15+ Male Routine	3,594
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: <15 Female Routine	306
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: 15+ Female Routine	6,164
TX_PVLS_DSD	Denominator: Indication: Routine	13,705
TX_PVLS_DSD	Denominator: Indication: Targeted	1,523
TX_PVLS_DSD	Denominator: Preg/BF by Indication: Pregnant Routine	767
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Male Targeted	30
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Male Targeted	532
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Female Targeted	44
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Female Targeted	913
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Male Routine	274
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Male Routine	4,798
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Female Routine	412
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Female Routine	8,222
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	2,615
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	3,340
TX_RET_DSD	Numerator by Status: Pregnant	428
TX_RET_DSD	Denominator by Status: Pregnant	428



TX_RET_DSD	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	60
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	983
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	89
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	1,483
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	68
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	1,168
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	101
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	2,003
TB_PREV_DSD	The number of ART patients who completed a course of TB preventive therapy or at least 6 months of Isoniazid Preventive Therapy (IPT) during the reporting	3,006



	period	
TB_PREV_DSD	The number of ART patients who were newly started on TB preventive therapy (including those who newly started on TB preventive therapy in this reporting period and those who started in the previous reporting period but had not been reported as they did not fulfill the minimum requirements for the previous reporting period).	3,340
TB_PREV_DSD	By Age/Sex (Denominator): <15, Female	101
TB_PREV_DSD	By Age/Sex (Denominator): <15, Male	68
TB_PREV_DSD	By Age/Sex (Denominator): 15+, Female	2,003
TB_PREV_DSD	By Age/Sex (Denominator): 15+, Male	1,168
TB_PREV_DSD	By Age/Sex (Numerator): <15, Female	90
TB_PREV_DSD	By Age/Sex (Numerator): <15, Male	60
TB_PREV_DSD	By Age/Sex (Numerator): 15+, Female	1,802
TB_PREV_DSD	By Age/Sex (Numerator): 15+, Male	1,053
TX_TB_DSD	Number of ART patients who were started on TB treatment during the reporting period.	263
TX_TB_DSD	Number of ART patients who were screened for TB at least once during the reporting period	13,316
TX_TB_DSD	Numerator: By Aggregated Age/Sex: <15, Female	3
TX_TB_DSD	Numerator: By Aggregated Age/Sex: <15, Male	8
TX_TB_DSD	Numerator: By Aggregated Age/Sex: 15+, Female	158
TX_TB_DSD	Numerator: By Aggregated Age/Sex: 15+, Male	93
TX_TB_DSD	Denominator: By Aggregated Age/Sex: <15, Female	400
TX_TB_DSD	Denominator: By Aggregated Age/Sex: <15, Male	266
TX_TB_DSD	Denominator: By Aggregated Age/Sex: 15+, Female	7,988
TX_TB_DSD	Denominator: By Aggregated Age/Sex: 15+, Male	4,660
TX_TB_DSD	Denominator: By Screen Result: Negative	12,911
TX_TB_DSD	Denominator: By Screen Result: Positive	405
TX_TB_DSD	Denominator: Number of ART patients who had a specimen sent for bacteriologic diagnosis of active TB disease	2,665



TX_TB_DSD	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Smear Only	1,332
TX_TB_DSD	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Gene Xpert MTB / R if Assay	1,332

**Implementing Mechanism Details**

<b>Mechanism ID: 18268</b>	<b>Mechanism Name: CMMB 1970</b>
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Catholic Medical Mission Board	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

<b>Total All Funding Sources: 5,600,000</b>	<b>Total Mechanism Pipeline: N/A</b>
<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 5,600,000</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	5,600,000

**Cross-Cutting Budget Attribution(s)**

Human Resources for Health	35,000
Food and Nutrition: Commodities	30,000
Renovation	9,840

**Budget Code Information**

<b>Mechanism ID:</b>	<b>18268</b>
<b>Mechanism Name:</b>	<b>CMMB 1970</b>
<b>Prime Partner Name:</b>	<b>Catholic Medical Mission Board</b>



Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	788,864	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	348,467	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	74,840	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	1,156,512	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	389,717	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	2,662,724	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	178,876	0

### Implementing Mechanism Indicator Information

Indicator Number	Label	2018
PMTCT_ART_DSD	Number of HIV-positive pregnant women who received ART to reduce risk of mother-to-child-transmission (MTCT) during pregnancy	517
PMTCT_ART_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	27,742
PMTCT_ART_DSD	New on ART	285
PMTCT_ART_DSD	Already on ART at beginning of current pregnancy	232



PMTCT_STAT_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	27,742
PMTCT_STAT_DSD	By Age (Denominator): Unknown Age	28,599
PMTCT_STAT_DSD	By Number of known positives: Unknown Age	285
PMTCT_STAT_DSD	By Number of new positives: Unknown Age	267
PMTCT_STAT_DSD	By Number of new negative: Unknown Age	27,190
PMTCT_STAT_DSD	By Age (Numerator): Unknown Age	544
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	117,613
HTC_TST_DSD	By Test Result: Positive	3,288
HTC_TST_DSD	Sum of Test Result disaggregates	3,288
HTC_TST_DSD	Service Delivery Point by Agg Age (Community) Homebased testing: 15+, Female, Negative	9
HTC_TST_DSD	Service Delivery Point by Agg Age (Community) Homebased testing: 15+, Female, Positive	0
HTC_TST_DSD	Service Delivery Point by Agg Age (Community) Homebased testing: 15+, Male, Negative	6
HTC_TST_DSD	Service Delivery Point by Agg Age (Community) Homebased testing: 15+, Male, Positive	0
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Inpatient: 15+, Female, Negative	97
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Inpatient: 15+, Female, Positive	5
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Inpatient: 15+, Male, Negative	64
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Inpatient: 15+, Male, Positive	3
HTC_TST_DSD	Service Delivery Point by Agg Age(Community) Mobile Testing: 15+, Female, Negative	597
HTC_TST_DSD	Service Delivery Point by Agg Age(Community) Mobile Testing: 15+, Female, Positive	15
HTC_TST_DSD	Service Delivery Point by Agg Age(Community) Mobile	398



	Testing: 15+, Male, Negative	
HTC_TST_DSD	Service Delivery Point by Agg Age(Community) Mobile Testing: 15+, Male, Positive	9
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Other PITC: <15, Female, Negative	0
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Other PITC: <15, Female, Positive	0
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Other PITC: <15, Male, Negative	0
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Other PITC: <15, Male, Positive	0
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Other PITC: 15+, Female, Negative	19,128
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Other PITC: 15+, Female, Positive	485
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Other PITC: 15+, Male, Negative	12,750
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Other PITC: 15+, Male, Positive	320
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) TB: <15, Female, Negative	0
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) TB: <15, Female, Positive	0
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) TB: <15, Male, Negative	0
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) TB: <15, Male, Positive	0
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) TB: 15+, Female, Negative	600
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) TB: 15+, Female, Positive	61
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) TB: 15+, Male, Negative	398
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) TB: 15+, Male, Positive	40



	Male, Positive	
HTC_TST_DSD	Service Delivery Point Agg Age (Facility) Index: <15, Female, Negative	0
HTC_TST_DSD	Service Delivery Point Agg Age (Facility) Index: <15, Female, Positive	0
HTC_TST_DSD	Service Delivery Point Agg Age (Facility) Index: <15, Male, Negative	0
HTC_TST_DSD	Service Delivery Point Agg Age (Facility) Index: <15, Male, Positive	0
HTC_TST_DSD	Service Delivery Point Agg Age (Facility) Index: 15+, Female, Negative	3,617
HTC_TST_DSD	Service Delivery Point Agg Age (Facility) Index: 15+, Female, Positive	295
HTC_TST_DSD	Service Delivery Point Agg Age (Facility) Index: 15+, Male, Negative	2,413
HTC_TST_DSD	Service Delivery Point Agg Age (Facility) Index: 15+, Male, Positive	196
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) VCT: <15, Female, Negative	7,990
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) VCT: <15, Female, Positive	94
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) VCT: <15, Male, Negative	5,325
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) VCT: <15, Male, Positive	62
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) VCT: 15+, Female, Negative	17,498
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) VCT: 15+, Female, Positive	671
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) VCT: 15+, Male, Negative	11,666
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) VCT: 15+, Male, Positive	448
TB_STAT_DSD	Number of registered new and relapsed TB cases with	1,351



	documented HIV status, during the reporting period.	
TB_STAT_DSD	Total number of registered new and relapsed TB cases, during the reporting period.	1,406
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	49
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	489
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	77
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	736
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	53
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	505
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	85
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	763
GEND_GBV_DSD	Number of people receiving post-GBV care	36
GEND_GBV_DSD	By type of service: Physical and/or Emotional Violence (Other Post-GBV Care)	4
GEND_GBV_DSD	By type of service: Sexual Violence (Post-Rape Care)	32
GEND_GBV_DSD	By PEP service provision (related to sexual violence services provided)	32
TB_ART_DSD	The number of registered new and relapse TB cases	213



	with documented HIV-positive status who are on ART during TB treatment during the reporting period	
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	213
TB_ART_DSD	Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	7
TB_ART_DSD	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	83
TB_ART_DSD	Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	12
TB_ART_DSD	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	111
TB_ART_DSD	Aggregated Age/Sex: Male <15 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	7
TB_ART_DSD	Aggregated Age/Sex: Male 15+ (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	83
TB_ART_DSD	Aggregated Age/Sex: Female <15 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	12
TB_ART_DSD	Aggregated Age/Sex: Female 15+ (Denominator: The number of registered new and relapse TB cases with	111



	documented HIV-positive status during TB treatment during the reporting period)	
PMTCT_EID_DSD	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	515
PMTCT_EID_DSD	Number of infants with a positive virological test result within 2 months of birth	6
PMTCT_EID_DSD	Number of infants with a negative virological test result within 2 months of birth	274
PMTCT_EID_DSD	Number of infants with a positive virological test result between 2 and 12 months of birth	8
PMTCT_EID_DSD	Number of infants with a negative virological test result between 2 and 12 months of birth	227
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	12,227
TX_CURR_DSD	Aggregated Age/Sex: <15 Male	436
TX_CURR_DSD	Aggregated Age/Sex: 15+ Male	4,391
TX_CURR_DSD	Aggregated Age/Sex: <15 Female	651
TX_CURR_DSD	Aggregated Age/Sex: 15+ Female	6,580
TX_CURR_DSD	Sum of Aggregated Age/Sex <15	1,087
TX_CURR_DSD	Sum of Aggregated Age/Sex 15+	10,971
TX_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	12,058
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	2,562
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Male	71
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Male	1,016
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Female	71
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Female	1,404
TX_NEW_DSD	Sum of Aggregated Age/Sex disaggregates	2,562
TX_NEW_DSD	Pregnancy status	285
TX_PVLS_DSD	Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months.	9,172



TX_PVLS_DSD	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	12,233
TX_PVLS_DSD	Numerator: Indication: Routine	8,256
TX_PVLS_DSD	Numerator: Indication: Targeted	916
TX_PVLS_DSD	Numerator: Preg/BF by Indication: Pregnant Routine	520
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: <15 Male Targeted	33
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: 15+ Male Targeted	305
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: <15 Female Targeted	50
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: 15+ Female Targeted	526
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: <15 Male Routine	298
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: 15+ Male Routine	2,758
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: <15 Female Routine	478
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: 15+ Female Routine	4,724
TX_PVLS_DSD	Denominator: Indication: Routine	9,160
TX_PVLS_DSD	Denominator: Indication: Targeted	1,113
TX_PVLS_DSD	Denominator: Preg/BF by Indication: Pregnant Routine	477
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Male Targeted	44
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Male Targeted	410
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Female Targeted	70
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Female Targeted	700
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15	399



	Male Routine	
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Male Routine	3,676
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Female Routine	639
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Female Routine	6,295
TX_PVLS_DSD	<15, Routine, Unknown Sex	0
TX_PVLS_DSD	15+, Routine, Unknown Sex	0
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	2,135
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	2,791
TX_RET_DSD	Numerator by Status: Pregnant	307
TX_RET_DSD	Denominator by Status: Pregnant	307
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	40
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	809
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	59
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	1,226
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	56



TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	976
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	84
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	1,675
TB_PREV_DSD	The number of ART patients who completed a course of TB preventive therapy or at least 6 months of Isoniazid Preventive Therapy (IPT) during the reporting period	2,516
TB_PREV_DSD	The number of ART patients who were newly started on TB preventive therapy (including those who newly started on TB preventive therapy in this reporting period and those who started in the previous reporting period but had not been reported as they did not fulfill the minimum requirements for the previous reporting period).	2,791
TB_PREV_DSD	By Age/Sex (Denominator): <15, Female	136
TB_PREV_DSD	By Age/Sex (Denominator): <15, Male	86
TB_PREV_DSD	By Age/Sex (Denominator): 15+, Female	1,623
TB_PREV_DSD	By Age/Sex (Denominator): 15+, Male	946
TB_PREV_DSD	By Age/Sex (Numerator): <15, Female	124
TB_PREV_DSD	By Age/Sex (Numerator): <15, Male	143
TB_PREV_DSD	By Age/Sex (Numerator): 15+, Female	1,395
TB_PREV_DSD	By Age/Sex (Numerator): 15+, Male	854
TX_TB_DSD	Number of ART patients who were started on TB	22



	treatment during the reporting period.	
TX_TB_DSD	Number of ART patients who were screened for TB at least once during the reporting period	10,693
TX_TB_DSD	Numerator: By Aggregated Age/Sex: <15, Female	0
TX_TB_DSD	Numerator: By Aggregated Age/Sex: <15, Male	0
TX_TB_DSD	Numerator: By Aggregated Age/Sex: 15+, Female	14
TX_TB_DSD	Numerator: By Aggregated Age/Sex: 15+, Male	8
TX_TB_DSD	Denominator: By Aggregated Age/Sex: <15, Female	639
TX_TB_DSD	Denominator: By Aggregated Age/Sex: <15, Male	397
TX_TB_DSD	Denominator: By Aggregated Age/Sex: 15+, Female	6,098
TX_TB_DSD	Denominator: By Aggregated Age/Sex: 15+, Male	3,559
TX_TB_DSD	Denominator: By Screen Result: Negative	8,552
TX_TB_DSD	Denominator: By Screen Result: Positive	2,140
TX_TB_DSD	Denominator: Number of ART patients who had a specimen sent for bacteriologic diagnosis of active TB disease	2,140
TX_TB_DSD	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Smear Only	1,070
TX_TB_DSD	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Gene Xpert MTB / R if Assay	1,070

### Implementing Mechanism Details

<b>Mechanism ID: 18269</b>	<b>Mechanism Name: GHESKIO 1969</b>
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Groupe Haitien d'Etude du Sarcome de Kaposi et des Infections Opportunistes	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

<b>Total All Funding Sources: 4,895,000</b>	<b>Total Mechanism Pipeline: N/A</b>
<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 4,895,000</b>	



Funding Source	Funding Amount
GHP-State	4,895,000

**Cross-Cutting Budget Attribution(s)**

(No data provided.)

**Budget Code Information**

<b>Mechanism ID:</b>	18269		
<b>Mechanism Name:</b>	GHESKIO 1969		
<b>Prime Partner Name:</b>	Groupe Haitien d'Etude du Sarcome de Kaposi et des Infections Opportunistes		
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	HBHC	250,011	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	HVTB	206,264	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	PDCS	39,349	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	HVCT	1,137,738	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	MTCT	338,429	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Treatment	HTXS	2,741,878	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>



Treatment	PDX	181,331	0
-----------	-----	---------	---

### Implementing Mechanism Indicator Information

Indicator Number	Label	2018
PMTCT_ART_DSD	Number of HIV-positive pregnant women who received ART to reduce risk of mother-to-child-transmission (MTCT) during pregnancy	401
PMTCT_ART_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	20,312
PMTCT_ART_DSD	New on ART	209
PMTCT_ART_DSD	Already on ART at beginning of current pregnancy	192
PMTCT_STAT_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	20,312
PMTCT_STAT_DSD	By Age (Denominator): Unknown Age	20,935
PMTCT_STAT_DSD	By Number of known positives: Unknown Age	203
PMTCT_STAT_DSD	By Number of new positives: Unknown Age	218
PMTCT_STAT_DSD	By Number of new negative: Unknown Age	19,889
PMTCT_STAT_DSD	By Age (Numerator): Unknown Age	422
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	122,500
HTC_TST_DSD	By Test Result: Positive	3,036
HTC_TST_DSD	Sum of Test Result disaggregates	3,036
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Inpatient: 15+, Female, Negative	0
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Inpatient: 15+, Female, Positive	0
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Inpatient: 15+, Male, Negative	0



HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Inpatient: 15+, Male, Positive	0
HTC_TST_DSD	Service Delivery Point by Agg Age(Community) Mobile Testing: 15+, Female, Negative	430
HTC_TST_DSD	Service Delivery Point by Agg Age(Community) Mobile Testing: 15+, Female, Positive	7
HTC_TST_DSD	Service Delivery Point by Agg Age(Community) Mobile Testing: 15+, Male, Negative	285
HTC_TST_DSD	Service Delivery Point by Agg Age(Community) Mobile Testing: 15+, Male, Positive	5
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Other PITC: 15+, Female, Negative	10,181
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Other PITC: 15+, Female, Positive	194
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Other PITC: 15+, Male, Negative	6,786
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Other PITC: 15+, Male, Positive	130
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) TB: 15+, Female, Negative	601
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) TB: 15+, Female, Positive	74
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) TB: 15+, Male, Negative	399
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) TB: 15+, Male, Positive	48
HTC_TST_DSD	Service Delivery Point Agg Age (Facility) Index: 15+, Female, Negative	3,759
HTC_TST_DSD	Service Delivery Point Agg Age (Facility) Index: 15+, Female, Positive	279
HTC_TST_DSD	Service Delivery Point Agg Age (Facility) Index: 15+, Male, Negative	2,505
HTC_TST_DSD	Service Delivery Point Agg Age (Facility) Index: 15+, Male, Positive	189



HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) VCT: <15, Female, Negative	15,020
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) VCT: <15, Female, Positive	155
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) VCT: <15, Male, Negative	10,016
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) VCT: <15, Male, Positive	105
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) VCT: 15+, Female, Negative	21,515
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) VCT: 15+, Female, Positive	845
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) VCT: 15+, Male, Negative	14,342
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) VCT: 15+, Male, Positive	565
TB_STAT_DSD	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	1,890
TB_STAT_DSD	Total number of registered new and relapsed TB cases, during the reporting period.	2,143
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	39
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	716
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	59
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	1,076
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Denominator: Total number of registered new and relapsed TB cases,	42



	during the reporting period)	
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	817
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	66
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	1,218
GEND_GBV_DSD	Number of people receiving post-GBV care	95
GEND_GBV_DSD	By type of service: Physical and/or Emotional Violence (Other Post-GBV Care)	9
GEND_GBV_DSD	By type of service: Sexual Violence (Post-Rape Care)	86
GEND_GBV_DSD	By PEP service provision (related to sexual violence services provided)	86
GEND_GBV_DSD	Unknown Age, Female, Physical and/or Emotional Violence	5
GEND_GBV_DSD	Unknown Age, Female, Sexual Violence (Post-Rape Care)	83
GEND_GBV_DSD	Unknown Age, Male, Physical and/or Emotional Violence	4
GEND_GBV_DSD	Unknown Age, Male, Sexual Violence (Post-Rape Care)	3
OVC_SERV_DSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	0
OVC_SERV_DSD	Age/Sex: 10-14 Male	0
OVC_SERV_DSD	Age/Sex: 15-17 Male	0
OVC_SERV_DSD	By: Age/sex: Male 18-24	0
OVC_SERV_DSD	By: Age/sex: Male 25+	0
OVC_SERV_DSD	Age/Sex: 10-14 Female	0
OVC_SERV_DSD	Age/Sex: 15-17 Female	0
OVC_SERV_DSD	By: Age/sex: 18-24 Female	0



OVC_SERV_DSD	By: Age/sex: 25+ Female	0
OVC_SERV_DSD	Sum of Age/Sex disaggregates	0
OVC_SERV_DSD	Age/Sex: <1	0
OVC_SERV_DSD	Age/Sex: 1-9	0
OVC_SERV_DSD	Program Completion: Active	0
OVC_SERV_DSD	Program Completion: Graduation	0
OVC_SERV_DSD	Program Completion: Transferred	0
OVC_SERV_DSD	Program Completion: Exited without graduation	0
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	223
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	223
TB_ART_DSD	Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	2
TB_ART_DSD	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	89
TB_ART_DSD	Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	6
TB_ART_DSD	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	126
TB_ART_DSD	Aggregated Age/Sex: Male <15 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	2



TB_ART_DSD	Aggregated Age/Sex: Male 15+ (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	89
TB_ART_DSD	Aggregated Age/Sex: Female <15 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	6
TB_ART_DSD	Aggregated Age/Sex: Female 15+ (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	126
PMTCT_EID_DSD	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	396
PMTCT_EID_DSD	Number of infants with a positive virological test result within 2 months of birth	2
PMTCT_EID_DSD	Number of infants with a negative virological test result within 2 months of birth	212
PMTCT_EID_DSD	Number of infants with a positive virological test result between 2 and 12 months of birth	6
PMTCT_EID_DSD	Number of infants with a negative virological test result between 2 and 12 months of birth	176
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	18,080
TX_CURR_DSD	Aggregated Age/Sex: <15 Male	373
TX_CURR_DSD	Aggregated Age/Sex: 15+ Male	6,859
TX_CURR_DSD	Aggregated Age/Sex: <15 Female	558
TX_CURR_DSD	Aggregated Age/Sex: 15+ Female	10,284
TX_CURR_DSD	Sum of Aggregated Age/Sex <15	931
TX_CURR_DSD	Sum of Aggregated Age/Sex 15+	17,143
TX_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	18,074
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	3,515
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Male	120



TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Male	1,372
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Female	120
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Female	1,902
TX_NEW_DSD	Sum of Aggregated Age/Sex disaggregates	3,514
TX_NEW_DSD	Pregnancy status	209
TX_NEW_DSD	Breastfeeding status	0
TX_PVLS_DSD	Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months.	13,559
TX_PVLS_DSD	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	18,080
TX_PVLS_DSD	Numerator: Indication: Routine	12,204
TX_PVLS_DSD	Numerator: Indication: Targeted	1,355
TX_PVLS_DSD	Numerator: Preg/BF by Indication: Pregnant Routine	417
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: <15 Male Targeted	26
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: 15+ Male Targeted	474
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: <15 Female Targeted	40
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: 15+ Female Targeted	811
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: <15 Male Routine	246
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: 15+ Male Routine	4,273
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: <15 Female Routine	364
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: 15+ Female Routine	7,322
TX_PVLS_DSD	Denominator: Indication: Routine	16,270
TX_PVLS_DSD	Denominator: Indication: Targeted	1,808



TX_PVLS_DSD	Denominator: Preg/BF by Indication: Pregnant Routine	417
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Male Targeted	32
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Male Targeted	632
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Female Targeted	57
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Female Targeted	1,083
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Male Routine	325
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Male Routine	5,696
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Female Routine	487
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Female Routine	9,760
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	2,275
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	2,993
TX_RET_DSD	Numerator by Status: Pregnant	182
TX_RET_DSD	Denominator by Status: Pregnant	182
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	46
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	862
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	63



TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	1,303
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	61
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	1,048
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	88
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	1,795
TB_PREV_DSD	The number of ART patients who completed a course of TB preventive therapy or at least 6 months of Isoniazid Preventive Therapy (IPT) during the reporting period	2,499
TB_PREV_DSD	The number of ART patients who were newly started on TB preventive therapy (including those who newly started on TB preventive therapy in this reporting period and those who started in the previous reporting period but had not been reported as they did not fulfill the minimum requirements for the previous reporting period).	2,776
TB_PREV_DSD	By Age/Sex (Denominator): <15, Female	81



TB_PREV_DSD	By Age/Sex (Denominator): <15, Male	57
TB_PREV_DSD	By Age/Sex (Denominator): 15+, Female	1,666
TB_PREV_DSD	By Age/Sex (Denominator): 15+, Male	971
TB_PREV_DSD	By Age/Sex (Numerator): <15, Female	76
TB_PREV_DSD	By Age/Sex (Numerator): <15, Male	49
TB_PREV_DSD	By Age/Sex (Numerator): 15+, Female	1,498
TB_PREV_DSD	By Age/Sex (Numerator): 15+, Male	875
TX_TB_DSD	Number of ART patients who were started on TB treatment during the reporting period.	349
TX_TB_DSD	Number of ART patients who were screened for TB at least once during the reporting period	17,310
TX_TB_DSD	Numerator: By Aggregated Age/Sex: <15, Female	7
TX_TB_DSD	Numerator: By Aggregated Age/Sex: <15, Male	10
TX_TB_DSD	Numerator: By Aggregated Age/Sex: 15+, Female	209
TX_TB_DSD	Numerator: By Aggregated Age/Sex: 15+, Male	123
TX_TB_DSD	Denominator: By Aggregated Age/Sex: <15, Female	519
TX_TB_DSD	Denominator: By Aggregated Age/Sex: <15, Male	347
TX_TB_DSD	Denominator: By Aggregated Age/Sex: 15+, Female	10,384
TX_TB_DSD	Denominator: By Aggregated Age/Sex: 15+, Male	6,060
TX_TB_DSD	Denominator: By Screen Result: Negative	16,961
TX_TB_DSD	Denominator: By Screen Result: Positive	349
TX_TB_DSD	Denominator: Number of ART patients who had a specimen sent for bacteriologic diagnosis of active TB disease	3,462
TX_TB_DSD	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Smear Only	1,732
TX_TB_DSD	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Gene Xpert MTB / R if Assay	1,732

### Implementing Mechanism Details

<b>Mechanism ID: 18270</b>	<b>Mechanism Name: FOSREF 1925</b>
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Foundation for Reproductive Health and Family Education	



Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

<b>Total All Funding Sources: 1,300,000</b>	<b>Total Mechanism Pipeline: N/A</b>
<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 1,300,000</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	1,300,000

### Cross-Cutting Budget Attribution(s)

Gender: GBV	25,000
Focus Area:	GBV Prevention
Sub Area:	Collection and Use of Gender-related Strategic Information
Key Populations: FSW	50,000
Focus Area:	Training of health workers and community outreach workers
Focus Area:	Implementation of core HIV prevention interventions for SWs consistent with PEPFAR guidance on sexual prevention
Key Populations: MSM and TG	50,000
Focus Area:	Implementation of core HIV prevention interventions for MSM/TG that are consistent with the current PEPFAR technical guidance
Focus Area:	Monitoring and evaluation of MSM/TG programs
Focus Area:	Conducting epidemiologic, social science, and operational research among MSM/TG and their sex partners
Human Resources for Health	300,000
Motor Vehicles: Purchased	40,000



### Budget Code Information

<b>Mechanism ID:</b> 18270			
<b>Mechanism Name:</b> FOSREF 1925			
<b>Prime Partner Name:</b> Foundation for Reproductive Health and Family Education			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	151,761	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	20,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	134,280	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	514,251	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	10,813	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	468,895	0

### Implementing Mechanism Indicator Information

Indicator Number	Label	2018
PMTCT_ART_DSD	Number of HIV-positive pregnant women who received ART to reduce risk of mother-to-child-transmission (MTCT) during pregnancy	25
PMTCT_ART_DSD	Number of pregnant women with known HIV status	1,539



	(includes women who were tested for HIV and received their results)	
PMTCT_ART_DSD	New on ART	16
PMTCT_ART_DSD	Already on ART at beginning of current pregnancy	9
PMTCT_STAT_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	1,539
PMTCT_STAT_DSD	By Age (Denominator): Unknown Age	1,587
PMTCT_STAT_DSD	By Number of known positives: Unknown Age	11
PMTCT_STAT_DSD	By Number of new positives: Unknown Age	17
PMTCT_STAT_DSD	By Number of new negative: Unknown Age	1,511
PMTCT_STAT_DSD	By Age (Numerator): Unknown Age	28
PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	8,896
PP_PREV_DSD	Age/sex: 20-24 Male	3,018
PP_PREV_DSD	Age/sex: 25-49 Male	5,527
PP_PREV_DSD	Age/sex: 20-24 Female	123
PP_PREV_DSD	Age/sex: 25-49 Female	228
PP_PREV_DSD	Sum of Age/Sex disaggregates	8,896
KP_PREV_DSD	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	34,782
KP_PREV_DSD	By key population type: Men who have sex with men who are sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	506
KP_PREV_DSD	By key population type: Men who have sex with men who are NOT sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	9,571



KP_PREV_DSD	By key population type: Female sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	24,705
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	31,420
HTC_TST_DSD	By Test Result: Positive	1,662
HTC_TST_DSD	Sum of Test Result disaggregates	1,662
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Inpatient: 15+, Female, Negative	0
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Inpatient: 15+, Female, Positive	0
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Inpatient: 15+, Male, Negative	0
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Inpatient: 15+, Male, Positive	0
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Other PITC: 15+, Female, Negative	440
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Other PITC: 15+, Female, Positive	20
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Other PITC: 15+, Male, Negative	293
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Other PITC: 15+, Male, Positive	13
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) TB: 15+, Female, Negative	36
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) TB: 15+, Female, Positive	11
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) TB: 15+, Male, Negative	24
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) TB: 15+, Male, Positive	8



HTC_TST_DSD	Service Delivery Point Agg Age (Facility) Index: 15+, Female, Negative	201
HTC_TST_DSD	Service Delivery Point Agg Age (Facility) Index: 15+, Female, Positive	56
HTC_TST_DSD	Service Delivery Point Agg Age (Facility) Index: 15+, Male, Negative	134
HTC_TST_DSD	Service Delivery Point Agg Age (Facility) Index: 15+, Male, Positive	37
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) VCT: <15, Female, Negative	0
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) VCT: <15, Female, Positive	0
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) VCT: <15, Male, Negative	0
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) VCT: <15, Male, Positive	0
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) VCT: 15+, Female, Negative	16,590
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) VCT: 15+, Female, Positive	980
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) VCT: 15+, Male, Negative	11,060
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) VCT: 15+, Male, Positive	654
TB_STAT_DSD	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	0
TB_STAT_DSD	Total number of registered new and relapsed TB cases, during the reporting period.	0
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	0
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	0



TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	0
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	0
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	0
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	0
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	0
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	0
GEND_GBV_DSD	Number of people receiving post-GBV care	1
GEND_GBV_DSD	By type of service: Physical and/or Emotional Violence (Other Post-GBV Care)	0
GEND_GBV_DSD	By type of service: Sexual Violence (Post-Rape Care)	1
GEND_GBV_DSD	By PEP service provision (related to sexual violence services provided)	1
OVC_SERV_DSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	0
OVC_SERV_DSD	Age/Sex: 10-14 Male	0
OVC_SERV_DSD	Age/Sex: 15-17 Male	0
OVC_SERV_DSD	By: Age/sex: Male 18-24	0
OVC_SERV_DSD	By: Age/sex: Male 25+	0
OVC_SERV_DSD	Age/Sex: 10-14 Female	0
OVC_SERV_DSD	Age/Sex: 15-17 Female	0
OVC_SERV_DSD	By: Age/sex: 18-24 Female	0



OVC_SERV_DSD	By: Age/sex: 25+ Female	0
OVC_SERV_DSD	Sum of Age/Sex disaggregates	0
OVC_SERV_DSD	Age/Sex: <1	0
OVC_SERV_DSD	Age/Sex: 1-9	0
OVC_SERV_DSD	Program Completion: Active	0
OVC_SERV_DSD	Program Completion: Graduation	0
OVC_SERV_DSD	Program Completion: Transferred	0
OVC_SERV_DSD	Program Completion: Exited without graduation	0
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	53
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	53
TB_ART_DSD	Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	0
TB_ART_DSD	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	53
TB_ART_DSD	Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	0
TB_ART_DSD	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	0
TB_ART_DSD	Aggregated Age/Sex: Male <15 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	0



TB_ART_DSD	Aggregated Age/Sex: Male 15+ (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	53
TB_ART_DSD	Aggregated Age/Sex: Female <15 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	0
TB_ART_DSD	Aggregated Age/Sex: Female 15+ (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	0
PMTCT_EID_DSD	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	27
PMTCT_EID_DSD	Number of infants with a positive virological test result within 2 months of birth	0
PMTCT_EID_DSD	Number of infants with a negative virological test result within 2 months of birth	17
PMTCT_EID_DSD	Number of infants with a positive virological test result between 2 and 12 months of birth	0
PMTCT_EID_DSD	Number of infants with a negative virological test result between 2 and 12 months of birth	10
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	3,686
TX_CURR_DSD	Aggregated Age/Sex: <15 Male	0
TX_CURR_DSD	Aggregated Age/Sex: 15+ Male	1,473
TX_CURR_DSD	Aggregated Age/Sex: <15 Female	0
TX_CURR_DSD	Aggregated Age/Sex: 15+ Female	2,213
TX_CURR_DSD	Sum of Aggregated Age/Sex <15	0
TX_CURR_DSD	Sum of Aggregated Age/Sex 15+	3,686
TX_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	3,686
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	1,464
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Male	0



TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Male	615
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Female	0
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Female	849
TX_NEW_DSD	Sum of Aggregated Age/Sex disaggregates	1,464
TX_NEW_DSD	Pregnancy status	16
TX_PVLS_DSD	Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months.	2,767
TX_PVLS_DSD	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	3,688
TX_PVLS_DSD	Numerator: Indication: Routine	2,489
TX_PVLS_DSD	Numerator: Indication: Targeted	278
TX_PVLS_DSD	Numerator: Preg/BF by Indication: Pregnant Routine	48
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: <15 Male Targeted	7
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: 15+ Male Targeted	97
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: <15 Female Targeted	8
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: 15+ Female Targeted	166
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: <15 Male Routine	50
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: 15+ Male Routine	872
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: <15 Female Routine	74
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: 15+ Female Routine	1,493
TX_PVLS_DSD	Denominator: Indication: Routine	3,319
TX_PVLS_DSD	Denominator: Indication: Targeted	369
TX_PVLS_DSD	Denominator: Preg/BF by Indication: Pregnant Routine	48



TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Male Targeted	9
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Male Targeted	129
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Female Targeted	9
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Female Targeted	222
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Male Routine	67
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Male Routine	1,162
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Female Routine	100
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Female Routine	1,990
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	514
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	662
TX_RET_DSD	Numerator by Status: Pregnant	35
TX_RET_DSD	Denominator by Status: Pregnant	35
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	9
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	222
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	13
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Numerator: Number	270



	of adults and children who are still alive and on treatment at 12 months after initiating ART)	
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	11
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	281
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	17
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	353
TB_PREV_DSD	The number of ART patients who completed a course of TB preventive therapy or at least 6 months of Isoniazid Preventive Therapy (IPT) during the reporting period	515
TB_PREV_DSD	The number of ART patients who were newly started on TB preventive therapy (including those who newly started on TB preventive therapy in this reporting period and those who started in the previous reporting period but had not been reported as they did not fulfill the minimum requirements for the previous reporting period).	572
TB_PREV_DSD	By Age/Sex (Denominator): <15, Female	17
TB_PREV_DSD	By Age/Sex (Denominator): <15, Male	11



TB_PREV_DSD	By Age/Sex (Denominator): 15+, Female	343
TB_PREV_DSD	By Age/Sex (Denominator): 15+, Male	201
TB_PREV_DSD	By Age/Sex (Numerator): <15, Female	15
TB_PREV_DSD	By Age/Sex (Numerator): <15, Male	9
TB_PREV_DSD	By Age/Sex (Numerator): 15+, Female	309
TB_PREV_DSD	By Age/Sex (Numerator): 15+, Male	182
TX_TB_DSD	Number of ART patients who were started on TB treatment during the reporting period.	22
TX_TB_DSD	Number of ART patients who were screened for TB at least once during the reporting period	1,172
TX_TB_DSD	Numerator: By Aggregated Age/Sex: <15, Female	0
TX_TB_DSD	Numerator: By Aggregated Age/Sex: <15, Male	0
TX_TB_DSD	Numerator: By Aggregated Age/Sex: 15+, Female	14
TX_TB_DSD	Numerator: By Aggregated Age/Sex: 15+, Male	8
TX_TB_DSD	Denominator: By Aggregated Age/Sex: <15, Female	35
TX_TB_DSD	Denominator: By Aggregated Age/Sex: <15, Male	23
TX_TB_DSD	Denominator: By Aggregated Age/Sex: 15+, Female	703
TX_TB_DSD	Denominator: By Aggregated Age/Sex: 15+, Male	411
TX_TB_DSD	Denominator: By Screen Result: Negative	962
TX_TB_DSD	Denominator: By Screen Result: Positive	210
TX_TB_DSD	Denominator: Number of ART patients who had a specimen sent for bacteriologic diagnosis of active TB disease	236
TX_TB_DSD	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Smear Only	117
TX_TB_DSD	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Gene Xpert MTB / R if Assay	117

### Implementing Mechanism Details

<b>Mechanism ID: 18425</b>	<b>Mechanism Name: EQUIP</b>
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Right To Care, South Africa	
Agreement Start Date: Redacted	Agreement End Date: Redacted

Approved



TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:
<b>Total All Funding Sources: 2,400,000</b>	<b>Total Mechanism Pipeline: N/A</b>
<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 2,400,000</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	2,400,000

**Cross-Cutting Budget Attribution(s)**

Motor Vehicles: Leased	220,000
------------------------	---------

**Budget Code Information**

<b>Mechanism ID: 18425</b>			
<b>Mechanism Name: EQUIP</b>			
<b>Prime Partner Name: Right To Care, South Africa</b>			
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	HBHC	300,000	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Governance and Systems	HLAB	275,000	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Governance and Systems	HVSI	75,000	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>



Prevention	CIRC	0	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	MTCT	400,000	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Treatment	HTXS	1,350,000	0

### Implementing Mechanism Indicator Information

(No data provided.)

### Implementing Mechanism Details

<b>Mechanism ID: 18443</b>	<b>Mechanism Name: SSQH Centre/Sud (Services de Santé de Qualité pour Haïti)</b>
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: JHPIEGO	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:
<b>Total All Funding Sources: 0</b>	<b>Total Mechanism Pipeline: N/A</b>
<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 0</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	0

### Cross-Cutting Budget Attribution(s)

(No data provided.)



### Budget Code Information

<b>Mechanism ID:</b>	18443		
<b>Mechanism Name:</b>	SSQH Centre/Sud (Services de Santé de Qualité pour Haïti)		
<b>Prime Partner Name:</b>	JHPIEGO		
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	HKID	0	0

### Implementing Mechanism Indicator Information

(No data provided.)

### Implementing Mechanism Details

<b>Mechanism ID: 18623</b>	<b>Mechanism Name: 4Children</b>
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Catholic Relief Services	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: Yes
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:
<b>Total All Funding Sources: 2,275,680</b>	<b>Total Mechanism Pipeline: N/A</b>
<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 2,275,680</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	2,275,680

### Cross-Cutting Budget Attribution(s)

Gender: GBV	50,000
Focus Area:	GBV Prevention
Sub Area:	Collection and Use of Gender-related Strategic



	Information
Focus Area:	Post GBV Care
Economic Strengthening	223,017
Education	223,017
Food and Nutrition: Policy, Tools, and Service Delivery	9,102

### Budget Code Information

<b>Mechanism ID: 18623</b>			
<b>Mechanism Name: 4Children</b>			
<b>Prime Partner Name: Catholic Relief Services</b>			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HKID	1,713,180	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVAB	562,500	0

### Implementing Mechanism Indicator Information

Indicator Number	Label	2018
PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	5,365
PP_PREV_DSD	Age/sex: 10-14 Female	3,272
PP_PREV_DSD	Age/sex: 15-19 Female	2,093
PP_PREV_DSD	Sum of Age/Sex disaggregates	5,365
OVC_SERV_DSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	15,258



OVC_SERV_DSD	Age/Sex: 10-14 Male	22
OVC_SERV_DSD	Age/Sex: 15-17 Male	16
OVC_SERV_DSD	By: Age/sex: Male 18-24	12
OVC_SERV_DSD	By: Age/sex: Male 25+	30
OVC_SERV_DSD	Age/Sex: 10-14 Female	7,303
OVC_SERV_DSD	Age/Sex: 15-17 Female	4,674
OVC_SERV_DSD	By: Age/sex: 18-24 Female	1,328
OVC_SERV_DSD	By: Age/sex: 25+ Female	1,823
OVC_SERV_DSD	Sum of Age/Sex disaggregates	12,015
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support Female 10-14	5,089
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support Female 15-17	1,395
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 10-14	180
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 25+	887
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Social Protection Female 10-14	3,405
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Social Protection Female 15-17	1,560
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Social Protection Female 18-24	111
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 18-24	131
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 25+	1,601
OVC_SERV_DSD	Age/Sex: <1	10
OVC_SERV_DSD	Age/Sex: 1-9	40
OVC_SERV_DSD	Program Completion: Active	13,284
OVC_SERV_DSD	Program Completion: Graduation	196
OVC_SERV_DSD	Program Completion: Transferred	1,512
OVC_SERV_DSD	Program Completion: Exited without graduation	266



### Implementing Mechanism Details

<b>Mechanism ID: 18624</b>	<b>Mechanism Name: US Census Bureau</b>
Funding Agency: USAID	Procurement Type: Inter-Agency Agreement
Prime Partner Name: US Bureau of the Census	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: Yes
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:
<b>Total All Funding Sources: 250,000</b>	<b>Total Mechanism Pipeline: N/A</b>
<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 250,000</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	250,000

### Cross-Cutting Budget Attribution(s)

(No data provided.)

### Budget Code Information

<b>Mechanism ID:</b>	18624		
<b>Mechanism Name:</b>	US Census Bureau		
<b>Prime Partner Name:</b>	US Bureau of the Census		
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	HKID	250,000	0

### Implementing Mechanism Indicator Information

(No data provided.)



### Implementing Mechanism Details

<b>Mechanism ID: 18625</b>	<b>TBD: Yes</b>
<b>REDACTED</b>	

### Implementing Mechanism Details

<b>Mechanism ID: 18626</b>	<b>Mechanism Name: Result Based Financing</b>
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Ministry of Health, Haiti	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: Yes
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

<b>Total All Funding Sources: 250,000</b>	<b>Total Mechanism Pipeline: N/A</b>
<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 250,000</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	250,000

### Cross-Cutting Budget Attribution(s)

(No data provided.)

### Budget Code Information

<b>Mechanism ID:</b>	18626		
<b>Mechanism Name:</b>	Result Based Financing		
<b>Prime Partner Name:</b>	Ministry of Health, Haiti		
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>

Approved



Treatment	HTXS	250,000	0
-----------	------	---------	---

### Implementing Mechanism Indicator Information

(No data provided.)

### Implementing Mechanism Details

Mechanism ID: 18631	TBD: Yes
REDACTED	



**Agency Information - Costs of Doing Business**  
**U.S. Agency for International Development**

Agency Cost of Doing Business	GAP	GHP-State	GHP-USAID	Funding Source Total	Applied Pipeline	Total All Funding Sources and Applied Pipeline Amount
Computers/IT Services		297,788		297,788	0	297,788
ICASS		950,000		950,000	0	950,000
Indirect Costs		124,453		124,453	0	124,453
Institutional Contractors		400,000		400,000	0	400,000
Management Meetings/Professional Development		128,881		128,881	0	128,881
Non-ICASS Administrative Costs		288,617		288,617	0	288,617
Staff Program Travel		258,212		258,212	0	258,212
USG Staff Salaries and Benefits - Internationally Recruited		683,283		683,283	0	683,283
USG Staff Salaries and Benefits - Locally		1,368,766		1,368,766	0	1,368,766



Recruited						
<b>Total</b>	<b>0</b>	<b>4,500,000</b>	<b>0</b>	<b>4,500,000</b>	<b>0</b>	<b>4,500,000</b>

**U.S. Department of Health and Human Services/Centers for Disease Control and Prevention**

Agency Cost of Doing Business	GAP	GHP-State	GHP-USAID	Funding Source Total	Applied Pipeline	Total All Funding Sources and Applied Pipeline Amount
Capital Security Cost Sharing		701,196		701,196	0	701,196
Computers/IT Services		550,000		550,000	0	550,000
ICASS		920,000		920,000	0	920,000
Institutional Contractors		96,000		96,000	0	96,000
Management Meetings/Professional Development		20,000		20,000	0	20,000
Non-ICASS Administrative Costs		901,550		901,550	0	901,550
Staff Program Travel		371,452		371,452	0	371,452
USG Staff Salaries and Benefits - Internationally Recruited	987,500	64,297		1,051,797	0	1,051,797
USG Staff		2,288,005		2,288,005	0	2,288,005



Salaries and Benefits - Locally Recruited						
<b>Total</b>	<b>987,500</b>	<b>5,912,500</b>	<b>0</b>	<b>6,900,000</b>	<b>0</b>	<b>6,900,000</b>

**U.S. Department of State**

Agency Cost of Doing Business	GAP	GHP-State	GHP-USAID	Funding Source Total	Applied Pipeline	Total All Funding Sources and Applied Pipeline Amount
Staff Program Travel		52,126		52,126	0	52,126
USG Staff Salaries and Benefits - Internationally Recruited		309,106		309,106	0	309,106
USG Staff Salaries and Benefits - Locally Recruited		50,000		50,000	0	50,000
<b>Total</b>	<b>0</b>	<b>411,232</b>	<b>0</b>	<b>411,232</b>	<b>0</b>	<b>411,232</b>